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Snakes are distributed over large parts around the world, especially in tropical 
and sub-tropical areas. Many snake species are venomous and some are potentially 
life-threatening to humans [1,2]. Snake envenoming is a common but very serious 
public health problem, particularly in Africa, Asia and Latin America [1,2]. More 
than 5.5 million humans are bitten by venomous snakes on yearly basis. These 
cause around 1.8 million human envenomings, of which an estimated 125,000 bites 
result in death, with three to five times more cases suffering from permanent 
physical disabilities and psychological problems (Figure 1) [1,2]. Besides humans, 
venomous snakes also bite livestock, which leads to a further economic burden and 
results in impoverishment [3,4]. Until recently, snake envenoming did not draw 
much attention from national health agencies, and financial support to aid in 
addressing this major worldwide health crisis was lacking [1,2]. In 2017, however, 
the World Health Organization (WHO) formally added snakebite to the top list of 
neglected tropical diseases (NTDs) [5]. 
 
Figure 1. Geographical distribution of the estimated number of snakebite envenomings and deaths. 
Figure adapted from Gutiérrez et al. [2]. 
Snake venoms are mixtures of proteins (of which many are enzymes), peptides, 
and many non-protein compounds, such as carbohydrates, lipids and metal ions 




(Figure 2). Certain venom peptides and proteins display strong and specific 
biological activities that together even may lead to morbidity and mortality of 
victims [1,2,6]. Snake venom composition widely varies among and within snake 
species [2,7,8]. Additionally, venom variability and complexity are increased as 
many other factors contribute to venom composition, such as geographical location, 
gender, age, habitat, food of the respective snake [2,7,8]. Important toxin families in 
snake venoms (SVs) are phospholipases A2 (PLA2s), metalloproteinases (SVMPs), 
serine proteases (SVSPs) and three-finger toxins (3FTxs) [7,9]. Other venom classes 
include C-type lectins (CTLs), kunitz-type protease inhibitors, L-amino acid 
oxidases (LAAOs), cysteine-rich secretory proteins, disintegrins and natriuretic 
peptides [7,9]. These venom toxins have evolved to disrupt physiological processes 
in prey animals. Many venom toxins target ion channels, membrane receptors or 
components of the hemostatic system, with high selectivity and affinity. Toxins in 
snake venoms commonly interfere with physiological processes such as coagulation 
and nerve conduction, or cause cellular, tissue and/or organ destruction, by 
processes such as hemorrhage and edema. Major pathologies in this regard can be 
classified into neurotoxicity, hemotoxicity, disruption of coagulation, cytotoxicity 
and myotoxicity [2,9], Cytotoxicity caused by snake venom is often tissue localized, 
whereas, for example, permanent sequelae are non-localized pathologies and can 
result in chronic disabilities, amputations, contractures, and accompanying 
psychological disorders [2]. Until now, more than 700 venomous snake species 
have been identified and can be classified within four families: Hydrophidae, 
Elapidae, Viperidae and Colubridae [8,10]. The Elapidae and Viperidae are the two 
main medically-important venomous snake families [8,9]. Most of the 
hemotoxicities are found in Viperidae, whereas most Elapidae venoms are of 
neurotoxic nature [8,9]. Snakebites of medically relevant vipers often result in 
hemotoxicity with hypovolemic shock sometimes followed by heart failure and 
renal injury, which may lead to death. Elapid snake envenomings often result in 
neurotoxicity with respiratory failure and flaccid paralysis. Besides these dominant 
toxicities, some viper venom components may cause neurotoxicity and some elapid 
venom components can cause bleeding disturbances [11,12]. The complexity of 
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venoms is not only based on the individual toxicities of snake venom toxins, but 
also on their synergetic functioning resulting in many systemic toxicological effects 
[7,13]. It is remarkable that some venom toxins within the same family show high 
protein sequence similarity but show different pharmacological effects [14]. 
 
Figure 2. Snake venom composition. Figure modified from Munawar et al. [15]. 
Currently, the standard snakebite treatment is antivenom, which may consist of 
intact IgGs, F(ab')2 or Fab fragments, and can partly or fully neutralize systemic 
envenomings [2,9,16]. After administration to a snakebite victim, efficient and 
correct antivenoms will neutralize venom toxins and alleviate pathological 
symptoms. However, antivenoms may show inability to treat local tissue damage 
and risks of adverse reactions, and often are poorly available and accessible, 
especially in many impoverished regions, also due to their relatively high price 
[2,9,16]. Advances in scientific knowledge on snake venom composition and 
snakebite pathologies can contribute to antivenom efficacy improvements by 
allowing rational optimization of antivenom production and purification, and by 
developing new generations of antivenoms. The next sections will discuss major 




snakebite pathologies in more detail and the snake venom toxin families responsible 
for evoking these pathologies. Subsequently, the current status of snakebite 
treatment using antivenoms and low-molecular-weight inhibitors will be discussed. 
Next, a brief overview of analytical techniques and methods for studying snake 
venoms and snakebite treatments will be given. Finally, the scope of this thesis and 
an outlook on its chapters will be provided. 
1.1. Pathological effects of important families of snake venom 
toxins 
1.1.1 Neurotoxicity 
Neurotoxicity of snake envenoming results from the perturbed 
neurotransmission of various neuromuscular junctions. Clinically, the most 
important effect of neurotoxic venoms is weakening of neuromuscular transmission, 
by acting as ion channel blockers and membrane receptor blockers. This leads to 
failure of nerve conduction and possibly results in neuromuscular paralysis and/or 
respiratory muscle and total flaccid paralysis [2,9]. Acute neuromuscular paralysis 
is one of the main reasons of morbidity and mortality caused by elapid snakebites 
[17]. Neurotoxins in elapid snake venoms can be classified as α-neurotoxins 
(postsynaptic) or β-neurotoxins (presynaptic), according to their interactions with 
neuromuscular junctions [2,18]. Many α-neurotoxins bind tightly to nicotinic 
acetylcholine receptors (nAChRs) and prevent muscle contraction, which can cause 
lethal effects by inhibiting the functioning of respiratory muscles [18]. By contrast, 
β-neurotoxins block transmission at the neuromuscular junction without affecting 
the sensitivity of the motor end plate to acetylcholine [18]. The most important 
snake venom neurotoxins belong to the neurotoxic 3FTx and PLA2 families [2,18]. 
Many 3FTxs can bind post-synaptically to muscle nAChRs and act as antagonists of 
these nicotinic (and also muscarinic) receptors (many of which are actually ion 
channels) thereby blocking the transmission of neuromuscular impulses [17,18]. 
PLA2s mainly work at presynaptic nerve terminals of neuromuscular junctions and 
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thereby act as pre-synaptic inhibitors that can cause acute neuromuscular paralysis 
[17,19]. 
1.1.2 Hemotoxicity 
Hemotoxicity caused by snake envenoming is often resulting from combinations 
of anticoagulant, procoagulant, fibrinolysin, hemorrhage and/or hemolysin factors, 
and can result in deregulating blood pressure, impairing clotting factors, interrupting 
platelet function, decreasing blood coagulability and damaging blood vessels 
[9,20,21]. These pathologies in turn can result in hypovolemic shock, secondary 
organ damage and direct pathologic thrombosis [9,20,21]. Hemorrhage caused by 
snake venom is usually a complicated process and can be exacerbated by 
coagulation disorders such as venom-induced consumption coagulopathy [9,20]. 
Hemorrhage is usually accompanied by local and systemic bleedings, which are 
major pathologies arising from especially viperid snake bites [9,20]. Hemostatic 
effects caused by snake venoms involve vasoconstriction that can reduce the blood 
flow, activate platelets and blood coagulation factors, and promote fibrinolysis 
[9,20]. Hemotoxins in snake venoms are major players in hemotoxicity that disturb 
the blood circulatory system [9,20,22]. They often function in combination with 
each other and as a result impair the whole hemostatic system to bring about severe 
pathologies such as cardiovascular shock and even can cause death [9,13]. 
Hemotoxic proteins are mainly found in venoms from Viperidae and Crotalidae 
snakes [9,21]. Some toxins that have effects on hemostasis are also found in 
Elapidae, but they are not common in venoms of these snakes [9,21]. Most of the 
hemotoxins in snake venoms are SVMPs, SVSPs and PLA2s [9,20,22]. 
Hemorrhagic SVMPs induce fibrosis and permanent tissue loss by disrupting 
capillary vessels and impairing skeletal muscle regeneration. This is often followed 
by muscle tissue bleeding and coagulopathy [9,20,22]. SVSPs can proteolytically 
degrade fibrinogen and release bradykinins from plasma kininogens [23,24]. PLA2s 
can prevent blood clotting via anticoagulant effects. 
Among the pathologies resulting from hemolytic snake venoms, venom-induced 
consumption coagulopathy (VICC) is one of the most common, but also serious 




pathological effects of venom-induced hemorrhage [25]. Snake venom toxins 
causing blood coagulopathy can be classified as pro-coagulants and anticoagulants. 
The pro-coagulants are mainly proteases found in Viperidae snake venoms (SVMPs 
and SVSPs) and can activate coagulation factors such as factor V, factor X, factor 
IX and prothrombin [9,21,22]. The anticoagulants include PLA2s, fibrinolytic 
enzymes and plasminogen activators, factor IX/X binding proteins, LAAOs, 
thrombin inhibitors and protein C activators. These anticoagulants inhibit blood 
clotting, can cause severe vasodilation and can keep blood incoagulable [9,21,22]. 
On the contrary, snake venom toxins that affect hemostatic system also may 
have the potential of becoming treatment candidates for several cardiovascular 
diseases [26]. Captopril® (Enalapril) was the first successful venom-based drug 
developed in 1975 after original isolation of an anticoagulant toxin from Bothrops 
jararaca venom [27,28]. Captopril functions as an angiotensin-converting enzyme 
inhibitor and is used to treat hypertension and congestive heart failure [29,30]. 
Following the approval of Captopril, other drugs have been developed and marketed 
that originated from specific toxins using venom as source. The design of the 
marketed drugs Integrilin® (Eptifibatide), Aggrastat® (Tirofiban), 
Defibrase®/Reptilase® (Batroxobin) and Hemocoagulase® are all based on 
Viperidae snake venom toxins and are used to treat cardiovascular diseases [26,30]. 
Many other snake venom components are now progressing through preclinical and 
clinical trials for a variety of therapeutic indications [26,30]. 
1.1.3 Cytotoxity/Myotoxicity 
Cytotoxicity is common for many viperid and elapid snake envenomings [31]. 
Cytotoxins commonly exert their initial effects around the bite site, followed by 
inducing cell necrosis and/or apoptosis in varying degrees and resulting in different 
pathological manifestations. Myotoxicity after snake envenoming is manifested as 
muscle necrosis and instantaneous diaphragmatic paralysis on skeletal muscles by 
damaging muscle fibers or by increasing muscle cell membrane permeability, 
through non-enzymatic interactions [32,33]. Cardiotoxins affect various types of 
heart cells, causing irreversible depolarization and impairment of the structure and 
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function of their cell membranes. They are basically membrane-active peptides and 
hence their most common site of action are cell membrane bilayers [30,34]. Venom 
cytotoxins/myotoxins/cardiotoxins can cause pathologies such as local necrosis, 
hemolysis, cardiotoxicity, myonecrosis, kidney injury, blistering and edema [35]. 
They can also synergistically impair cardiac myocytes, inhibit platelet aggregation, 
induce erythrocytes lysis, and are associated with renal alterations and hyperkalemia 
[13,31,35]. SVMPs, non-enzymatic cytotoxic 3FTxs and PLA2s are crucial in many 
snake venoms for causing cytotoxicity. PLA2s in this regard are recognized as 
abundant myotoxic venom components in many snake venoms and are most often 
found in venoms of vipers. They can rapidly lead to necrosis of skeletal muscle 
fibers [33,36]. Myotoxic PLA2s can excite skeletal muscle cells and hydrolyze 
phospholipids in their cell membrane thereby perturbing membrane bilayers, 
inducing myonecrosis and also affecting lymphatic vessels [33,35,36]. For example, 
the non-catalytic Lys49-PLA2s display myotoxicity through membrane disrupting 
actions brought upon by its cationic C-terminus [37]. Cytotoxic SVMPs on the other 
hand can result in complications like hemolysis and renal cell death after 
envenoming [38]. LAAOs can lead to local tissue necrosis through the liberation of 
hydrogen peroxide [35,38]. Cytotoxic 3FTxs are known to cause tissue membrane 
disorganization by non-enzymatic imbedding into cell membranes [39]. Some of 
them are also known for inducing pore formation in cell membranes [40], of which 
the exact molecular mechanisms are still unclear. 
1.2. Snake envenoming treatment and treatment candidates 
1.2.1 Antivenom 
At present, the only standard treatment for snakebite is animal-derived 
antivenom, which was introduced already in 1894, simultaneously by A. Calmette 
as well as by C. Phisalix and G. Bertrand [2,8,41-46]. Adequate treatment of 
envenoming relies heavily on the ability of antivenoms to neutralize the 
pathological symptoms evoked by venoms, such as hemorrhage, hypotensive shock, 
venom-induced coagulopathy and other signs of systemic envenoming [8,9,25]. By 




intravenously administering antivenom in hospital settings, current antivenoms, 
which consist of purified (and optionally further processed) animal 
immunoglobulins, can bind with high affinity to snake venom toxins to mitigate 
their toxic effects on the victim. Antivenom is usually obtained from partially 
purified serum and/or plasma of hyperimmunized animals. For this, animals are 
immunized by one or multiple selected snake venoms, and after generation of an 
immunological response, the animals will start to produce antibodies against the 
venom(s) used for immunization [25,41]. Hyperimmunized horse serum represents 
the main source of antivenom worldwide, because each horse can supply a large 
blood volume for immunoglobulin purification in comparison to other animals 
[25,41]. Next to horses, sheep, goats and rabbits have been used for antivenom 
production [25,47]. 
 
Figure 3. Photos of ‘big four’ medically important Indian snake species. a: Naja naja, b: Bungarus 
caeruleus, c: Daboia russelii, and d: Echis carinatus. Photos were kindly provided by Wolfgang 
Wüster. 
Antivenoms continue to significantly reduce the morbidity and mortality rates of 
snakebite victims worldwide as the only medically accepted, intravenous-based, 
treatment. For treating elapid snakebites, also additional medical devices such as 
ventilators can be used to maintain circulation and battle paralysis [48]. Many 
antivenoms have efficacy issues when used at different geographical locations as 
Chapter 1 
10 
venoms of the same snake species in different geographical locations often have 
different compositions [49,50]. In order to increase antivenom efficacy, polyvalent 
antivenoms are often used. Polyvalent antivenoms are produced by injecting a 
cocktail of medically important snake venoms from a certain geographical area into 
animals for immunization [9,51]. These antivenoms have the added advantage that 
they also can be used if a snakebite victim did not recognize the snake species that 
gave the bite [50,51]. A typical example is Indian antivenom that is effective against 
the ‘big four’ medically important Indian species (Figure 3): Naja naja (Elapidae), 
Bungarus caeruleus (Elapidae), Daboia russelii (Viperidae) and Echis carinatus 
(Viperidae) [2]. However, they have the disadvantage that the concentration of each 
individual venom used for immunization is much lower than for monovalent 
antivenom productions and as such less antibodies are produced in the animals for 
each venom used for immunization [9]. Consequently higher antivenom doses are 
needed to exert therapeutic effects with the downside of increased risk for adverse 
effects by exogenous proteins [9,52]. Moreover, higher amounts of these 
antivenoms needed for treatment will also make these treatments more costly [9,52]. 
The latter aspects inevitably further decrease the availability and accessibility of 
antivenoms to poor people in underdeveloped tropical countries of Sub-Saharan 
Africa, Asia and Latin America, where snake envenoming occurs most frequently in 
rural farmer communities [53,54]. The sooner a victim receives effective treatment, 
the higher the chances are at full recovery [16,50]. The low availability of 
antivenoms in regions where they are needed most, precludes timely administration 
to victims. Due to this hampered accessibility to antivenoms, and their 
ineffectiveness to local tissue damage and neurotoxicity, many snakebite victims 
suffer temporary or permanent disabilities, such as amputations, blindness, nerve 
and organ damage [1,53-55]. Moreover, even when administered timely, most 
antivenoms cannot counteract all clinical symptoms [16,55]. As mentioned, the use 
of polyvalent antivenoms increases the risk of adverse reactions [9,41,56]. Acute 
reactions take place within the first 24 h after antivenom injection and include 
anaphylactic and pyrogenic reactions. Delayed reactions generally give serum 
sickness (a type III hypersensitivity reaction) and may occur 5-24 days after 




antivenom injection. These adverse effects are characterized by fever, arthralgia, 
urticaria, myalgia, lymphadenopathy arthritis, and gastrointestinal disorders [41]. 
Considering the issues associated with current antivenoms, the development of a 
new generation of antivenoms is clearly indicated [9,57]. The last few years, the 
WHO encouraged preclinical evaluation of new antivenom treatments that exhibit 
good manufacturing practice, improved regulatory control, better safety and 
stability profiles, and lower production costs. This should facilitate the development 
of a new generation of antivenoms that are available, accessible, and affordable to 
many [50]. Several potential treatments have gained interest recently. These new 
treatment options are discussed in the following sections. 
1.2.2 Small molecule therapeutic candidates 
Enzymatic toxins in snake venoms, such as PLA2s, SVMPs and SVSPs, in 
principle can be inhibited by small (i.e. low molecular-weight) molecules [57-61]. 
This is the basis of recent developments towards small molecule inhibitors as novel 
candidates for pre-referral snakebite treatment [57,58]. These inhibitors can be 
administered directly after a snakebite, e.g. orally or injected at the location of the 
bite, prior to transfer of the patient to hospital settings [57,58,61]. Inhibitors could 
potentially also be used in combination with antivenom administration in a hospital, 
as complementary treatment.  
As of yet, no inhibitor-based drug for snakebite treatment has been approved 
[58]. So far, the most extensively investigated small-molecule inhibitors for treating 
snakebite are varespladib and its orally available pro-drug methyl-varespladib 
[59,62-69]. These two compounds are previous drug candidates for treatment of 
acute coronary syndrome, but ultimately failed in clinical trials [70,71]. Varespladib 
is an indole-based nonspecific pan-secretory PLA2 inhibitor that potently inhibits 
mammalian sPLA2-IIa, sPLA2-V, and sPLA2-X, and it was recently shown to be 
highly potent in suppressing venom-induced PLA2 activities in snake venoms 
[59,72]. After snake envenoming, varespladib and methyl-varespladib can inhibit 
anticoagulation, hemorrhage and myotoxicity caused by PLA2s [63-65]. As PLA2s 
are found in venoms of almost every family of venomous snakes, and especially in 
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Elapidae and Viperidae which by far have the highest medical relevance [73], snake 
venom PLA2s are regarded as suitable targets for new small-molecule based 
treatments. Still, some medically relevant snakes, such as the black mamba 
(Dendroaspis polylepis), lack abundant PLA2s in their venoms [74,75]. 
SVMPs are another class of abundant enzymatic toxins present in many 
medically relevant snake venoms. These are also considered promising targets for 
inhibitor-based snakebite therapies. The matrix metalloproteinase inhibitors 
batimastat and the orally available pro-drug marimastat, which previously have 
been investigated as potential anticancer drugs, were found to effectively inhibit 
coagulant, hemorrhagic and necrotic pathologies induced by Echis ocellatus venom. 
Batimastat showed a higher potency than marimastat in inhibiting hemorrhagic 
activities, whereas marimastat showed a higher potency in inhibiting 
defibrinogenating activities [60,76,77]. Other metalloprotease inhibitors like 
prinomastat, CGS-270 23A and Bay-12-9566 also have shown potential as 
snakebite treatment candidates [78-80]. SVMPs rely on the presence of a 
coordinated Zn2+ ion at their active site, rendering the proteases inactive when Zn2+ 
is removed [61,81]. The metal chelator EDTA was reported to be able to inhibit 
prothrombin degradation, inhibit hemorrhagic and necrotic activity, reduce 
procoagulant activity, and prevent lethality induced by snake venoms [78,82]. 
BAPTA (bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid) is another metal 
chelator that can inhibit venom induced hemorrhagic activity [78]. Recent research 
on the potential use of metal chelators as snakebite treatment is described by 
Albulescu et al. [61]. This study reported that the metal chelators dimercaprol and 
2,3-dimercapto-1-propanesulfonic acid (DMPS), which both are approved drugs for 
treatment of heavy metal poisoning, provide protection against the lethal effects in 
mice of venom from saw-scaled vipers (Echis spp.), a group of medically important 
snakes found widely distributed across parts of Africa and Asia. In in vivo studies it 
was shown that oral administration of DMPS after envenoming provided protection 
against the venoms under study. These effects were enhanced by simultaneous 
administration of sub-optimal doses of conventional antivenom. DMPS also 
appeared able to drastically reduce local tissue damage. From these results it was 




concluded that small molecule inhibitors are promising adjunctive snakebite 
treatment candidates. 
Traditionally, medicinal plants, and extracts thereof, have been of great interest 
to rural and tribal people to treat diseases, including snakebites [83,84]. Local 
application of plant products directly at the bite area is the most frequent used 
method in this regard. Folk medicines have been there since ancient times and are 
still used for treating insect and animal bites in general, and for snakebites in 
particular. Some modern studies focus on such natural extracts and compounds to 
find candidates for treating snakebite [85-88]. Traditional herb medicines, which 
can be a rich source of natural inhibitors and other pharmacologically active 
compounds [83,89], are currently looked at for their potential as adjuvant and/or 
complementary therapy candidates to treat snakebites [83,90-92]. However, the 
molecular mechanisms underlying the functioning of these medicinal extracts with 
respect to modulating antivenom activity is still largely unknown [85,93]. 
1.2.3 Other therapies 
Next to small-molecule inhibitors, other options to effectively counteract 
pathologies of snakebite envenoming have been studied. Heparin was shown to 
inhibit both platelet aggregation and blood clotting evoked by certain snake venoms. 
By prolonging clotting time and by neutralizing thrombin produced from factor X 
activation by heparin, myonecrosis could be inhibited after envenoming by Echis 
carinatus venom [94,95]. However, the utility of heparin for snakebite treatment 
remains controversial as other studies showed little evidence for its effectiveness 
[96-98]. Apigenin derivatives known for inhibiting SVMPs were found effective in 
inhibiting Echis carinatus venom-induced local hemorrhage, tissue necrosis and 
myotoxicity [99]. The drug suramin, was reported to alleviate cardiotoxicity and 
myotoxicity induced by Bothrops jararacussu and Bothrops asper venoms [88,100], 
and was an effective inhibitor of β-bungarotoxin from Bungarus multicintus venom 
[101]. Glycyrrhizin, a triterpenoid saponin polyanion, has shown inhibiting effects 
on hemostatic toxicity induced by Bothrops jararacussu venom [102]. The 
antibothropic complex, a protein complex derived from Didelphis marsupialis 
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(South American opossum) serum, was reported to be able to counteract 
hemorrhagic activity induced by Bothrops jararaca venom with greater efficacy 
than commercial antivenom [103,104]. This protein complex, however, is a non-
human protein complex thereby introducing serious risks of immunological side 
effects when advancing as envenoming therapy candidate [103]. 
The development of monoclonal antibody (mAb) technologies paved the way for 
alternative antivenom production processes [105,106]. The use of human mAbs for 
snakebite treatment potentially could drastically decrease immunological side 
effects following administration, as compared to traditional antivenoms from bovine 
or equine origin. Various mAbs have been developed against venom toxins from 
different venomous species by applying the phage display technology [107-111]. 
These human antivenom mAbs have shown to be effective in neutralizing 
neurotoxicity, myotoxicity and hemorrhage in mice after envenoming [112-114]. 
Additionally, their production costs are lower as compared to costs made to produce 
traditional antivenoms, and when purified, mAbs are much more stable than 
commercial antivenoms [57,105,115]. These merits, together with encouraging in 
vitro and in vivo research results obtained so far, established a firm foundation for 
further development of mAbs into novel snake envenoming therapies. However, 
some drawbacks of mAbs still exist as mAbs have limited efficacy to counteract 
localized pathologies such as hemorrhage and tissue damage induced by snake 
venom cytotoxicity. An important reason for this is that the size of some mAbs 
prevents them from reaching local bite sites. Further, mAbs are specific towards one 
snake venom toxin, or one toxin family at most. To effectively treat snakebite, 
different mAbs will be needed in combination as oligoclonal mixtures which will 
complicate development and will result in an increase of eventual treatment costs. 
1.3. Analytical platforms for studying snake venoms and 
snakebite treatments 
A complete elucidation of snake venom composition contributes to better 
understanding of venom variation, envenoming pathogenesis and therapeutics  





Figure 4. Scheme of typical steps in snake venomics analysis. 
Figure modified from Gutiérrez et al. [116]. 
exploration [8]. Traditionally, venom toxins from crude venoms were analytically 
and pharmacologically characterized after multiple tedious isolation and purification 
steps using classical low-pressure liquid chromatographic (LC) techniques. Current 
high- and ultra-performance LC separations using porous small-particle stationary 
phases under high pressure, allow for much higher separation efficiencies in 
considerably shorter analysis times. Modern LC techniques nowadays can be 
efficiently combined with state-of-the-art mass spectrometry (MS) techniques, 
which due to their high mass resolution and ion-fragmentation options allow for 
reliable and specific assignment of toxins. Moreover, advanced LC-MS approaches 
have opened up proteomics workflows (coined ‘venomics’) for unambiguous, 
sensitive and fast determination of toxin identities in a given venom [47,116], even 
allowing (relative) quantification [117]. Venomics represents the integration of 
proteomic, genomic and transcriptomic approaches to study venoms [8,47,118]. A 
generic workflow in venomics involves snake venom analysis by LC followed by 
SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) analysis 
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of obtained LC fractions. Subsequently, each protein band from SDS-PAGE is 
subjected to proteomics analysis by (nano)LC-MS after in-gel tryptic digestion. 
Alternatively, two-dimensional electrophoresis (2-DE) analysis has been performed 
in order to achieve better separation of the various venom toxins [47,116]. Figure 4 
shows a scheme of the typical analytical steps involved in snake venomics analysis. 
Venomics stimulated research in characterization of venoms from a wide variety of 
snake species, including studies on venom variations with respect to e.g. 
geographical location, sex and/or age of snakes. The group of Calvete, who 
pioneered and greatly advanced venomics, studied a large number of viper venoms 
over the past decade [8,118]. These studies include full viperid venom 
characterization, investigation of venom variation and venom evolution, and 
examining antivenom efficacy in binding to toxins in venoms (i.e. antivenomics 
studies) [8]. 
 
Figure 5. Scheme of typical steps in snake antivenomics analysis. 
Antivenomics was developed in 2009 and involves an immunodepletion step of 
toxins from crude venom by incubation with antivenom under study [8]. A generic 
scheme of the analytical procedures involved in antivenomics is shown in Figure 5. 
After this, venomics approaches are used in order to investigate to which venom 
toxins the antivenom binds [8,119]. Antivenomics allows qualitative and 




quantitative assessment of the binding potency of an antivenom to the specific 
toxins in a given venom. It can also efficiently be used to study antivenom cross 
reactivity among different venoms, and to guide development of new antivenoms 
with higher immunological activity [8,47]. Venom variations can drastically affect 
antivenom efficacy, as mentioned above. Studying antivenom binding affinity at the 
individual venom toxin level by antivenomics approaches therefore gives handles to 
develop and improve antivenoms of the future. Finally, antivenomics tools can help 
in the selection process of choosing the most appropriate animal species for 
antivenom production [118]. 
Antivenomics approaches have evolved over time, and until now, one can speak 
of three generations of antivenomics that have developed. The first generation of 
antivenomics, as introduced above, was based on in-solution immunodepletion of 
antivenom bound toxins after incubating crude venom with purified antivenom IgGs. 
For the immunodepletion step, incubation with secondary antibodies (e.g. anti-horse 
IgGs) or with immobilized IgG-binding moieties (e.g. protein-A or protein-G) is 
performed [8,47,116]. Following these two incubation steps, the antivenom-venom 
toxin complexes are pulled-down by a centrifugation step whereas non-bound 
venom toxins remain in the supernatant. These remaining toxins are often those 
which failed to raise an immunogenic response during immunization or triggered 
the production of low-affinity antibodies. After immunoprecipitation, toxins in the 
supernatant fraction are analyzed by LC. In parallel, crude venom is treated as 
control sample by incubation with PBS (instead of antivenom) which is then treated 
using the same procedure [8]. Next, the chromatographic profiles obtained for the 
supernatant fractions of antivenom-treated and crude venom are compared [8] and 
non-bound and low affinity toxins are pinpointed. These can subsequently be 
characterized by using proteomics data obtained from crude venom analysis using a 
venomics approach [8]. This strategy is straightforward to implement in analytical 
laboratories and is valuable in assessment of antivenom immunoreactivity and in 
assessment of antivenom efficacy towards homologous and heterologous venoms 
[8,47,116]. However, this first generation antivenomics only probes the non-bound 
toxins in solution after the immunoprecipitation step and can only be applied to 
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antivenoms based on full IgGs [120]. There are no commercially available anti-IgG 
antibodies (secondary antibodies) that are able to efficiently immunoprecipitate 
F(ab')2 and Fab antibody fragments [120]. 
Further developments in antivenomics protocols resulted in second generation 
antivenomics which is based on immunoaffinity chromatography (IAC) [119,121]. 
Antivenom antibodies or antibody fragments are chemically bound to column 
material particles with protein-reactive functional groups which are packed into an 
IAC column. Crude venom is applied to the IAC column, followed by a column 
washing step to remove non-retained toxins. Desorption of bound toxins is 
accomplished by flushing with an elution buffer that disrupts the antivenom-toxins 
complexes. This means that both the non-retained and the antivenom-captured 
toxins can be collected for further analysis by LC. In parallel, crude venom 
incubated with mock matrix and with matrix-coupled pre-immune antibodies is also 
subjected to LC separation and to toxin identification by proteomics/venomics tools. 
By comparing the three sets of chromatographic profiles, both the non-retained and 
the antivenom-captured venom toxins can be identified [121]. Second generation 
antivenomics is also suitable for antivenoms based on F(ab')2 and Fab antibody 
fragments, and information on both the non-binding and on the bound venom toxins 
is obtained [121].  
Third generation antivenomics involved several analytical advances [120,122]. 
The column support matrix used for preparation of the IAC column is cyanogen 
bromide-activated (as compared to N-hydroxysuccinimide activated for second 
generation antivenomics). This is done in order to eliminate the adverse effect of 
released N-hydroxysuccinimide on the quantitative determination of non-bound 
antibodies during affinity column preparation. The absorbance of N-
hydroxysuccinimide at 280 nm hinders accurate determination of non-bound 
antibodies by UV detection. This is not the case for cyanogen bromide allowing 
reliable assessment of antivenom coupling yields [122]. In third generation 
antivenomics crude venom is loaded at varying amounts during different 
experiments by using several parallel prepared IAC columns (in second generation 
antivenomics one fixed venom-antivenom ratio is used). By monitoring the 




concentration-dependent LC profiles of unretained venom toxins during increasing 
venom loads, the binding efficacy and the maximal binding capacity of an 
antivenom towards each venom toxin can be determined [122]. In addition, during 
separate experiments, venom is incubated with antivenom in solution after which 
the percentage of antibodies in antivenom with binding affinity to venom toxins is 
obtained by analyzing the relative peak areas of venom-antivenom complexes and 
non-complexed antibodies by size-exclusion chromatography (SEC). This yields the 
percentage of toxin-specific antibodies present in the antivenom under study. To 
summarize, third generation antivenomics allows quantification of the binding 
efficacy and the maximum binding capacity of antivenoms for each toxin present in 
a target venom, and also the determination of the percentage of venom-toxin-
binding antibodies in an antivenom. 
Venomics and antivenomics studies have increased our knowledge on snake 
venom composition and on antivenom efficacy in binding venom toxins. However, 
obtaining in-depth understanding of biochemical functioning and pathological 
effects of venom toxins, and how these can be specifically neutralized by antivenom 
or other neutralization agents, is still very challenging. Additional acquisition of 
biochemical, pharmacological and toxicological information on toxins by involving 
functional and pathology assay formats is required to obtain a more comprehensive 
picture. Ideally, these assay techniques are combined with venomics and 
antivenomics approaches. During the past decades, high throughput screening (HTS) 
technologies have drawn significant attention and many traditional assays have been 
adapted to HTS formats for acquiring bioactivity information in a fast and 
automated manner. Integration of biological and biochemical HTS assay formats 
with state-of-the-art chromatographic separations and MS-based characterization 
methods provides good opportunities for comprehensive venom analysis [123-126]. 
Elaborating on the concept of bioassay-guided fractionation, recently a so-called 
nanofractionation platform (Figure 6) was introduced to the toxinological 
community. Nanofractionation analytics combine high-resolution LC fractionation 





Figure 6. Schematic overview of the nanofractionation analytics platform. Crude snake venom is 
separated by HPLC and the post-column effluent flow with eluting venom toxins is split into two parts. 
The larger part is directed to a FractioMate fraction collector for collecting the fractions in high 
resolution on 384 well plates, while the smaller part is directed to UV detection followed by MS 
analysis. After high resolution fractionation, the well plates are vacuum centrifuged to dryness 
followed by performing a bioassay. Then, so-called bioactivity chromatograms are constructed by 
plotting the fractionation time of each well on the x-axis versus the corresponding bioassay signal per 
well on the y-axis. By aligning the LC-UV, LC-MS and bioactivity chromatograms, the accurate 
masses of the venom toxins responsible for detected bioactivities are determined. 
The nanofractionation approach can be used effectively for screening crude 
venoms on venom toxins with a particular (pre-defined) bioactivity, including their 
identification [127,128]. It involves LC separation with UV absorbance detection 
followed by parallel MS detection and collection of low-volume fractions of the 
column effluent at high frequency (2-10 s per fraction) in high-density well plates 
[127]. The content of each well is subjected to high-throughput biochemical 
analysis using a bioassay of choice. The bioassay readouts are correlated to the 
parallel obtained MS data allowing assignment of bioactivity to specific component 
masses. Subsequent optional proteomics analysis of obtained fractions allows for 
unambiguous identification of venom proteins providing direct correlation of venom 
toxin identities with their specific bioactivities. Hence, the integrated 
nanofractionation platform allows for rapid, high-resolution, high-content profiling 
of toxins in crude venoms deciphering their pathological and pharmacological 




activities. In this respect the platform can be regarded complementary to venom 
profiling using venomics approaches [127,128]. 
Recent nanofractionation-based studies of snake venom include the work of 
Neumann et al. in which a generic HTS protease activity assay was incorporated in 
order to profile crude venoms on toxin components exhibiting protease activities 
[129]. In two similar studies, Still et al. developed HTS-based coagulation and 
PLA2 assays for use in nanofractionation analytics, and demonstrated its usefulness 
for the profiling of snake venoms on coagulopathic toxins and enzymatically active 
PLA2s, respectively [130,131]. Slagboom et al. further advanced the 
nanofractionation approach by introducing venom proteomics to the analytics [132]. 
This enabled full toxin characterization and correlation of identified toxins with 
their coagulopathic properties, as shown by profiling medically relevant 
coagulopathic toxins in snake venoms. The high-resolution and high-throughput 
biological activity profiling of snake venoms combined with toxin assignment and 
identification is the key feature of the nanofractionation approach. Still, the 
availability of small, well-defined venom fractions in well plates opens up 
interesting opportunities for further investigations, such as venom toxin 
neutralization, as will be demonstrated in this thesis. 
1.4. Scope of the thesis 
This thesis mainly focuses on the use of nanofractionation analytics for the 
investigation of the potency of antivenoms and small-molecule inhibitors in 
neutralizing the toxicities of individual toxins from crude snake venoms. The effects 
of inhibiting species can be studied in detail by incorporating them in the bioassays 
applied to the venom fractions. Goal is to build a better understanding on which 
snake venom toxins can or cannot be neutralized by antivenoms and/or specific low-
molecular-weight compounds. Ultimately, these studies would aid venom research 
by providing new insights in the toxicity-neutralizing capacities of existing and 
candidate snakebite treatments at the venom toxin level. Next to evaluation of 
antivenom and inhibitors, this thesis also describes research on the development of 
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dedicated bioassays for the assessment of specific venom component 
pathologies/toxicities in a nanofractionation setting. In particular, the objective is to 
design and apply a straightforward cytotoxicity assay in miniaturized 384-well plate 
format suitable for use in nanofractionation analytics. 
Chapter 1 introduces the serious problem and challenge that bites of venomous 
snakes invoke around the word and points out that snakebite actually is a NTD, 
recently placed on the top priority list of NTDs by the WHO. The composition of 
venoms and their toxins and corresponding pathologies are summarized. Various 
existing and potential treatments for snakebite envenoming are discussed, together 
with their advantages and disadvantages. Different analytical platforms for studying 
snake venom and the functioning of antivenom treatments at the venom toxin level 
are also reviewed. 
In Chapter 2, a previously developed HTS coagulation assay is incorporated 
into a nanofractionation platform with the goal to assess the coagulopathic 
properties of snake venom toxins following LC separation of crude venoms. The 
coagulation profiles of venoms from a number of medically important snake species 
are investigated. Subsequently, the neutralization potency of antivenoms towards 
the coagulopathic activities of individual venom toxins is studied. Additionally, the 
cross-reactivity of antivenoms against venoms of closely-related snake species is 
evaluated. Detected coagulopathic venom toxins are identified using in parallel 
acquired MS and proteomics data. The obtained results are put in the perspective of 
potentially broadening the knowledge on the relative efficacy and cross-reactivity of 
existing antivenom therapies and the possibility to guide developments of next-
generation antivenom treatments. 
Chapter 3 investigates the inhibiting effects of varespladib (a nonspecific PLA2 
inhibitor) on individual snake-venom PLA2s by employing nanofractionation 
analytics involving a coagulation bioassay and a PLA2 bioassay. The coagulation 
toxicities of venoms from a number of medically important snake species are 
investigated after LC fractionation onto 384-well plates allowing bioassaying of 
fractions in high resolution. Bioactivity chromatograms are constructed using the 
fractionation time of each fraction on the x-axis and the corresponding bioassay 




readout on the y-axis. The capacity of varespladib to inhibit the activity of 
enzymatic PLA2s and the coagulopathic toxicities induced by snake venom toxins 
are evaluated. Venom toxins responsible for the observed activities are identified by 
parallel recorded MS data and proteomics data obtained on the fractions. The 
potential clinical utility of varespladib in mitigating the toxic effects of certain 
snakebites is discussed. 
In Chapters 4 and 5, the inhibiting effects of the low-molecular-weight 
(candidate) drugs varespladib, marimastat (broad spectrum matrix metalloprotease 
inhibitor), dimercaprol (metal chelator) and DMPS (metal chelator) on the 
coagulation pathologies generated by Viperinae and Crotalinae snake venoms are 
investigated. Venoms from these snake families are known for their potent 
coagulopathic and hemorrhagic toxicities, caused by combined actions of mainly 
PLA2s, SVMPs and SVSPs present in these venoms. The investigated low-
molecular-weight compounds are known for their potential to act as inhibitors of 
enzymatic activities of PLA2s or SVMPs. The venoms under study are profiled by 
LC-based nanofractionation analytics involving the coagulation assay and parallel 
MS detection. Specifically, crude venoms are separated into high-resolution 
fractions followed by bioassaying of these fractions in presence of an inhibitor. This 
way, the inhibitory capabilities of the molecules under study against the 
coagulopathic toxicities of the snake venom fractions are revealed. Bioactivity 
chromatograms are finally correlated to parallel recorded mass spectrometric and 
proteomics data, to assign the venom toxins responsible for coagulopathic activity 
and to assess which of these toxins could be neutralized by the inhibitors under 
investigation. 
In Chapter 6, a HTS hemolytic assay that allows profiling of erythrocyte lysis 
by venom cytotoxins is developed in 384-well plate format. The assay relies on the 
absorbance measurement of the red coloration of the medium after lysis of 
erythrocytes. The direct integration of the new assay format into nanofractionation 
analytics is examined. Various conditions, including the NaCl concentration of the 
assay medium, erythrocyte count, and incubation time are optimized, alongside 
assessment of the effects of surfactants on promoting erythrocyte lysis. The 
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potential cytotoxicity enhancing effect of phospholipids from egg yolk emulsions 
which facilitate indirect lysis is also studied. The optimized developed assay is 
validated in a nanofractionation setting using venoms from a number of medically 
important snake species (viz. Calloselasma rhodostoma, Daboia russelii, Naja 
mossambica, Naja nigricollis and Naja pallida). Moreover, the applicability of this 
new method for evaluation of conventional snakebite antivenom and a small-
molecule drug candidate towards neutralization of venom cytotoxins is assessed. 
Chapter 7 provides a summary and a general conclusion on the research 
described in this thesis, followed by future perspectives on further improving 
analytics for investigating snakebite treatments. 
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Venomous snakebite is one of the world’s most lethal neglected tropical diseases. 
Animal-derived antivenoms are the only standardized specific therapies currently 
available for treating snakebite envenoming, but due to venom variation, often this 
treatment is not effective in counteracting all clinical symptoms caused by the 
multitude of injected toxins. In this study, the coagulopathic toxicities of venoms 
from the medically relevant snake species Bothrops asper, Calloselasma 
rhodostoma, Deinagkistrodon acutus, Daboia russelii, Echis carinatus and Echis 
ocellatus were assessed. The venoms were separated by liquid chromatography (LC) 
followed by nanofractionation and parallel mass spectrometry (MS). A recently 
developed high-throughput coagulation assay was employed to assess both the pro- 
and anticoagulant activity of separated venom toxins. The neutralization capacity of 
antivenoms on separated venom components was assessed and the coagulopathic 
venom peptides and enzymes that were either neutralized or remained active in the 
presence of antivenom were identified by correlating bioassay results with the MS 
data and with off-line generated proteomics data. The results showed that most 
snake venoms analyzed contained both procoagulants and anticoagulants. Most 
anticoagulants were identified as phospholipases A2 (PLA2s) and most 
procoagulants correlated with snake venom metalloproteinases (SVMPs) and serine 
proteases (SVSPs). This information can be used to better understand antivenom 
neutralization and can aid in the development of next-generation antivenom 
treatments. 
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According to the World Health Organization around 5.5 million people get bitten 
by snakes, per year causing more than 1.8 million envenomings, resulting in 81,000-
138,000 deaths [1-4]. Furthermore, around 400,000 are estimated to suffer from 
long-term morbidity including amputation, blindness, and nerve damage [3,5-8].  
Most snake venoms are abundant in peptides and proteins, many of which are of 
pathological importance and capable of affecting important physiological functions 
including blood coagulation, blood pressure regulation, and the transmission of 
nervous and muscular impulses. One of the most common but serious pathological 
effects of envenoming by snakes is coagulopathy [9], which is caused by the 
deregulation of blood coagulation by hemotoxic compounds [10]. Coagulopathy-
inducing venom components can be categorized based on their procoagulant and 
anticoagulant properties. Important procoagulant toxins include certain clotting 
factor activating snake venom metalloproteinases (SVMPs) and serine proteases 
(SVSPs) [8,11,12], whereas anticoagulant toxins include enzymatic (e.g., 
phospholipases A2 (PLA2s), fibrin(ogen)olytics and L-amino acid oxidases) and 
non-enzymatic proteins (e.g., C-type lectin-like proteins (CTL), three-finger toxins, 
and Kunitz-type proteinase inhibitors) [13]. They often synergistically disturb the 
hemostatic system and can lead to coagulopathy [8,9,14,15]. 
The only standardized specific treatment currently available for neutralizing the 
medically important effects of snake venom toxins is antivenom [8,9,12]. However, 
due to limited availability of antivenom, the need for cold storage, varying quality 
and specificity, and because of ontogenetic, individual and geographic inter-specific 
venom variation, antivenom administration often does not provide an adequately 
effective treatment. Frequently, inappropriate antivenoms are applied. Even when a 
suitable antivenom is administered in many cases, not all clinical symptoms are 
counteracted, i.e., not all toxins from the injected venom cocktails are (fully) 
neutralized. The limited paraspecific immunological cross-reactivity of each 
particular antivenom and the variation in snake venoms at every taxonomic level 
therefore requires many different antivenoms and/or polyvalent antivenoms to be 
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available. Nevertheless, the proportion of antibodies specific to any particular 
venom in polyvalent antivenoms are relatively low, meaning that larger doses of 
these antivenoms are typically required to effect cure [12,16]. This not only results 
in higher treatment costs, but also increases the risk of adverse immunological 
reactions [12,17-19]. Therefore it is important to develop a new generation of 
antivenoms that are paraspecifically effective at much lower doses than currently 
used [12,20]. Although antivenomics [21] have been successfully used to evaluate 
which venom toxins can bind efficiently to antivenom, this technique does not 
reveal whether the binding of antivenom to venom components neutralizes their 
toxicity (which has to be assessed by one or several biological assays). New 
analytics that can assess the effectiveness of antivenoms in neutralizing the 
pathology induced by individual venom toxins would be a valuable complementary 
tool to antivenomics. Nanofractionation analytics is regarded as an effective method 
for screening complex crude venoms to rapidly identify and characterize separated 
venom toxins [22,23]. Such nanofractionation analytics include liquid 
chromatographic (LC) separation, UV absorbance, and mass spectrometric (MS) 
detection followed by a bioassay after collection of low-volume fractions of the 
column effluent at a resolution of 2 s to 10 s [22]. Among many existing assays 
available to assess coagulopathic nature of snake venoms, the assay developed 
recently by Still et al. [10] is a sensitive high throughput and low volume 384-well 
format assay, which can directly be combined with nanofractionation analytics. In 
the study of Still et al., several other coagulation assay formats are also discussed in 
detail. 
In this study, we present an integrated analytical approach providing a valuable 
complementary tool for antivenomics in antivenom research. We used the 
aforementioned, recently developed, high-throughput screening (HTS) coagulation 
assay [10] integrated into nanofractionation analytics to assess the coagulopathic 
properties of fractionated venom toxins following LC separation. The profiles of 
fractionated venom toxins from a number of medically important snake species 
capable of causing coagulopathic effects were obtained after which the neutralizing 
potency of antivenoms against these activities was assessed. The species included in 
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this study were Bothrops asper, Calloselasma rhodostoma, Deinagkistrodon acutus, 
Daboia russelii, Echis carinatus and Echis ocellatus. Moreover, the fractioned 
coagulopathic venom toxins were identified using mass spectrometry and 
proteomics data acquired by Slagboom et al. [24]. Finally, the cross-reactivity of 
antivenoms against venoms of closely related snake species was evaluated to assess 
their efficacy, or lack thereof, in the neutralization of these venom components. 
These results will broaden our knowledge on the relative efficacy and cross-
reactivity of existing antivenom therapies and can guide the future development of 
next-generation antivenom treatments. 
2.2. Materials and methods  
2.2.1. Chemicals 
Water was purified using a Milli-Q Plus system from Millipore (Amsterdam, 
The Netherlands). Acetonitrile (ACN; LC/MS grade) and formic acid (FA) were 
obtained from Biosolve (Valkenswaard, The Netherlands). Calcium chloride (CaCl2) 
and phosphate-buffered saline (PBS) were purchased from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Bovine plasma (500 mL, Sodium Citrated, Sterile 
Filtered, Product Code: S0260) was purchased from Biowest (Nuaillé, France). 
Lyophilized snake venoms were stored at −20 °C. Prior to analysis, the snake 
venoms were dissolved in water at a concentration of 5.0  0.1 mg/mL and then 
diluted in water to the defined concentrations in this study. After analysis, the 
venom solution samples were stored at −80 °C for further use. Antivenoms were 
stored at ~4 °C, according to the manufacturer’s instructions. 
2.2.2. List of venoms and antivenoms included in this study 
All venoms under study and their corresponding antivenoms were provided by 
the Centre for Snakebite Research and Interventions, Liverpool School of Tropical 
Medicine (LSTM, Liverpool, United Kingdom). Suero Antiofidico polyvalente 
(Anti-Botropico, Anti-Crotalico, Anti-Laquesico) was obtained from the Clodomiro 
Picado Institute, University of Costa Rica (San Jose, Costa Rica) and was used as 
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antivenom for B. asper (Costa Rica) venom. Malayan pit viper Antivenin from the 
Queen Saovabha Memorial Institute, The Thai Red Cross Society (Bangkok, 
Thailand) was used for neutralizing C. rhodostoma (Thailand) venom. Antivenin of 
D. acutus against D. acutus (captive bred, China ancestry) venom was sourced from 
the Center for Disease Control, NanKang (TaiPei, Taiwan). Russell’s viper 
antivenin (Thailand) obtained from the Queen Saovabha Memorial Institute, The 
Thai Red Cross Society (Bangkok, Thailand) was used to neutralize D. russelii (Sri 
Lanka) venom. SAIMR Echis antivenom used to neutralize E. ocellatus (Nigeria) 
was sourced from South African Vaccine Producers (PTY) Lid. (Edenvale, South 
Africa). Snake Antivenin IP (Haffkine) for neutralizing E. carinatus (India) venom 
was obtained from the Haffkine Bio-pharmaceutical Corporation Ltd. (Pimpri, 
India). Note that the Indian E. carinatus venom was collected from a single 
specimen that was inadvertently imported to the UK via a boat shipment of stone, 
and then rehoused at LSTM on the request of the UK Royal Society for the 
Prevention of Cruelty to Animals (RCPCA).  
2.2.3. LC-MS nanofractionation 
Venom separation was performed on a Shimadzu UPLC system ('s 
Hertogenbosch, The Netherlands) controlled by the Shimadzu Lab Solutions 
software. For analysis, 50 μL venom solutions were injected by a Shimadzu SIL-
30AC autosampler. The gradient separation was performed on a Waters XBridge 
reverse-phase C18 column (a 4.6 × 250 mm analytical column; with a 3.5 μm 
particle size diameter and a 300 Å pore size) at 30 °C. The column temperature was 
maintained by a Shimadzu CTO-30A column oven. The total solvent flow rate of 
0.5 mL/min was controlled by two Shimadzu LC-30AD parallel pumps. Mobile 
phase A was made up of 98% H2O, 2% ACN and 0.1% FA and mobile phase B was 
98% ACN, 2% H2O and 0.1% FA. The following LC gradient was used for 
separation: a linear increase from 0 to 50% B in 20 min followed by a linear 
increase from 50% to 90% B in 4 min followed by isocratic elution at 90% B for 5 
min. Equilibration was done by a decrease from 90 to 0% B in 1 min followed by 10 
min isocratic elution at 0% B. A 1 to 9 split ratio was implemented after the column 
Antivenom neutralization of coagulopathic snake venom toxins assessed  




of which the 10% fraction of the effluent was sent to a UV detector (Shimadzu 
SPD-M20A Prominence diode array detector) and the 90% fraction was directed to 
a Gilson 235P autoinjector modified into a nanofraction collector controlled by an 
in-house written software Ariadne, or to a FractioMateTM nanofractionator (SPARK-
Holland & VU, Netherlands, Emmen & Amsterdam) controlled by FractioMator 
software (Spark-Holland, The Netherlands, Emmen). The nanofractions were 
collected onto transparent 384-well plates (F-bottom, rounded square well, 
polystyrene, without lid, clear, non-sterile; Greiner Bio One, Alphen aan den Rijn, 
The Netherlands) at a resolution of 6 s/well. After fractionation, the plates with 
venom fractions were dried overnight using a Christ Rotational Vacuum 
Concentrator (RVC 2−33 CD plus, Zalm en Kipp, Breukelen, The Netherlands) in 
combination with a cooling trap at −80 °C. Freeze-dried plates were stored at 
−20 °C until bioassays were performed. 
2.2.4. Plasma coagulation activity assay 
For aliquoting plasma from new bottles, a plasma bottle (500 mL bottle, Sodium 
Citrate, Sterile Filtered; Biowest, Nuaillé, France) stored at −80 °C was warmed up 
in a warm water bath until just fully defrosted and then quickly aliquoted in 15 mL 
CentriStarTM tubes (Corning Science, Reynosa, Mexico), which were immediately 
stored at −80 °C. Prior to performing coagulation activity assays, aliquoted plasma 
was defrosted to room temperature in a warm water bath and then centrifuged at 
2000 rpm (805  g) for 4 min to remove possible particulate matter. The bioassay 
followed the method described recently by Still et al. [10]: A 20 mM CaCl2 solution 
(20 μL per well) at room temperature was pipetted onto a 384-well plate with 
freeze-dried nanofractionated venom fractions using a Multidrop™ 384 Reagent 
Dispenser (Thermo Fisher Scientific, Ermelo, The Netherlands). Then, plasma was 
pipetted into the plate using the same dispenser system (20 μL/well). In the first set 
of experiments, only varying concentrations of nanofractionated venoms were 
analyzed for their coagulopathic effects. For these experiments, where no antivenom 
was added to the incubations, the final assay volume was 40 μL/well. Immediately 
after plasma addition, a kinetic absorbance measurement was performed on a 
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Varioskan™ Flash Multimode Reader (Thermo Fisher Scientific, Ermelo, The 
Netherlands) at a wavelength of 595 nm at 25 °C. The coagulation activity in each 
well was measured kinetically over 100 min. The resulting coagulation curves were 
normalized by dividing each slope value by the median of all the values obtained in 
a single measurement and plotted in several different graphs, that is, the slope of the 
average of the 0–5 min readings for fast coagulation, the slope of the average of the 
0–20 min readings for slightly/medium increased coagulation, and the slope of the 
single reading at 100 min for anticoagulation. Finally, for each coagulopathic 
parameter (anticoagulation, fast coagulation, and extremely fast coagulation), the 
processed values per well were plotted against the chromatographic time of each 
fraction to generate bioactivity chromatograms. Procoagulant activity was plotted in 
two different ways to distinguish the slightly and medium increased coagulation 
velocity from the fast coagulation velocity. In this study, fast coagulation is 
considered full coagulation, resulting in maximum absorbance in the bioassay 
within 5 min. By plotting the slope of the readings from 0 to 5 min only, the slightly 
or medium increased coagulation velocity is not observed, as significant clotting is 
not yet observed. By plotting the slope of the readings from 0 to 20 min, all 
coagulation velocities reaching full coagulation before 20 min display the same 
slope and therefore their real coagulation velocities cannot be distinguished from 
each other.  
To analyze the effect of antivenom on nanofractionated venom components, 
antivenom (10 µL; prepared as different dilutions from the clinically used 
antivenom solutions) was added to all wells of the 384-well plates containing 
freeze-dried nanofractionated venom. The diluted antivenom solutions were diluted 
5, 25, 125 and 625-fold in PBS from the normal clinical concentration. Next, each 
plate was centrifuged for 1 min at 2000 rpm (805  g) using a 5810 R centrifuge 
(Eppendorf, Germany) and then pre-incubated for 30 min at room temperature. 
Following this incubation period, the calcium and plasma solutions were added to 
the plates as described above, and then the plates were measured on the platereader. 
Each fraction was analyzed at least in duplicate. For comparison, to venom-only 
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plates (without any antivenom added), 10 µL PBS was added to each well and pre-
incubated in the same manner as done for the plates where antivenom was added.  
2.2.5. Correlation of coagulation data with MS and proteomics data 
For each procoagulant and anticoagulant peak observed in the bioactivity 
chromatogram, the corresponding accurate mass(es) was extracted from the MS 
chromatogram acquired in parallel. In addition, the proteomics data were also 
available from recent work in our group [24]. To import the proteomics data for the 
venoms included in this study, the fingerprint profile LC-UV traces (measured at 
220 nm, 254 nm and 280 nm) for the same venom analyses acquired in both studies 
were used to align the chromatograms to each other by inspecting potential slight 
retention times differences followed by aligning one of the two chromatograms to 
the other when needed. Then the coagulation bioassay activities from this study 
could be correlated to the MS and proteomics data acquired from the same eluting 
venom toxins analyzed by Slagboom et al. [24]. Specifically, the UV data, 
coagulation bioassay data, MS-Total Ion Current (TIC) and Extracted Ion Current 
(XIC) data in the chromatographic profiles from Slagboom et al. were exactly 
aligned to those in our study, thus allowing for the comparison of all datasets and 
the matching of corresponding accurate masses and proteomics-based venom toxin 
identifications with each coagulation and anticoagulation peak. In this way, accurate 
masses and proteomics-based venom toxin identifications were obtained for most 
coagulation and anticoagulation peaks, without the need to establish these again in 
the present study. The UniprotKB database was used to search for information on 
toxin class and potentially known functions of the relevant toxins. 
2.3. Results 
In this study, a nanofractionation approach was used to evaluate antivenom 
efficacy in neutralizing the coagulopathic properties of individual venom proteins. 
Following LC separation, both the procoagulant and anticoagulant activities of 
venom fractions were assessed using a low volume HTS coagulation bioassay 
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performed in 384-well plates. An assessment of the coagulation activity of each 
venom fraction in the presence of varying concentrations of homologous (i.e., 
species-specific) antivenom was then performed. Coagulopathic activity was 
correlated with the MS and proteomics data obtained in parallel to determine which 
types of venom components were neutralized and if so to what extent. 
Table 1. Correlated LC-UV peaks, LC-MS masses and proteomics data for coagulopathic venom 
toxins (peaks numbers of the pro- and anticoagulant peaks are indicated in Figure 1; CTL = C-Type 
Lectin; PLA2 = Phospholipase A2; SVMP = Snake Venom Metalloproteinase; SVSP = Snake Venom 
























BA 1 19.1 PA2H2_BOTAS 13,714.5646 13,714.56817 PLA2 
BA 2 19.4–20.2 PA2HA_BOTAS 13,912.4649 13,896.51308 PLA2 
BA 2 19.4–20.2 PA2H3_BOTAS 13,765.5812 13,765.58896 PLA2 
BA 3 20.5–20.8 PA2B3_BOTAS 13,957.5333 13,957.48720 PLA2 
BA 3 20.5–20.8 VM2_BOTAS - 53,564 SVMP 
BA 3 20.5–20.8 PA2A2_BOTAS - 14,194 PLA2 
BA 4 20.6 VSPL_BOTAS - 28,019 SVSP 
BA 4 20.6 VM1B1_BOTAS - 45,936 SVMP 
BA 5 21.1–21.3 SLA_BOTAS - 7,084 CTL 








CR 1 19.7–20.5 PA2BD_CALRH 13,665.0848 13,665.0237 PLA2 
CR 1 19.7–20.5 VSPF1_CALRH - 26,570 SVSP 
CR 1 19.7–20.5 SLEA_CALRH - 15,962 CTL 
CR 1 19.7–20.5 SLEB_CALRH - 15,190 CTL 
CR 1 19.7–20.5 PA2AB_CALRH - 14,352 PLA2 
CR 2 19.6–19.7 VSPF2_CALRH - 29,145 SVSP 
CR 3 20.1–20.7 VSPF2_CALRH - 29,145 SVSP 
CR 4 20.8–21.2 VSPF2_CALRH - 29,145 SVSP 
CR 4 20.8–21.2 SLYA_CALRH - 15,796 CTL 
CR 5 21.5–21.7 SLYA_CALRH - 15,796 CTL 






DA 1 20.6–20.9 PA2A_DEIAC - 14,820 PLA2 
DA 1 20.6–20.9 SL_DEIAC - 18,332 CTL 
DA 2 21.3–21.7 SLCB_DEIAC - 17,133 CTL 
DA 2 21.3–21.7 VSP1_DEIAC - 29,480 SVSP 
DA 2 21.3–21.7 VSPA_DEIAC - 26,132 SVSP 
DA 2 21.3–21.7 VM1AC_DEIAC - 47,690 SVMP 
DA 2 21.3–21.7 VM11_DEIAC - 47,845 SVMP 
DA 2 21.3–21.7 VM1H5_DEIAC - 46,518 SVMP 
DA 2 21.3–21.7 VM3AK_DEIAC - 69,752 SVMP 
DA 3 21.8–22.1 VM11_DEIAC - 47,845 SVSP 
DA 3 21.8–22.1 VM1H5_DEIAC - 46,518 SVSP 
DA 4 22.8–23.1 VM3A2_DEIAC - 27,151 SVMP 
DA 4 22.8–23.1 VM3AH_DEIAC - 70,721 SVMP 
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Table 1. (Continuation of table from previous page). Correlated LC-UV peaks, LC-MS  masses and 
proteomics data for coagulopathic venom toxins (peaks numbers of the pro- and anticoagulant peaks 
are indicated in Figure 1; CTL = C-Type Lectin; PLA2 = Phospholipase A2; SVMP = Snake Venom 
Metalloproteinase; SVSP = Snake Venom Serine Protease). The MS data and results originate from 























 DRR 1 18.3–21.7 PA2B8_DABRR 13,587.2248 13,587.2027 PLA2 
DRR 1 18.3–21.7 PA2B5_DABRR - 13,587 PLA2 
DRR 1 18.3–21.7 PA2B3_DABRR - 13,687 PLA2 








      
EC 1 19.6–19.7 PA2A1_ECHCA - 16,310 PLA2 
EC 2 21.9–22.3 - - - - 
EC 3 22.3–22.9 - - - - 







EO 1 19.4–19.8 PA2A5_ECHOC 13,856.1382 13,856.0665 PLA2 
EO 2 21.8–21.9 VM3E2_ECHOC - 69,426 SVMP 
EO 2 21.8–21.9 VM3E6_ECHOC - 57,658 SVMP 
EO 2 21.8–21.9 SL1_ECHOC - 16,601 CTL 
EO 2 21.8–21.9 SL124_ECHOC - 16,882 CTL 
EO 3 22.0–23.1 VM3E6_ECHOC - 57,658 SVMP 
EO 3 22.0–23.1 SL1_ECHOC - 16,601 CTL 
EO 3 22.0–23.1 SL124_ECHOC - 16,882 CTL 
2.3.1. Correlation of coagulopathic toxins to coagulant peaks 
Coagulopathic venom components were correlated to coagulant peaks in each 
snake venom as described in the experimental section. The results are listed in Table 
1. The table contains a numbered identifier for each positive or negative 
coagulopathic peak (these numbers are also given in Figure 1 where they indicate 
the respective peaks) together with Mascot results, accurate mass, toxin class, and 
activity. In multiple venom fractions, more than one venom toxin was assigned due 
to co-elution. Many snake venom PLA2s are known to exert anticoagulant activities 
[25,26]. Identified PLA2s that eluted in anticoagulant bioactivity regions are listed 
in Table 1 including those for which no data on their anticoagulation activity could 
be found in the literature and/or was reported in UniprotKB. The characteristic 
profiles of the UV chromatograms obtained for each venom were used to connect 
the results with MS and proteomics data obtained for the same venoms by 
Slagboom et al. [24]. This way, coagulopathic activities could be linked to accurate 
molecular masses and tentative protein identities. The exact mass data from LC-MS 
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measurements and the proteomics results from the in-well tryptic digests of 
bioactive wells (performed by Slagboom et al. [24]) are presented in Table 1. 
Where no exact mass data could be acquired by LC-MS, the proteomics mass data 
obtained from the Mascot searches are provided. 
2.3.2. Effect of nanofractionated venom toxins on plasma coagulation 
The effect of nanofractionated snake venom proteins on plasma coagulation was 
first studied in a dose-response manner. Reconstructed coagulation bioassay 
chromatograms are shown in Figure 1. For all venoms analyzed, both procoagulant 
and anticoagulant effects were observed at a venom concentration of 1.0 mg/mL. 
The chromatographic retention times of the anticoagulants were within a similar 
time frame as those of the procoagulants, whereas the anticoagulants eluted closely 
together before the procoagulants. An exception was observed for C. rhodostoma 
venom for which the small anticoagulant peak (only observed at the highest venom 
concentration tested) eluted in between the cluster of procoagulant peaks. Some 
coagulopathic activities were observed as several sharp peaks as observed for B. 
asper venom, while other venoms showed only broad peaks in their chromatograms 
such as the anticoagulation activity of D. russelii venom. This broad anticoagulant 
peak most likely represents the bioactivity of multiple closely eluting peaks from 
several peptides and/or enzymes involved in the anticoagulant activity measured. As 
anticipated, when diluting injected venoms, all procoagulant and anticoagulant 
signals were concentration-dependent, i.e., both the height and broadness of the 
positive and negative peaks were reduced with decreasing venom concentrations 
until the signal disappeared. All coagulopathic signals in all tested venoms 
disappeared at a 0.04 mg/mL venom concentration, except for D. russelii venom, 
where the anticoagulant peak was still retained indicating full anticoagulant activity 
at this concentration. Only by further diluting this venom to 0.008 mg/mL we 
observed the disappearance of this potent anticoagulant peak. A detailed description 
of all observed coagulopathic peaks analyzed in duplicate for all venoms and their 
relative potencies are given in the Supporting Information (Section S1). Based on 
results from Slagboom et al. [24], the venom of the Australian elapid snake 
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Figure 1. Reconstructed coagulation chromatograms for B. asper, C. rhodostoma, D. acutus, D. 
russelii, E. carinatus and E. ocellatus venoms after nanofractionation at different concentrations. 
Numbers in the figures represent protein IDs and are listed in Table 1. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
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Oxyuranus scutellatus also displayed potent coagulopathic toxicity. Its effects on 
plasma coagulation and the neutralization efficacy of the corresponding Polyvalent 
Snake Antivenom (Australia-PNG) (CSL Limited, Parkville, Victoria Australia) 
against this venom are presented in the Supporting Information (Section S4). 
2.3.3. Antivenom neutralization potency 
The capability of antivenoms to neutralize nanofractionated snake venom 
proteins involved in modulating plasma coagulation was studied at a venom 
concentration of 1.0 mg/mL. For all venoms the corresponding antivenom was 
analyzed at a minimum of three different concentrations, representing the normal 
clinically used antivenom concentration (undiluted), and the respective 5- and 25-
fold antivenom dilutions. For some venoms, 125- and 625-fold antivenom dilutions 
were also evaluated (Figure 2). For most venoms, both the procoagulant and 
anticoagulant activities decreased with increasing antivenom concentrations. 
Specifically, when analyzed in the presence of undiluted antivenom, all 
coagulopathic signals were neutralized for B. asper, C. rhodostoma and E. ocellatus 
venoms. All procoagulant signals were fully neutralized for the D. acutus, D. 
russelii and E. carinatus venoms, whereas their anticoagulant activities were not 
fully neutralized or not neutralized at all. For the D. acutus and E. carinatus venoms, 
no neutralization of the single sharp anticoagulant peak was observed in their 
anticoagulation chromatograms at any of their respective antivenom concentrations. 
In case of D. russelii venom the anticoagulant neutralization (of the broad 
anticoagulant peak) did occur partly although this is not clearly visible in Figure 2, 
but when testing anticoagulation neutralization by undiluted antivenom using a 5-
times lower D. russelii venom concentration, the neutralization was clearly visible 
(Figure 3). The coagulopathic activities neutralized by undiluted antivenom 
increased with decreasing antivenom concentrations. For both B. asper and E. 
ocellatus venoms, the procoagulant and anticoagulant peaks reappeared at the 25- 
and 5-fold antivenom dilutions, respectively. The procoagulant and anticoagulant 
activities in C. rhodostoma venom reappeared at the 5- and 25-fold antivenom 
dilutions, respectively. For D. acutus, E. carinatus and D. russelii venoms of which 
Antivenom neutralization of coagulopathic snake venom toxins assessed  
by bioactivity profiling using nanofractionation analytics 
49 
C






































































































Figure 2. Coagulation chromatograms showing antivenom neutralization efficacy against 
nanofractionated venom proteins involved in modulating plasma coagulation. B. asper, C. rhodostoma, 
D. acutus, D. russelii, E. carinatus and E. ocellatus venoms analyzed in presence of different 
amounts/concentrations of antivenoms (i.e., no antivenom, x-fold dilution and undiluted antivenom). 
The top superimposed chromatograms are characteristic profiles of UV traces measured at 220, 254 
and 280 nm. 
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the procoagulant activities could be fully neutralized by their respective undiluted 
antivenoms, their procoagulant activity peaks started to appear at a 5-fold 
antivenom dilution for D. acutus and E. carinatus venoms, and at a 125-fold 
antivenom dilution for D. russelii venom. Finally, for the slightly/medium increased 
coagulation activities observed in the D. acutus venom chromatograms, the last two 
positive peaks were fully neutralized at a 25-fold antivenom dilution, while the first 
eluting positive peak was only efficiently neutralized by undiluted antivenom. The 
duplicate bioassay chromatograms and a detailed description of all coagulation 
activities neutralized by their corresponding antivenoms are given in the Supporting 
Information (Section S2). 















Figure 3. Coagulation chromatograms showing antivenom neutralization of venom proteins involved 
in modulating plasma coagulation. Nanofractionated D. russelii venom samples analyzed at 0.2 mg/mL 
(note: for all other antivenom analyses, 1.0 mg/mL venom concentrations were nanofractionated). The 
top superimposed chromatograms are characteristic profiles of UV traces measured at 220, 254 and 
280 nm. 
As shown in Figure 2, the anticoagulant profile for D. russelii venom at 1.0 
mg/mL could not even be neutralized by undiluted Russell’s viper antivenom. 
Therefore, a lower venom concentration (0.2 mg/mL) was subsequently analyzed, 
both with and without undiluted Russell’s viper antivenom (Figure 3). Importantly, 
the Russell’s viper antivenom used here (Russell’s viper antivenom, Thai Red Cross) 
is purified from equine immunoglobulins after hyperimmunization with D. 
siamensis (Thailand) venom, while the venom used in this study is from the sister 
Antivenom neutralization of coagulopathic snake venom toxins assessed  




species D. russelii from Sri Lanka. The nanofractionated D. russelii venom 
displayed a sharp positive procoagulant peak and a broad negative anticoagulant 
peak at a concentration of 0.2 mg/mL, similar to those observed for the 1.0 mg/mL 
venom concentration, but slightly narrower, as expected. In the presence of 
undiluted antivenom, the procoagulant signals disappeared completely while the 
broad anticoagulant negative peak became narrower and smaller, indicating that 
most of the anticoagulant toxicities were neutralized by antivenom under these 
conditions. 
2.3.4. Antivenom cross-reactivity 
While antivenom cross-reactivity for venoms of closely related snake species 
can perhaps be expected (although note our findings with Daboia spp. described 
above), more phylogenetically divergent venoms should display little to no cross-
reactivity [27-29]. The venom of D. russelii showed potent (i.e., large and/or broad 
peaks) pro- and anticoagulant activities. Therefore, this venom was selected to 
evaluate the potential of our method for studying antivenom cross-reactivity, that is, 
evaluating antivenom potencies towards venoms other than their target venoms. Six 
undiluted antivenoms were evaluated against D. russelii venom after 
nanofractionation at a concentration of 1.0 mg/mL (Figure 4a). Our resulting data 
show that Snake Antivenin IP (Haffkine, India) and SAIMR Echis antivenom 
(SAVP, South Africa) can effectively neutralize the coagulopathic components of D. 
russelii venom. No coagulopathic activity was detected in the presence of undiluted 
Snake Antivenin IP and fast coagulation activity was readily neutralized by its 25-
fold dilution (Figure 4b). These findings are perhaps not surprising when 
considering that this antivenom is made using Indian D. russelii venom as one of 
four immunogens. However, the procoagulant activities of D. russelii venom were 
also fully neutralized by undiluted SAIMR Echis antivenom, although a small sharp 
negative anticoagulant peak was still retained. In sharp contrast, “D. acutus 
Antivenin” (CDC, China) and “Suero Antiofidico Polyvalente” (ICP, Costa Rica) 
antivenoms could only partly neutralize the pro-coagulopathic activities observed in 
D. russelii venom, and most anticoagulant peaks were not neutralized. Moreover, 
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both “Malayan pit viper antivenom” (Thai Red Cross, Thailand) and “Polyvalent 
Snake Antivenom” (CSL, Australia) could fully neutralize the fast procoagulant 
activity but could only partially reduce the slightly/medium increased procoagulant 
and anticoagulant activities. 
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Figure 4. Coagulation chromatograms of antivenom cross-reactivity against nanofractionated D. 
russelii venom proteins: (a) The neutralization efficacy of various undiluted antivenoms against 
coagulopathic toxicities was assessed; (b) Snake Antivenin IP was selected and further analyzed at 
different antivenom concentrations. The top superimposed chromatograms are characteristic profiles of 
UV traces measured at 220, 254 and 280 nm. 
Although venom composition similarities might be expected for E. ocellatus and 
E. carinatus, as they both belong to the Echis genus [30-32], studies have shown 
that anti-E. ocellatus antivenom is preclinically ineffective against the venom of E. 
carinatus [33], while clinical studies have shown that using anti-E. carinatus 
antivenoms for treating bites by E. ocellatus result in dramatic increases in patient 
case fatality rates [34]. To explore such complex interactions between these two 
medically important snake venoms and their antivenoms we analyzed the 
neutralization of E. ocellatus coagulotoxins by Snake Antivenin IP and that of E. 
carinatus venom by SAIMR Echis antivenom (anti-E. ocellatus and E. pyramidum) 
were analyzed (Figure 5). Perhaps surprisingly, undiluted Snake Antivenin IP fully 
neutralized the procoagulant and anticoagulant activities in E. ocellatus venom, with 
E. ocellatus venom being more effectively neutralized than E. carinatus venom. 
However, SAIMR Echis antivenom showed limited paraspecificity against the 
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coagulopathic toxicity of E. carinatus venom and could only neutralize its fast 
procoagulant activity, even though it effectively neutralized all activities observed 
in the E. ocellatus venom. These findings suggest that toxins involved in causing 
other pathologies, such as hemorrhage, may be responsible for the described lack of 
clinical efficacy between Indian E. carinatus antivenom and snakebites by E. 
ocellatus. The duplicate chromatograms for SAIMR Echis antivenom vs. E. 
carinatus, Snake Antivenin IP vs. E. ocellatus and Snake Antivenin IP vs. D. 
russelii are presented in the Supporting Information (Section S3). 

































Figure 5. Coagulation chromatograms of antivenom cross-reactivity: (a) SAIMR Echis antivenom 
neutralization of nanofractionated E. carinatus venom toxins; (b) Snake Antivenin IP neutralization of 
nanofractionated E. ocellatus venom toxins. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
2.3.5. Limitations 
As a critical note, although venom toxins are commonly highly stable and 
typically remain active when exposed to organic solvents used in reverse-phase LC, 
some might become (partly) denatured during separation and thereby lose their 
biological activity. This is perhaps most likely the case when considering relatively 
non-polar venom toxins eluting at higher concentrations of organic modifiers (i.e., 
acetonitrile). In contrary to LC-MS and venomics studies, in nanofractionation 
analytics the venom toxins have to survive the analytical separation non-denatured 
in order to perform post-column assays with the separated venom toxins. 
Additionally, the LC eluents have to be compatible with ESI-MS. The currently 
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most efficient LC-MS separations of venoms available rely on trifluoroacetic acid 
(TFA) in the mobile phases for reversed-phase separations. The low pH resulting 
from the ion pairing agent TFA in the eluent, however, results in (partial or full) 
denaturation of certain toxins, particularly larger enzymes, including many pro-
coagulopathic enzymes (data from preliminary studies conducted in our laboratory). 
Additionally, TFA in LC eluents is well known to reduce sensitivity and cause ion 
pairing observed in MS when performing LC-MS with directly coupled ESI-MS to 
the separation. Therefore, our reversed phase separations use formic acid (FA) 
instead when performing nanofractionation analytics. FA renders many venom toxin 
enzymes intact during separation but gives lower resolution and thus peak capacity 
resulting in more venom toxins being not fully separated from each other. As a 
consequence, for bioactive peaks in the bioactivity chromatograms, there are often 
closely eluting overlapping toxin candidates which can be responsible for the 
bioactivity observed. We are currently investigating different MS compatible 
separations and eluent compositions to get (1) high peak capacity, (2) eluted 
enzyme toxins in their native state and, (3) ESI-MS compatibility. 
2.4. Discussion 
Based on the data presented in Table 1 and Figures 2–5 (which show antivenom 
neutralization of nanofractionated venom toxins), we assessed which coagulopathic 
venom protein(s) were efficiently neutralized, and which were less efficiently or not 
neutralized. 
The B. asper anticoagulants (PA2H2_BOTAS and VM2_BOTAS) and 
procoagulants (VSPL_BOTAS, VM1B1_BOTAS and SLA_BOTAS) were 
neutralized by 25-fold dilutions and 5-fold dilutions of the species-relevant 
antivenom Suero Antiofidico polyvalente, respectively. Four B. asper PLA2s 
identified in Mascot searches (PA2H3_BOTAS, PA2HA_BOTAS, PA2B3_BOTAS 
and PA2A2_BOTAS) were matched to anticoagulant peaks, despite the fact that no 
anticoagulant activity has been reported for these enzymes in UniprotKB. However, 
many snake venom PLA2s are known to exert anticoagulant activities [25,26]. The 
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anticoagulant activities of these PLA2s were neutralized but required doses of either 
undiluted or 25-fold dilution of Suero Antiofidico polyvalente antivenom. For C. 
rhodostoma three procoagulant (SLYA_CALRH, SLYB_CALRH and 
VSPF2_CALRH) and four anticoagulant (VSPF1_CALRH, SLEA_CALRH, 
SLEB_CALRH and PA2AB_CALRH) toxins were neutralized by a 25-fold dilution 
and 5-fold dilution of Malayan pit viper antivenom, respectively. The 
PA2BD_CALRH (PLA2) identified from Mascot searches was matched to 
anticoagulant peaks, displays calcium-independent myotoxicity [35] and was 
neutralized by a 5-fold dilution of Malayan pit viper antivenom. The PA2A_DEIAC 
and SL_DEIAC anticoagulants could not be neutralized by Antivenin of D. acutus. 
The VM11_DEIAC, VM1H5_DEIAC, VM3A2_DEIAC and VM3AH_DEIAC 
procoagulants, and the SLCB_DEIAC, VSP1_DEIAC, VSPA_DEIAC, 
VM1AC_DEIAC and VM3AK_DEIAC procoagulants were neutralized by a 25-
fold dilution of and undiluted Antivenin of D. acutus. The PA2B8_DABRR, 
PA2B5_DABRR and PA2B3_DABRR PLA2s were identified as anticoagulants in 
D. russelii venom, and were neutralized by undiluted Snake Antivenin IP antivenom, 
undiluted SAIMR Echis antivenom and undiluted Russell’s viper antivenom, of 
which only PA2B8_DABRR was reported to exhibit anticoagulant activity [36]. 
The PA2A1_ECHCA (PLA2) was assigned as a tentative anticoagulant in the 
proteomics searches, was reported to be non-lethal to mice and devoid of 
neurotoxicity, myotoxicity, hemorrhage, anticoagulant activity and cytotoxicity [37], 
was not neutralized by either undiluted Snake Antivenin IP or SAIMR Echis 
antivenoms. The tentative anticoagulant PA2A5_ECHOC was neutralized by 
undiluted SAIMR Echis antivenom and undiluted Snake Antivenin IP. The 
VM3E2_ECHOC, VM3E6_ECHOC, SL1_ECHOC and SL124_ECHOC 
procoagulants were neutralized by a 5-fold dilution of SAIMR Echis antivenom and 
undiluted Snake Antivenin IP.  
2.5. Conclusions 
The neutralization potency of various antivenoms against the coagulopathic 
activities of (individual) venom toxins from several medically important snake 
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venoms was assessed using a HTS coagulation assay following nanofractionation. 
When antivenoms were tested at their clinically used concentrations, all detected 
coagulopathic activities in B. asper and C. rhodostoma venoms were fully 
neutralized by their corresponding antivenoms. Antivenin of D. acutus was found to 
neutralize the procoagulant activities of the homologous venom, although the 
anticoagulant peaks were only partially neutralized. Surprisingly the Indian 
antivenom, Snake Antivenin IP (Haffkine), could fully neutralize coagulopathic 
toxins of both West African E. ocellatus and Indian E. carinatus venoms, with a 
higher potency against E. ocellatus. Conversely, the African SAIMR Echis 
antivenom was only capable of neutralizing the fast procoagulant activity of E. 
carinatus venom, but was effective against all coagulopathic activities exhibited by 
E. ocellatus venom. Most anticoagulant venom proteins in Sri Lankan D. russelii 
venom could only be neutralized by undiluted Russell’s viper antivenom (Thailand) 
when nanofractionated at a low (0.2 mg/mL), but not at the typically tested (1.0 
mg/mL), concentrations. The Russell’s viper antivenom (Thailand) was, however, 
able to effectively neutralize all procoagulant toxicities caused by this venom. These 
findings suggest that considerable inter-specific differences exist between the 
anticoagulant toxins found in D. russelii and D. siamensis venoms. Almost all 
coagulopathic venom toxins in D. russelii venom were neutralized by the Snake 
Antivenin IP (Haffkine) antivenom, which includes Indian D. russelii venom as an 
immunogen, while the SAIMR Echis antivenom also exhibit some neutralizing 
potency against this paraspecific venom. 
Thus, here we have demonstrated that by applying nanofractionation analytics, 
one can study the neutralization of separated venom toxins by antivenom instead of 
looking solely at crude venoms. As demonstrated in this study, the cross-reactivity 
of antivenoms against separated venom toxins can add great value in terms of 
informing antivenom neutralization capabilities in vitro, although careful 
interpretation of these findings must be applied, as the resulting neutralization 
profiles relate specifically to the bioassay being used, and careful consideration of 
the multifunctionality of snake venoms must be applied. Thus, neutralization of 
coagulopathic toxins may not necessarily mean that an antivenom will be clinically 
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effective. However, by incorporating parallel conducted LC-MS and proteomics 
analyses (using data from Slagboom et al. [24]), we generated tentative 
identifications of the separated bioactive venom toxins thus further informing these 
neutralization profiles. The nanofractionation analytics described herein, therefore, 
serves as a valuable complementary antivenomics tool in antivenom research. 
Furthermore, such analytical approaches are also useful for studying environmental 
pollutants, plant extracts, and metabolic mixtures [38-40]. Ultimately, our data on 
antivenom neutralization can guide future research on the development of next 
generation antivenoms for treating snakebite. The cross-reactivity results are 
valuable for evaluating the potential use of antivenoms on distinct (but related) 
snake species and/or the same snake species from different geographic locations. 
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S1. Effect of nanofractionated venom toxins on plasma coagulation 
The reconstructed coagulation bioassay chromatograms showing the effect of 
individual venom proteins for Bothrops asper (Costa Rica), Calloselasma 
rhodostoma (Thailand), Deinagkistrodon acutus (captive bred, China ancestry), 
Daboia russelii (Sri Lanka), Echis carinatus (India) and Echis ocellatus (Nigeria) 
venoms after nanofractionation at different concentrations are shown in Figure S1. 
In this study, each coagulation bioassay was performed at least in duplicate 
following nanofractionation for assessing reproducibility. In each Figure, the 
bioassay chromatograms depicted on the right which do not have superimposed 
correlated UV data represent replicates of the chromatograms on the left. For each 
venom, the lower series of superimposed bioassay chromatograms represent the 
analyses of fast coagulation for different venom concentrations (1.0 mg/ml being 
the highest concentration tested). The middle set represents slightly/medium 
increased coagulation and the upper series represents anticoagulation. 
When the venoms were analyzed at 1.0 mg/ml, strong positive fast and 
slightly/medium procoagulant peaks were observed for B. asper venom, in addition 
to a clear (full anticoagulation) broad negative peak. This broad negative peak most 
probably represents the bioactivity of multiple closely eluting peaks from several 
peptides and/or enzymes involved in this activity. For both C. rhodostoma and D. 
acutus venoms, strong procoagulant (positive) and moderate anticoagulant (negative) 
peaks were observed. For D. russelii venom, a strong and broad anticoagulant 
activity peak, together with an extensive slightly/medium procoagulant and a 
moderate fast procoagulant peak were observed. E. carinatus venom exhibited a 
similar pattern to B. asper venom, as strong but sharp peaks were observed in the 
fast procoagulant, the slightly/medium procoagulant, and the anticoagulant 
chromatograms. E. ocellatus venom did not display fast procoagulant activity, but 
exhibited significant activity in both the slightly/medium procoagulant and the 
anticoagulant chromatograms.  
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Figure S1. Reconstructed duplicate coagulation bioassay chromatograms for B. asper, C. rhodostoma, 
D. acutus, D. russelii, E. carinatus and E. ocellatus venoms following nanofractionation, analyzed at 
different concentrations. The top superimposed chromatograms are characteristic profiles of UV traces 
measured at 220, 254 and 280 nm. 
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Figure S1. (Continued) Reconstructed duplicate coagulation bioassay chromatograms for B. asper, C. 
rhodostoma, D. acutus, D. russelii, E. carinatus and E. ocellatus venoms following nanofractionation, 
analyzed at different concentrations. The top superimposed chromatograms are characteristic profiles 
of UV traces measured at 220, 254 and 280 nm. 
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Following the dilution of injected venoms, all procoagulant and anticoagulant 
signals decreased until all signals disappeared. For B. asper venom, at a venom 
concentration of 0.2 mg/ml, only a sharp positive peak was observed for both the 
fast procoagulant and the slightly/medium procoagulant activity, while a broad 
negative peak was still apparent at this concentration for the anticoagulant activity, 
despite being much narrower than that observed at 1.0 mg/ml. At a 0.04 mg/ml 
venom concentration, no procoagulant activity was retained, and only a small 
fraction of the initial anticoagulant activity was still observed as a sharp negative 
peak. The C. rhodostoma and E. ocellatus venoms displayed anticoagulant activity 
only at the highest concentration (1.0 mg/ml; 50 µl) and no anticoagulant activity 
was observed after further dilution (at 0.2 mg/ml and 0.04 mg/ml). With regards to 
procoagulant activity, two broad fast procoagulant and slightly/medium 
procoagulant peaks were observed at 1.0 mg/ml for C. rhodostoma, which narrowed 
to one sharp positive peak upon dilution, implying that one or several very closely 
eluting procoagulants are responsible for the majority of procoagulant effects 
observed in this venom; for E. ocellatus, the slightly/medium procoagulant activity 
disappeared at 0.04 mg/ml, while the fast procoagulant activity was not detected for 
any of the analyzed venom concentrations. The sharp and weak anticoagulant 
activity observed for D. acutus venom was only observed at the 1.0 and the 0.2 
mg/ml venom concentrations, disappearing after further dilution to 0.04 mg/ml. No 
slightly/medium procoagulant peaks were observed after further dilution. A weak 
but sharp positive peak was noted at 0.2 mg/ml for fast procoagulation, and no 
activity was observed at the 0.04 mg/ml venom concentration. The E. carinatus 
venom showed a similar anticoagulant activity profile as E. ocellatus venom at the 
highest concentration, and the activity was also observed at a 0.2 mg/ml venom 
concentration, but disappeared at 0.04 mg/ml. All procoagulant peaks in E. 
carinatus disappeared at a venom concentration of 0.2 mg/ml. The remarkably 
strong and broad anticoagulant activity (negative) peak observed in D. russelii 
venom at 1.0 mg/ml remained roughly unchanged at 0.2 mg/ml, and only at a 25-
fold venom dilution (0.04 mg/ml) did the anticoagulant peak become narrower, yet 
still retained full anticoagulant activity, which was lost at 0.008 mg/ml. However, 
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no fast procoagulant activity was observed at 0.2 mg/ml, while a weak but sharp 
slightly/medium procoagulant (positive) peak was retained. This positive peak 
disappeared in subsequent dilutions.  
S2. Antivenom neutralization potency  
Reconstructed coagulation bioassay chromatograms showing antivenom 
neutralization potencies against nanofractionated venom proteins involved in 
modulating plasma coagulation for B. asper, C. rhodostoma, D. acutus, D. russelii, 
E. carinatus and E. ocellatus venoms are depicted in Figure S2. Venoms were 
nanofractionation at a concentration of 1.0 mg/ml for all analyses. For B. asper 
venom, in the venom-only chromatogram (10 µl PBS solution was added before 
pre-incubation and is shown as “no antivenom” in the graphs), three sharp positive 
peaks were observed for the fast coagulation activity profile. One intense sharp 
positive peak followed by a relative broad intense positive peak were detected for 
the slightly/medium increased coagulation activity. A sharp negative peak followed 
by a broad negative peak and another sharp negative peak were observed in the 
anticoagulation activity chromatogram. For the undiluted antivenom trace, all the 
signals observed in the venom-only sample disappeared, indicating that all 
coagulopathic activities were neutralized by the antivenom. For the 5-fold 
antivenom dilution, the procoagulant fractions did not show any activity peaks. In 
the anticoagulation chromatogram however, the broad negative peak appeared as a 
sharp and weak negative peak, while the two sharp negative peaks were not 
observed. By further decreasing the antivenom concentration to a 25-fold dilution, 
two positive peaks were retained in both the fast coagulation and the 
slightly/medium increased coagulation activity chromatograms, while the third 
positive peak remained fully neutralized. Furthermore, in the anticoagulation 
chromatogram, the first sharp negative peak was still fully neutralized, and only the 
broad negative peak, followed by a sharp negative peak, were observed. For C. 
rhodostoma venom, two positive peaks were observed for the fast coagulation 
activity and three positive peaks for the slightly/medium increased coagulation 
activity in the venom-only analysis; no activity was detected for the undiluted 
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antivenom trace, as all the detected coagulopathic toxicity peaks were fully 
neutralized. Only the first eluted positive peak could be observed at a 5-fold 
antivenom dilution analysis both in fast coagulation chromatograms and in 
slightly/medium increased coagulation chromatograms, while all other positive 
peaks were fully neutralized. For the 25-fold antivenom dilution, the two fast 
procoagulant peaks appeared weaker and sharper than those in the venom-only 
chromatogram; two positive peaks were now detected for the slightly/medium 
increased coagulation activity, while the third positive peak was still fully 
neutralized. Furthermore, for the anticoagulation activity, two negative peaks were 
observed in the venom-only trace and both activities were fully neutralized by 
undiluted or 5-fold diluted antivenom. The weak negative peak observed in the 
venom-only analysis was still neutralized by a 25-fold antivenom dilution, while the 
strong negative peak was retained. For D. acutus venom, in the case of the undiluted 
concentration antivenom analysis, all procoagulant activities were neutralized. 
Many positive peaks representing procoagulant activity were fully neutralized both 
at the 5- and 25-fold antivenom dilutions. One positive peak decreased with 
increasing antivenom concentrations in a concentration-dependent manner. In the 
125-fold antivenom dilution profile, procoagulant signals were observed, but were 
weaker compared to the venom-only analysis. In contrast to the efficient 
neutralization of the procoagulant peaks, the sharp but significant negative signal 
representing anticoagulant proteins could not even be neutralized by undiluted 
antivenom. Only the first weak negative peak present in the venom-only trace 
disappeared at the 125-fold antivenom dilution, while the third negative peak in 
venom-only chromatogram disappeared only following incubation with undiluted 
antivenom. For D. russelii venom, the venom-only trace displayed a positive peak 
in the fast coagulation chromatogram and an intense positive peak in the 
slightly/medium increased activity chromatogram. A broad and strong negative 
activity peak was observed in the anticoagulation chromatogram. The procoagulant 
signals were fully neutralized by undiluted antivenom while the extensive and 
strong anticoagulant activity was not neutralized at all. By decreasing the antivenom 
concentration, the fast coagulation activity was neutralized up to the 625-fold 
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antivenom dilution, while the slightly/medium increased coagulation activity was 
apparent at the 125-fold antivenom dilution. For E. carinatus venom, the sharp 
anticoagulant activity was not neutralized, while the procoagulant activity was fully 
neutralized by undiluted antivenom. There were two positive peaks indicating fast 
coagulation activity, the weak peak was neutralized by the 5- and 25-fold antivenom 
dilutions, while the strong positive peak was not. A weak positive peak followed by 
a strong and broad positive peak and a sharp positive peak were detected in the 
venom-only trace in the slightly/medium increased coagulation chromatogram; the 
front weak and the tailing sharp positive peaks were readily neutralized by a 25-fold 
antivenom dilution, while the broad positive peak was retained and split into three 
sharp positive peaks with a lower total intensity than that measured in the venom-
only analysis; of these three sharp positive peaks, only one was observed when 
incubating with a 5-fold antivenom dilution. For E. ocellatus venom, all 
procoagulant and anticoagulant toxicities were fully neutralized by undiluted 
antivenom. The procoagulant toxicities were also fully neutralized by a 5-fold 
antivenom dilution, whereas the anticoagulant toxicities were only partly 
neutralized. For the 25-fold antivenom dilution analysis, the slightly/medium 
increased coagulation activity neutralized most coagulopathic toxicities, while the 
fast coagulation and the anticoagulation chromatograms displayed a slight decrease 
in total activity when compared to that in the venom-only analysis. 
Duplicate analysis results showing neutralization by undiluted Russell’s viper 
antivenom (Thailand) of D. russelii (Sri Lanka) venom nanofractionated at a 0.2 
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Figure S2. Duplicate chromatograms for antivenom neutralization of nanofractionated venom proteins 
involved in modulating plasma coagulation for B. asper, C. rhodostoma, D. acutus, D. russelii, E. 
carinatus and E. ocellatus venoms. The top superimposed chromatograms are characteristic profiles of 
UV traces measured at 220, 254 and 280 nm. 
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Figure S2. (Continued) Duplicate chromatograms for antivenom neutralization of nanofractionated 
venom proteins involved in modulating plasma coagulation for B. asper, C. rhodostoma, D. acutus, D. 
russelii, E. carinatus and E. ocellatus venoms. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
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Figure S3. Duplicate chromatograms of 0.2 mg/ml nanofractionated D. russelii venom showing 
antivenom neutralization of venom proteins involved in modulating plasma coagulation (note: for all 
other antivenom experiments, 1.0 mg/ml venom concentrations were nanofractionated). The top 
superimposed chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 
nm. 
S3. Antivenom cross-reactivity 
The results of duplicate analyses for antivenom cross-reactivity - SAIMR Echis 
antivenom vs E. carinatus, Snake Antivenin IP vs E. ocellatus and Snake Antivenin 
IP vs D. russelii - are shown in Figure S4. All venoms were nanofractionated at a 
concentration of 1.0 mg/ml. In the SAIMR Echis antivenom vs E. carinatus 
chromatograms, only the fast coagulation toxicities were fully neutralized by 
undiluted antivenom, while most of the positive peaks in the slightly/medium 
increased coagulation chromatogram were inhibited. The broad positive peak 
observed for the slightly/medium increased coagulation activity was reduced to a 
sharp positive peak, while the sharp but significant negative signal for the 
anticoagulation activity could not be neutralized at any antivenom concentration. By 
decreasing the antivenom concentration, the fast coagulation activity reappeared at 
the 5-fold antivenom dilution, while the weak and sharp positive peak observed in 
the venom-only analysis for fast coagulation was still fully neutralized by a 25-fold 
antivenom dilution. The activity of the sharp positive peak observed in the 
slightly/medium increased coagulation chromatogram in the undiluted antivenom 
analysis increased with decreasing antivenom concentrations. Conversely, both the 
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Figure S4. Duplicate bioassay chromatograms of evaluating antivenom cross-reactivity in neutralizing 
venom components involved in modulating plasma coagulation for SAIMR Echis antivenom vs E. 
carinatus, Snake Antivenin IP vs E. ocellatus and Snake Antivenin IP vs D. russelii. The top 




first eluted and the last eluted sharp positive peaks present in the venom-only 
analysis for the slightly/medium increased coagulation activity were still fully 
neutralized by the 25-fold antivenom dilution. 
In the Snake Antivenin IP vs E. ocellatus chromatograms, the Snake Antivenin 
IP was indeed able to neutralize the coagulant activity of E. ocellatus for which a 
clear concentration-dependence was observed. In the undiluted antivenom trace, no 
activity could be detected, implying that all measurable coagulopathic toxicities 
were fully neutralized. By decreasing the antivenom concentration, the 
coagulopathic activities started to appear, showing very weak activity for the 5-fold 
antivenom dilution, which increased at the 25-fold dilution. 
When assessing the efficacy of Snake Antivenin IP vs D. russelii venom, all 
toxicities were fully neutralized by undiluted Snake Antivenin IP, as opposed to the 
antivenom analysis using Russell’s viper antivenom (Thailand), where the 
procoagulant but not the anticoagulant toxicities were neutralized (as discussed 
above in section S2). Moreover, by decreasing the concentration of Snake Antivenin 
IP, the fast coagulation activity reappeared at the 125-fold antivenom dilution. For 
the slightly/medium increased coagulation profile, the peak intensity showed a clear 
concentration-dependence, for which only a weak positive peak appeared at the 5-
fold antivenom dilution. The procoagulant peak intensity became stronger by 
further decreasing the antivenom concentration 25-fold and again when decreasing 
it 125-fold. Moreover, the broad negative anticoagulant peak became sharper and 
changed into several non-baseline separated negative peaks at the 5-fold antivenom 
dilution, while stronger negative peaks were apparent at the 25-fold dilution. When 
using the 125-fold antivenom dilution, the results were similar to those of the 
venom-only analysis, implying that at this antivenom concentration no significant 
neutralization effects were observed. 
S4. Coagulopathic properties of the Australian elapid venom Oxyuranus 
scutellatus and corresponding antivenom neutralization 
Both the plasma coagulation modulating activities of O. scutellatus venom and 
the neutralization capability of Polyvalent Snake Antivenom (Australia-PNG) 
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against nanofractionated O. scutellatus venom proteins were studied in a dose-
response manner. The antivenom used to neutralize O. scutellatus venom, 
Polyvalent Snake Antivenom (Australia-PNG), was acquired from CSL Limited, 
Parkville, Victoria Australia. The duplicated reconstructed coagulation bioassay 
chromatograms are shown in Figures S5 and S6. In the venom activity 
chromatograms, a strong and broad anticoagulant peak was apparent, but no 
procoagulant peaks were observed at a concentration of 1.0 mg/ml. Slagboom et al. 
did identify several procoagulant peaks while analyzing O. scutellatus venom, but 
analyzed this venom at a 5-fold higher concentration (i.e. 5.0 mg/ml venom) than 
the highest concentration tested in this study (i.e. 1.0 mg/ml venom) [1]. By 
decreasing the venom concentration, the strong and broad anticoagulant signals 
became narrower and sharper, splitting into multiple non-baseline negative peaks, 
but they were still apparent as a sharp negative peak at the 0.04 mg/ml venom 
concentration tested. No activity was observed anymore at the nanofractionation 
analysis of the low venom concentration of 0.008 mg/ml. In the presence of 
antivenom, the anticoagulant peaks were visualized as separate negative peaks, with 
increasing antivenom concentrations resulting in a reduction in the height of first 
cluster of negative peaks and eventually in their disappearance. Conversely, the 
second cluster of negative peaks was significantly reduced but not completely 
abolished, even in the presence of undiluted antivenom. From proteomics data 
retrieved from Slagboom et al. for O. scutelatus venom, VKT_OXYSC and 
VKT3_OXYSC, classified as the Kunitz-type serine protease inhibitor taicotoxin 
and scutellin-3, respectively, were identified as anticoagulant proteins. These are 
both serine protease inhibitors and VKT_OXYSC can inhibit factor Xa and α-factor 
XIIa. From the MS data, an m/z value of 788.16419+ with a corresponding mass of 
6993.2858 Da could be matched to VKT_OXYSC and an m/z value of 1091.80426+ 
with a corresponding mass of 6536.8065 could be matched to VKT3_OXYSC. As 
these masses are in the range of the three-finger toxin family of proteins, it is likely 
that these toxins coeluted with other venom toxins that have anticoagulant 
properties. Moreover, PA2TA_OXYSC (PLA2), PA2TB_OXYSC (PLA2), 
PA21_OXYSC (PLA2) and PA2TC_OXYSC (PLA2) were also recovered from 
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Mascot searches. These toxins are PLA2s, but with no assigned anticoagulation 
activity. The PA2TA_OXYSC (PLA2) and PA2TB_OXYSC (PLA2) were reported 
as neurotoxins [2,3], and the PA2TA_OXYSC (PLA2) can also catalyze the Ca
2+-
dependent hydrolysis of 2-acyl groups in 3-sn-phosphoglycerides [2]. 


























Figure S5. Reconstructed duplicate coagulation bioassay chromatograms of the Elapid venom of O. 
scutellatus after nanofractionation, analyzed at different concentrations. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
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Figure S6. Duplicate bioassay chromatograms showing antivenom neutralization of nanofractionated 
O. scutellatus venom proteins involved in modulating plasma coagulation. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
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Phospholipase A2 (PLA2) enzymes are important toxins found in many snake 
venoms, and they can exhibit a variety of toxic activities including causing 
hemolysis and/or anticoagulation. In this study, the inhibiting effects of the small 
molecule PLA2 inhibitor varespladib on snake venom PLA2s was investigated by 
nanofractionation analytics, which combined chromatography, mass spectrometry 
(MS), and bioassays. The venoms of the medically important snake species 
Bothrops asper, Calloselasma rhodostoma, Deinagkistrodon acutus, Daboia 
russelii, Echis carinatus, Echis ocellatus, and Oxyuranus scutellatus were separated 
by liquid chromatography (LC) followed by nanofractionation and interrogation of 
the fractions by a coagulation assay and a PLA2 assay. Next, we assessed the ability 
of varespladib to inhibit the activity of enzymatic PLA2s and the coagulopathic 
toxicities induced by fractionated snake venom toxins, and identified these bioactive 
venom toxins and those inhibited by varespladib by using parallel recorded LC-MS 
data and proteomics analysis. We demonstrated here that varespladib was not only 
capable of inhibiting the PLA2 activities of hemotoxic snake venoms, but can also 
effectively neutralize the coagulopathic toxicities (most profoundly anticoagulation) 
induced by venom toxins. While varespladib effectively inhibited PLA2 toxins 
responsible for anticoagulant effects, we also found some evidence that this 
inhibitory molecule can partially abrogate procoagulant venom effects caused by 
different toxin families. These findings further emphasize the potential clinical 
utility of varespladib in mitigating the toxic effects of certain snakebites. 
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Phospholipases A2 (PLA2s) are key enzymes involved in many events in cellular 
signaling and act by cleaving ester bonds in phospholipids to generate fatty acids 
(hydrolysis reactions) [1-3]. They are pervasive in the mammalian pancreas and are 
highly abundant in many animal venoms [4,5]. Venom PLA2 enzymes show a wide 
variety of functional activities, and thus can contribute to several distinct 
pathologies in envenomed prey/people, as well as potentially helping with prey 
digestion [4,5]. They are recognized as the most thoroughly investigated venom 
toxins both in hemotoxic and neurotoxic snake venoms [6,7]. Snake venom PLA2s 
are capable of contributing to presynaptic and/or postsynaptic neurotoxicity, 
myotoxicity, and cardiotoxicity, which can induce platelet aggregation disorders, 
hemolysis, anticoagulation, convulsions, hypotension, edema, and necrosis [4,5,8]. 
They play an important role in contributing to the morbidity and mortality of 
snakebite victims, via paralysis and destruction of respiratory muscle tissues, and/or 
due to their effect on homeostatic mechanisms involved in coagulation and oxygen 
transport [9]. Although snakebite envenoming is a severe medical problem that was 
recently added to the World Health Organization (WHO) list of Neglected Tropical 
Diseases [10], it has for a long time been systematically neglected by governments 
worldwide, despite over 100,000 people dying annually [11]. Although current 
snakebite treatments, known as antivenoms (equine/ovine polyclonal antibodies), 
can be effective therapies capable of reducing morbidity and mortality, they have 
many limitations associated with them, leaving a critical therapeutic gap between 
snakebite and effective treatment [6,12]. Small molecule toxin inhibitor-based 
approaches are gaining much traction as promising alternatives and/or 
complementary treatments for snakebite [12-16], as they show a number of 
characteristics desirable for use as either early prehospital or adjunct therapies [13]. 
Varespladib is an indole-based nonspecific pan-secretory PLA2 (sPLA2) inhibitor 
that potently inhibits mammalian sPLA2-IIa, sPLA2-V, and sPLA2-X, and in 
addition has been shown to inhibit venom PLA2 toxins [17-20]. Varespladib was 
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originally found to reduce PLA2 concentrations in vivo, making it a candidate 
treatment for several cardiovascular diseases [17,21,22], including the treatment of 
acute coronary syndrome and systemic inflammatory response syndrome, but it was 
abandoned during Phase III clinical trials due to lack of efficacy [17,23-25]. 
Recently, varespladib was repurposed for exploration as a potential therapeutic 
candidate for snakebite, with early findings showing that varespladib and its orally 
bioavailable prodrug methyl-varespladib effectively suppress venom-induced PLA2 
activity both in vitro and in vivo [9]. Moreover, varespladib effectively reduces 
hemorrhage, edema, myonecrosis, and neurotoxicity in mice caused by venoms of 
several medically important snakes, and as such is a potential prereferral drug 
candidate for treating snakebites [25-28]. In addition to varespladib, the orally 
available prodrug methyl-varespladib is effective in inhibiting neurotoxicity, 
reversing neuromuscular paralysis, delaying or abrogating lethality, both 
immediately after envenoming and after onset of symptoms [25,28,29]. In 
combination, these studies have highlighted the great potential of varespladib as an 
orally available small molecule drug for use as a rapid snakebite intervention.  
Consequently, in this study we aimed to investigate which specific venom 
components can be inhibited by varespladib, with a focus on snake venoms that 
cause coagulopathic effects. Venoms from the medically relevant snake species 
Bothrops asper, Calloselasma rhodostoma, Deinagkistrodon acutus, Daboia 
russelii, Echis carinatus, Echis ocellatus, and Oxyuranus scutellatus were separated 
by liquid chromatography (LC) followed by high resolution fractionation 
(nanofractionation) onto 384-well plates allowing bioassaying of individual 
fractions for PLA2 and coagulation activities. Then, the potential inhibition of the 
detected activities by varespladib was evaluated and the toxins were identified by 
correlating parallel obtained mass spectrometry (MS) with proteomics data. Our 
findings show that varespladib is effective in inhibiting enzymatic activities of 
venom PLA2s as well as inhibiting coagulopathic toxins (of which many were 
tentatively identified as venom PLA2s). 
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Water was purified using a Milli-Q Plus system (Millipore, Amsterdam, The 
Netherlands). Acetronitrile (ACN) (HPLC grade) and formic acid (FA) were 
purchased from Biosolve (Valkenswaard, The Netherlands). Calcium chloride 
(CaCl2, Dihydrate, ≥ 99%), NaCl, KCl, Tris base, Phosphate buffered saline (PBS) 
tablets, Triton X-100, L-a-Phosphatidylcholine, Varespladib (A-001, LY315920), 
and Cresol red were obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Bovine plasma was obtained from Biowest (Nuaillé, France) and stored at −80 °C 
until use. Pooled venoms from B. asper (Costa Rica “Atlantic”), C. rhodostoma 
(captive bred, Thailand ancestry), D. acutus (captive bred, China ancestry), D. 
russelii (Sri Lanka), E. carinatus (India), E. ocellatus (Nigeria), and O. scutellatus 
(Papua New Guinea) were obtained from animals maintained in, or from the 
historical venom collection of, the Centre for Snakebite Research and Interventions, 
Liverpool School of Tropical Medicine (UK). These freeze-dried venoms were 
dissolved in water to a concentration of 5.0  0.1 mg/mL and stored at −80 °C until 
use. PBS was prepared by dissolving PBS tablets in water according to the 
manufacturer’s instructions and stored at 4 °C for no longer than seven days. 
Varespladib was dissolved in DMSO (≥ 99.9%, Sigma-Aldrich, Zwijndrecht, The 
Netherlands) and stored at −20 °C. Prior to use, this varespladib stock solution was 
diluted in PBS to the required concentrations. 
3.2.2. LC with parallel nanofractionation and MS detection 
Venom toxins were separated on a Shimadzu UPLC system ('s Hertogenbosch, 
The Netherlands) which was controlled by the Shimadzu Lab Solutions software. 
Venom solutions were diluted to 1.0 mg/mL in MilliQ water of which 50 µL was 
injected by a Shimadzu SIL-30AC autosampler. A Waters XBridge reverse-phase 
C18 column (4.6 × 250 mm column with a 3.5 μm particle size and a 300 Å pore 
size) was used under gradient elution at 30 °C. The temperature of the column was 
controlled by a Shimadzu CTO-30A column oven. By using two Shimadzu LC-
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30AD parallel pumps, the total solvent flow rate was maintained at 0.5 mL/min. 
Mobile phase A consisted of 98% H2O, 2% ACN, and 0.1% FA, while mobile phase 
B was composed of 98% ACN, 2% H2O, and 0.1% FA. The eluent was made by 
mixing mobile phase A and B in a mixing unit with a total volume of 2.5 ml causing 
a 5-min dwell time. For gradient elution, mobile phase B was increased linearly 
from 0% to 50% in 20 min, then from 50% to 90% in 4 min. After reaching 90%, 
the flow rate of mobile phase B was kept at 90% for 5 min. For reconditioning, the 
mobile phase B was decreased from 90% to 0% in 1 min and kept at 0% for 10 min. 
The column effluent was split into two parts (9:1) of which the 10% fraction was 
sent to a UV detector (Shimadzu SPD-M20A Prominence diode array detector) 
while the remaining 90% was directed to a nanofraction collector. This was either a 
modified Gilson 235P autosampler programmed for nanofractionation and 
controlled by the in-house written software Ariadne, or a commercially available 
FractioMateTM nanofractionator (SPARK-Holland and VU, Netherlands, Emmen 
and Amsterdam) controlled by the FractioMator software. Fractions were collected 
onto transparent 384-well plates (F-bottom, rounded square well, polystyrene, no lid, 
clear, non-sterile; Greiner Bio One, Alphen aan den Rijn, The Netherlands) at a 
resolution of 6 s/well. The plates with collected fractions were subsequently dried 
overnight using a Christ Rotational Vacuum Concentrator (RVC 2−33 CD plus, 
Zalm en Kipp, Breukelen, The Netherlands) equipped with a −80 °C cooling trap 
during the vacuum-drying process. The evaporated plates were stored at −20 °C 
until further use. 
3.2.3. Phospholipase A2 activity assay 
The PLA2 activity assay was carried out according to the method recently 
reported by Still et al. [30] using cresol red as a pH indicator. The PLA2 assay 
monitors the decrease in pH caused by the enzymatic conversion of L-a-
Phosphatidylcholine to fatty acids. The assay solution was prepared freshly by 
dissolving NaCl (100 mM, final concentration), KCl (100 mM), CaCl2 (10 mM), 
Triton X-100 (0.875 mM), cresol red (0.02 mg/mL), and L-a-Phosphatidylcholine 
(0.875 mM) in a Tris buffer (1.0 mM, pH 8.0). The pH of the bioassay solution was 
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checked prior to each run and adjusted to pH 8.0 by HCl if needed. For 
measurements, 40 µL of the assay solution was rapidly pipetted into each well of a 
vacuum-centrifuge-dried 384-well plate with venom fractions using a VWR 
Multichannel Electronic Pipette (10–200 µL; VWR International B.V., Amsterdam, 
The Netherlands) and a kinetic absorbance measurement at 572 nm was initiated 
immediately at room temperature using a platereader (Varioskan™ Flash 
Multimode Reader, Thermo Fisher Scientific, Ermelo, The Netherlands). Kinetic 
measurements were collected over 40 min, and the PLA2 activity in each well was 
normalized by dividing the slope obtained for each well by the median of all the 
slope values obtained across the plate. For investigating PLA2 inhibition by 
varespladib, 10 µL aliquots of various concentrations varespladib (final 
concentrations of 20, 4, and 0.8 μΜ) were pipetted into each well of freeze-dried 
384-well plates using a VWR Multichannel Electronic Pipette. Thereafter, the plates 
were centrifuged for 1 min at 805 × g (2000 rpm) in a 5810 R centrifuge (Eppendorf, 
Germany) to remove potential air bubbles formed during the automated pipetting 
process, and then pre-incubated for 30 min at room temperature. Next, the PLA2 
assay solutions were added as described above, and platereader measurements were 
initiated. For comparison, 10 µL of PBS were added to each well and pre-incubated 
in the same manner as for the control experiments (indicated as PBS in the Figures). 
All analyses were performed in at least duplicate. 
3.2.4. Plasma coagulation activity assay 
In-house aliquoted plasma was stored in 15 mL CentriStarTM tubes (Corning 
Science, Reynosa, Mexico) at −80 °C. For preparing the aliquots, a 500 mL bottle 
of sodium citrate plasma (Sterile Filtered; Biowest, Nuaillé, France) stored at 
−80 °C was warmed in warm water until fully defrosted, after which the plasma was 
quickly aliquoted in 15 mL CentriStarTM tubes, which were then immediately frozen 
at −80 °C, and stored until use. Prior to use, the 15 mL CentriStarTM tubes were 
defrosted to room temperature in a warm water bath and then centrifuged at 805 × g 
(2000 rpm) (AllegraTM X-12 Centrifuge, Beckman Coulter) for 4 min to remove 
possible particulate matter. 
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For the coagulation assay, we followed our previously described approach 
[31,32]. Briefly, 20 µL CaCl2 solution (20 mM) was pipetted into each well of a 
freeze-dried plate using a Multidrop™ 384 Reagent Dispenser (Thermo Fisher 
Scientific, Ermelo, The Netherlands). This was followed by pipetting 20 µL of 
centrifuged plasma using the same Multidrop™ 384 Reagent Dispenser (after in-
between rinsing the Multidrop with Milli-Q). Next, absorbance at 595 nm was 
monitored kinetically at room temperature on a platereader (Varioskan™ Flash 
Multimode Reader, Thermo Fisher Scientific, Ermelo, The Netherlands). 
Measurements were collected over 100 min, and the slope of each well was 
normalized by dividing the slope measured in each well by the median of all slope 
values across the plate. The slope of the average 0–5 min reading was used for 
depicting very fast coagulation, whereas the slope of the average 0–20 min reading 
denoted slightly/medium increased coagulation. The slope of the single reading at 
100 min was used to depict anticoagulation activity. Detailed explanations on the 
rationale of processing and plotting the data in this way are provided in [32,33]. 
To investigate whether varespladib was capable of inhibiting coagulopathic 
venom activity, 10 µL of various concentrations of the varespladib solution were 
added to each well of a freeze-dried 384-well plate (10 µL of PBS was added to the 
venom-only control). For all bioassay pipetting steps, a VWR Multichannel 
Electronic Pipette was used. The final concentrations of varespladib in the 
coagulation bioassay were 20, 4, and 0.8 μΜ (and in some cases also 0.16 and 0.032 
μM). Directly after pipetting the varespladib solutions, plates were centrifuged for 1 
min at 805 × g (2000 rpm) using a 5810 R centrifuge (Eppendorf, Germany) and 
then pre-incubated for 30 min at room temperature. Meanwhile, the plasma 
coagulation activity assay solutions were prepared as described above and added to 
the plates after the pre-incubation step, after which the plates were measured on the 
platereader. All analyses were performed in at least duplicate. 
3.2.5. Correlation of biological and MS data 
In our previous study [33], the same snake venoms as currently studied were 
analyzed using the nanofractionation approach, yielding accurate mass(es) of 
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eluting venom toxins by MS and coagulopathic activities of fractions in parallel. In 
addition, proteomics data were acquired by an in-well tryptic digestion of the 
content of the wells that showed bioactivity followed by the LC-MS/MS analysis. 
The acquired MS and proteomics data [33] was also used for the current study in 
order to avoid time-consuming re-measuring of samples and processing of the same 
data. The UniprotKB database was used to search for information on the class and 
possible known functions of relevant toxins. Correlation of the chromatographic 
LC-UV data acquired in the present study with the corresponding data obtained in 
the previous study [33] to negotiate the retention time shifts, permitted the bioassay 
data generated in this study to be correlated with the MS and proteomics data 
previously obtained [33]. In order to identify potential molecular masses of 
bioactive toxins, firstly for each peak found in the bioassay trace, a mass spectrum 
was extracted by averaging the recorded spectra in the LC-MS trace over the 
corresponding time width at half maximum/minimum of the bioactive peak. Then, 
from all the detected ions in the average mass spectrum, extracted-ion 
chromatograms (XICs) were plotted. For XICs showing a peak shape and retention 
time matching to the bioactive peak under consideration, the corresponding m/z 
value was assigned to the bioactive compound. Finally, the deconvolution option in 
the MS software was used to determine the accurate monoisotopic masses of the 
bioactive compound. 
3.3. Results and discussion 
In this study, a nanofractionation approach was used to evaluate the effects of 
varespladib on inhibiting PLA2 enzymatic activity and coagulopathic properties of 
individual venom toxins. After LC fractionation of venoms in 384-well plates, both 
the PLA2 enzymatic activities and the clotting activities of the individual venom 
fractions were evaluated. The inhibition of the measured venom toxin activities was 
assessed under different varespladib concentrations, and each active fraction 
detected was correlated with MS and proteomics data obtained in parallel to 
determine the identity of inhibited venom toxins. 
Chapter 3 
86 
3.3.1. PLA2 bioactivity profiles of nanofractionated venom toxins 
The PLA2 activity profiles of the snake venoms obtained after LC fractionation 
are shown as bioactivity chromatograms in Figure 1. Both O. scutellatus and E. 
carinatus venoms displayed relatively sharp peaks (two at 23.0 and 24.6 min for O. 
scutellatus and one at 23.6 min for E. carinatus). Conversely, D. russelii venom 
exhibited a broad and clear PLA2 activity peak (23.8–26.8 min), while B. asper 
displayed two closely eluting peaks (24.1 and 25.1 min) of which the first one (24.1 
min) was observed close to the background level and the latter eluting peak (25.1 
min) was distinctive and broad. For the other three venoms (E. ocellatus, D. acutus, 
and C. rhodostoma), no clear PLA2 bioactivity was observed at the analyzed venom 
concentration (1.0 mg/mL). All PLA2 bioactivity chromatograms resulting from 
duplicate measurements are presented in the Supporting Information (Section S1). 









Figure 1. Phospholipase A2 (PLA2) bioactivity chromatograms of nanofractionated venom toxins. 
Positive peaks indicate PLA2 activity. 
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3.3.2. Coagulopathic bioactivity profiles of nanofractionated venom toxins 
The coagulopathic bioactivities of nanofractionated venom components are 
shown in Figure 2. Most of the venoms displayed both pro and anticoagulant 
activities, except for the venom of O. scutellatus, for which only anticoagulant 
activity was observed. Note that during chromatographic separations under 
reversed-phase conditions non-stable toxin complexes and large toxins can denature, 
which could explain the lack of procoagulation observed for O. scutellatus, but a 
recent study demonstrated that higher venom concentrations were required to 
observe this effect with this venom after nanofractionation (i.e., 5.0 instead of 1.0 
mg/mL) [33]. For both D. russelii and O. scutellatus venoms, the very broad 
anticoagulant peak observed indicates the presence of many closely eluting 
anticoagulant toxins- this activity was sufficiently potent to be observed visually on 
the plates after measurement. Among venoms with procoagulant activity, E. 
ocellatus venom only displayed a slightly/medium increased procoagulant activity, 
while very fast procoagulant activity was not observed. C. rhodostoma venom had a 
relatively weak anticoagulant and a strong procoagulant activity (for both very fast 
and slightly/medium increased coagulation). Note that despite the fact that in 
general venom toxins are rather stable, during RPLC within the nanofractionation 
analytics pipeline some venom toxins might have (partly) denatured and thereby lost 
their enzymatic activity. Bioactivity chromatograms of duplicate measurements and a 
detailed description of all observed coagulopathic peaks are shown in the Supporting 
Information (Section S2). 
3.3.3. Neutralization capabilities of varespladib on the enzymatic PLA2 activity of 
venom toxins 
As discussed in Section 3.1, only LC fractions of the B. asper, D. russelii, E. 
carinatus, and O. scutellatus venoms were found to possess an abundantly 
detectable enzymatic activity in the PLA2 assay. Therefore, these four snake venoms 
were selected to assess the inhibitory effect of varespladib on the observed PLA2 
activities of the fractions (Figure 3). As anticipated, the observed PLA2 activities for 
these four snake venoms decreased with increasing concentrations of varespladib. 
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Figure 2. Coagulopathic bioactivity chromatograms of nanofractionated venom toxins. 
Anticoagulation is measured as negative signals and procoagulation as positive signals. 
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Figure 3. Superimposed PLA2 bioactivity chromatograms for nanofractionated venom toxins 
measured in the presence of the indicated concentrations of varespladib: (a) B. asper, (b) D. russelii, 
(c) E. carinatus, and (d) O. scutellatus. Top traces are the online LC-UV chromatograms recorded at 
220, 254, and 280 nm for the respective venoms (allowing a correlation with LC-MS and proteomics 
data from Slagboom et al. [33]). PBS indicates venom only samples where PBS was used as a control 
for varespladib. 
The PLA2 activities of B. asper, D. russelii, and O. scutellatus venoms were fully 
neutralized by 20 μM varespladib, whereas the activity observed for E. carinatus 
venom was abolished by 4 μM varespladib. These data indicate broad-spectrum 
venom PLA2 inhibition by varespladib. The duplicate bioassay chromatograms are 
presented in the Supporting Information (Section S3). 
3.3.4. Neutralization capabilities of varespladib on plasma coagulation activity of 
venom toxins 
Next, we assessed the inhibition of coagulopathic toxins identified in the various 
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venom fractions by varespladib (Figure 4). Surprisingly, varespladib not only 
inhibited the anticoagulant activities of a number of the nanofractionated venom 
toxins, but also had an effect on some of the procoagulant venom fractions. 
Specifically, the anticoagulant activity of E. carinatus, E. ocellatus, and O. 
scutellatus venoms were fully neutralized by 20 μM varespladib. Varespladib was 
particularly effective in inhibiting the anticoagulant activity of toxins in O. 
scutellatus venom, and demonstrated a clear dose-response relationship. The 
anticoagulant activity of D. acutus and D. russelii venom components were almost 
completely abrogated by 20 μM varespladib, although trace activities remained. 
Contrastingly, varespladib did not considerably inhibit the anticoagulant toxicities 
observed in B. asper and C. rhodostoma venoms, with the exception that the first 
anticoagulant peak (23.1–24.2 min) in B. asper venom was fully inhibited at a very 
low concentration (0.8 μM varespladib). 
Varespladib also showed some inhibitory capabilities against the procoagulant 
activities of B. asper, C. rhodostoma, D. acutus, D. russelii, E. carinatus, and E. 
ocellatus venom (Figure 4). The extent of inhibition observed varied extensively, 
although full inhibition was not achieved across any of the venoms. The greatest 
effect was observed against the venom of E. carinatus, where the very fast 
coagulation activity was fully neutralized at 4 μM varespladib and most of the 
slightly/medium increased procoagulant activity was fully inhibited at 20 μM 
varespladib. The potent procoagulant activities of D. russelii venom were noticeably 
reduced in a dose-dependent manner, although full inhibition was not achieved, 
even when using the 20 μM varespladib concentration. Similar findings were 
observed with the venoms of B. asper, C. rhodostoma, D. acutus, and E. ocellatus, 
where procoagulant peaks were generally reduced in height with the highest 
concentrations of varespladib, suggesting perhaps a nonspecific inhibitory effect. 
The duplicate bioassay chromatograms and a detailed description of all coagulation-
related activities neutralized by different concentrations of varespladib are provided 
in the Supporting Information (Section S4). 
Snake venom PLA2s are well-known for their anticoagulant toxicities [34-36]. 
Our results show that varespladib effectively inhibits anticoagulant activities across 
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a wide variety of medically important snake venoms. Additionally, we also find that 
varespladib can reduce the procoagulant venom activity, possibly by directly 
inhibiting enzymatic procoagulant toxins or blocking protein-protein interactions. 
However, the concentration of varespladib required to show noticeable inhibition of 
procoagulant venom activities was generally high (i.e., 20 μM), relative to that 
required for neutralizing anticoagulant activities. 


























































Figure 4. Coagulopathic toxicity chromatograms in the presence of various varespladib concentrations 
for nanofractionated venom toxins from (a) B. asper, (b) C. rhodostoma, (c) D. acutus, (d) D. russelii, 
(e) E. carinatus, (f) E. ocellatus, and (g) O. scutellatus. Top traces are the online LC-UV 
chromatograms recorded at 220, 254, and 280 nm for the respective venoms (allowing a correlation 
with LC-MS data and proteomics data from Slagboom et al. [33]). PBS indicates venom only samples 
where PBS was used as a control for varespladib. 
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Figure 4. (Continued) Coagulopathic toxicity chromatograms in the presence of various varespladib 
concentrations for nanofractionated venom toxins from (a) B. asper, (b) C. rhodostoma, (c) D. acutus, 
(d) D. russelii, (e) E. carinatus, (f) E. ocellatus, and (g) O. scutellatus. Top traces are the online LC-
UV chromatograms recorded at 220, 254, and 280 nm for the respective venoms (allowing a 
correlation with LC-MS data and proteomics data from Slagboom et al. [33]). PBS indicates venom 
only samples where PBS was used as a control for varespladib. 
3.3.5. Identification of venom toxins neutralized by varespladib 
The correlated LC-MS (i.e., accurate masses of eluting venom toxins) and 
proteomics data obtained by Slagboom et al. [33] were used to identify venom 
toxins with enzymatic PLA2 and coagulopathic activities (Tables 1 and 2). Large 
part of these LC-MS and proteomics data was already stated in Table 1 of Chapter 2. 
For clarity and convenience it is provided here again. Bioactivities were linked to 
accurate molecular masses and tentative protein identities by aligning the 
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characteristic LC-UV chromatograms obtained for each venom in both studies. 
When no exact mass data could be acquired by LC-MS, only the proteomics mass 
data obtained from the Mascot searches are provided. 
Based on the results displayed in Table 1 and Figure 3, the PLA2 enzymes that were 
neutralized by varespladib could be tentatively identified. From the four species 
exhibiting enzymatic PLA2 activity after nanofractionation (i.e., B. asper, E. carinatus, 
D. russelii, and O. scutellatus) we detected a total of 13 toxins, of which all were 
unsurprisingly identified as PLA2 toxins. Eleven toxins were fully neutralized by 20 μM 
varespladib, while two were inhibited by much lower doses (0.8 μM varespladib). 
Variations were observed among the species, however, with five bioactive PLA2 
enzymes identified in the venom of B. asper, four in O. scutellatus, three in D. russelii, 
and only one in E. carinatus (Table 1).  
The assigned toxins responsible for the coagulation activities observed are displayed 
in Table 2. Based on the data in Table 2 and Figure 4, the inhibitory potency of 
varespladib on the coagulopathic venom protein(s) was assessed. All tentatively 
identified anticoagulant toxins for the anticoagulant peaks from venoms of B. asper, D. 
acutus, D. russelii, E. carinatus, E. ocellatus, and O. scutellatus were fully abrogated by 
varespladib, while the anticoagulant toxins from C. rhodostoma were not inhibited by 
varespladib. No procoagulant toxins could be identified for the procoagulant peaks from 
the Mascot results for D. russelii, E. carinatus, and O. scutellatus venoms. Procoagulant 
toxins were identified from Mascot results for B. asper, C. rhodostoma, D. acutus, and 
E. ocellatus venoms, but we could not determine exactly which toxins were partially 
inhibited by varespladib as multiple venom toxins were found to be co-eluted in each 
case. Thus, unambiguously assigning single toxins to each detected bioactivity is 
problematic at this resolution, especially if broad bioactivity peaks are observed. 
Additionally, when for example multiple potent anticoagulant toxins and a weak 
procoagulant toxin elute closely together, the net observed effect would be 
anticoagulation and the procoagulant toxin would not be detectable as a procoagulant. 
While distinction of all bioactive compounds in such cases requires further improving 
LC separations under toxin non-denaturating and MS compatible eluent conditions, it is 
worth noting that none of the tentatively assigned procoagulant toxins found here that 
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were fully or partially inhibited by varespladib were PLA2s (see Table 2), suggesting 
varespladib may interact with other venom toxins. A detailed description of the results 
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A recently developed analytical platform combining LC, MS, and PLA2 and 
coagulation activity bioassays was applied to evaluate the inhibitory properties of 
varespladib against the enzymatic PLA2 and coagulopathic activities of toxins found 
in the venoms of several medically important snake species. All venoms analyzed in 
this study showed constituents with clear coagulopathic toxicities, while only the 
venoms of B. asper, D. russelii, E. carinatus, and O. scutellatus displayed 
components with a clear enzymatic PLA2 activity. All components with detected 
enzymatic PLA2 activities were identified as PLA2 toxins and were fully neutralized 
by the small molecule toxin inhibitor varespladib. We demonstrated here that 
varespladib inhibited many of the anticoagulant bioactivities of the toxin 
components found in these venoms, similar to findings recently described by others 
for certain snakes of the genera Naja, Pseudechis and Bitis [16,37,38], and we 
confirmed that the toxins responsible are likely to be PLA2s based on correlations 
between MS and proteomics data and the bioactivity chromatograms. However, we 
also revealed that several of the procoagulant venom toxins were also neutralized to 
some degree by varespladib. These findings suggest that the mechanism underlying 
venom inhibition may not be solely based on inhibition of the active site of venom 
PLA2s, as other toxin types are typically responsible for procoagulant venom 
activities. However, we cannot rule out that nonspecific effects at high inhibitor 
concentrations are responsible for these observations, and thus future work is 
required to robustly explore this. Note that during chromatographic separations 
under reversed-phase conditions nonstable toxin complexes and large toxins can 
denature. Currently, we cannot circumvent this potential drawback of the 
nanofractionation analytics. Overall, our data further support the value of 
varespladib as a potential new therapeutic for mitigating the toxic effects of certain 
snakebites [9], and they re-emphasize that while this small molecule toxin inhibitor 
is a highly promising treatment for combatting neurotoxicity [25,28,29], it may also 
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S1. Duplicate PLA2 bioactivity chromatograms of nanofractionated venom 
toxins 
The PLA2 bioactivity chromatograms of the individual venom toxins from 
Bothrops asper, Calloselasma rhodostoma, Deinagkistrodon acutus, Daboia 
russelii, Echis carinatus, Echis ocellatus and Oxyuranus scutellatus after 
nanofractionation at 1.0 mg/ml are shown in Figure S1. In this study, each 
measurement was performed at least in duplicate following nanofractionation for 
assessing repeatability. 



















Figure S1. Duplicate PLA2 bioactivity chromatograms of nanofractionated venom toxins. Positive 




S2. Coagulopathic pathologies of nanofractionated venom toxins 
The duplicate coagulation bioassay chromatograms are shown in Figure S2. 
Each venom was nanofractionated at 1.0 mg/ml. For B. asper venom, a sharp potent 
positive peak was observed in both the very fast and the slightly/medium increased 
coagulation chromatograms, whereas a broad potent negative peak was seen in the 
anticoagulation chromatogram. For C. rhodostoma venom, a sharp potent positive 
peak, followed by several potent none-baseline positive peaks was observed in both 
the very fast and the slightly/medium increased coagulation chromatograms, while 
only a relatively weak negative peak present in anticoagulation chromatogram. For 
both D. acutus and E. carinatus venoms, a sharp potent positive peak was noted in 
the very fast and the slightly/medium increased coagulation chromatograms, while a 
sharp potent negative peak was observed in the anticoagulation chromatograms. For 
D. russelii venom, a sharp potent positive peak was observed in both the very fast 
and the slightly/medium increased coagulation chromatograms. A relatively broad 
and potent negative peak, which was generated by several coagulopathic proteins 
eluting closely together, was observed in the anticoagulation chromatogram. For E. 
ocellatus venom, a sharp potent peak was observed in both the slightly/medium 
increased procoagulation and the anticoagulation chromatograms, while no activity 
was observed in the very fast coagulation chromatogram. For O. scutellatus venom, 
a clear broad anticoagulant peak was observed, similar to that in D. russelii venom. 
However, no procoagulant activity was observed with O. scutellatus venom at the 
tested concentration of 1.0 mg/ml. 
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Figure S2. Duplicate coagulopathic toxicity chromatograms of the nanofractionated venom toxins. 
Anticoagulation is measured as negative signals and procoagulation as positive signals. 
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S3. Duplicate chromatograms displaying the inhibitory effects of varespladib 
on enzymatic PLA2 activity. 
Duplicate PLA2 bioactivity chromatograms showing the ability of varespladib to 
neutralize nanofractionated venom proteins from B. asper, D. russelii, E. carinatus 
and O. scutellatus are depicted in Figure S3. In each figure, the bioassay 
chromatograms depicted on the right side (which do not have superimposed 
correlated UV data) represent replicates of the chromatograms on the left side 
(which are also presented in the main manuscript). 




































Figure S3. Duplicate PLA2 bioactivity chromatograms of B. asper, D. russelii, E. carinatus and O. 
scutellatus venoms in presence of various varespladib concentrations. Top traces are the online LC-UV 
chromatograms recorded at 220, 254, and 280 nm for the respective venoms. PBS indicates venom 
only samples where PBS was used as a control for varespladib. 
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Figure S3. (Continued) Duplicate PLA2 bioactivity chromatograms of B. asper, D. russelii, E. 
carinatus and O. scutellatus venoms in presence of various varespladib concentrations. Top traces are 
the online LC-UV chromatograms recorded at 220, 254, and 280 nm for the respective venoms. PBS 
indicates venom only samples where PBS was used as a control for varespladib. 
S4. Duplicate chromatograms displaying the inhibitory effects of varespladib 
on coagulopathic venom toxins. 
The inhibitory capabilities of varespladib against the nanofractionated venom 
proteins involved in modulating plasma coagulation for B. asper, C. rhodostoma, D. 
acutus, D. russelii, E. carinatus, E. ocellatus and O. scutellatus venoms was 
assessed after nanofractionation of 1.0 mg/ml venom concentrations. The duplicate 
coagulation bioassay chromatograms are shown in Figure S4. For all venoms, 
varespladib was assayed at concentrations of 20 μM, 4 μM and 0.8 μM. Where the 
0.8 μM varespladib concentration still inhibited the coagulopathic venom 
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components, lower concentrations were additionally evaluated (i.e. 0.16 μM and 
0.032 μM if needed). 
In the venom-only chromatograms for B. asper venom, a sharp positive peak 
together with a broad none-baseline co-eluting positive peak were identified both 
for the very fast and the slightly/medium increased coagulation activities, whereas a 
broad negative peak followed by a series of potent co-eluting negative peaks ending 
in a relatively sharp negative peak could be observed for anticoagulant activity. In 
the presence of varespladib, all procoagulant activities were inhibited with peaks 
becoming sharper in a concentration-dependent manner. The tailing peak in the very 
fast coagulation chromatogram was effectively neutralized by 4 μM varespladib, 
whereas the two front-eluting peaks were still visible. At the highest varespladib 
concentration, the peaks were further reduced in intensity, but could not be fully 
neutralized. For the slightly/medium increased coagulation activity, both peaks were 
reduced dose-dependently by varespladib, but moderate activity was still observed 
at 20 μM varespladib. For the anticoagulant activity profile, the front broad negative 
peak was only visible for the venom-only measurements, suggesting that 
varespladib could effectively inhibit the eluted venom protein(s). In contrast, the 
other activity peaks were not affected by varespladib, demonstrating that these 
toxins could not be inhibited by varespladib. 
For C. rhodostoma venom, two clear peaks were noted in the very fast 
procoagulation activity chromatogram, which were equally reduced in intensity by 
increasing varespladib concentrations, but to a limited extent, as none could be fully 
neutralized by 20 μM varespladib. The same was observed for the slightly/medium 
increased coagulation activity. Here, the second (largest) peak consisted of three 
closely co-eluting peaks, of which the third peak was largely neutralized by 20 μM 
varespladib. The other two peaks were also partially neutralized, but to a lesser 
extent. Two peaks can clearly be seen in the anticoagulant activity chromatogram 
and were not significantly affected by varespladib. 
For D. acutus venom, both the very fast coagulation and the slightly/medium 
increased coagulation activities resulted in multiple co-eluting chromatographic 
peaks. The intensity of these peaks decreased with increasing varespladib 
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concentrations, suggesting inhibition of most procoagulant proteins in this venom. 
The front two peaks in the procoagulation bioactivity chromatograms alone could 
not be fully inhibited by 20 μM varespladib.  Moreover, one potent sharp negative 
peak and a much smaller later eluting negative peak could be observed in the 
anticoagulation chromatograms. The intensity of the sharp negative front peak 
decreased in a concentration-dependent manner in the presence of varespladib, and 
was fully neutralized by 20 μM varespladib, while the later eluting weak negative 
peak was unaffected by varespladib. 
For D. russelii venom, a strong and broad peak in the very fast procoagulant 
profile was visible, while several overlapping procoagulant peaks were noted in the 
slightly/medium increased coagulation chromatograms in the venom-only analysis. 
In the anticoagulation profile, one very broad anticoagulation signal (which also can 
be seen by visually inspecting a plate after the measurement, as the respective wells 
did not show any plasma coagulation) was observed in the venom-only analysis. 
This negative broad peak indicates many closely eluting proteins. With increasing 
varespladib concentrations, the signal for the very fast procoagulant activity 
decreased in a similar manner as the slightly/medium increased coagulation activity. 
In both bioactivity chromatograms, the broad peak profiles were split into two non-
baseline peak areas, representing multiple eluting procoagulant proteins. A clear 
dose-response effect was observed, but varespladib could not fully inhibit 
procoagulant activity at the highest concentration tested (20 μM). The very broad 
and potent negative peak in the anticoagulation chromatogram was drastically 
reduced and narrowed until only a weak peak was retained. This indicated the 
efficient neutralization of anticoagulant activity by varespladib. 
For E. carinatus venom, a sharp peak was observed in the very fast coagulation 
activity chromatogram in the venom-only analysis, which was neutralized by 4 μM 
varespladib. The slightly/medium increased procoagulant activity displayed two 
areas of potent broad positive peaks in the venom-only analysis, of which the front 
area of peaks was efficiently neutralized at the low varespladib concentrations of 4 
μM. The later eluting peaks were only partially inhibited by varespladib and one of 
these decreased in intensity in a concentration-dependent fashion; however, a full 
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inactivation of this peak was not achieved even at 20 μM varespladib. In the 
anticoagulation chromatogram, one sharp negative peak was detected and was 
reduced by varespladib in a dose-dependent manner; full neutralization was 
observed at 20 μM varespladib. 
For E. ocellatus venom, a very weak positive peak followed by a potent sharp 
positive peak was observed in the very fast coagulation chromatogram in the 
venom-only analysis. The front weak positive peak was fully neutralized by 
varespladib at the very low concentration of 0.16 μM. The activity of the strong 
positive peak decreased with increasing concentrations of varespladib, despite full 
inactivation not being achieved even at 20 μM varespladib. The slightly/medium 
increased coagulation chromatogram displayed two sharp positive non-baseline 
peaks. Varespladib also inhibited this positive shoulder peak in a concentration-
dependent manner, while full inactivation was not achieved at 20 μM varespladib. 
In contrast to the procoagulant profile, the anticoagulation activity profile was 
effectively neutralized by varespladib. A potent sharp negative peak followed by a 
later eluting weak negative peak was observed in the venom-only chromatogram. 
The front potent sharp negative peak decreased with increasing concentrations of 
varespladib, and some residual activity was observed at a 0.8 μM varespladib. No 
activity was detected at 4 μM varespladib. The later eluting weak negative peak was 
not influenced by varespladib at low concentrations and only was fully neutralized 
by 20 μM varespladib. 
For O. scutellatus venom, no activity was detected for both the very fast 
coagulation and the slightly/medium increased coagulation chromatograms. A 
moderate negative peak followed by a very broad and strong negative peak and 
finally a sharp negative peak were observed in the anticoagulation chromatogram 
for the venom-only analysis. At the very low varespladib concentration of 0.032 μM, 
the effective inhibition of anticoagulant activity was observed. The main broad 
negative peak was reduced into four individual negative peaks, which were 
observed as a broad negative peak followed by two sharp negative peaks and one 
additional broad negative peak. The latest eluting sharp negative peak observed in 
the venom-only chromatogram was fully neutralized by 0.032 μM varespladib. By 
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further increasing the varespladib concentration to 0.16 μM, the four individual 
negative peaks observed in the 0.032 μM varespladib analysis decreased further in 
both peak broadness and height, and the middle two sharp negative peaks were 
neutralized. The two potent negative left peaks were effectively decreased by 
further increasing varespladib concentrations; of which the front eluting negative 
peak was fully neutralized by 20 μM varespladib and the later eluting negative peak 
was fully neutralized by 4 μM varespladib. No activity was detected at a varespladib 
concentration of 20 μM. 




















































Figure S4. Duplicate coagulopathic toxicity bioassay chromatograms of nanofractionated venom 
toxins from B. asper, C. rhodostoma, D. acutus, D. russelii, E. carinatus, E. ocellatus and O. 
scutellatus in the presence of various concentrations of varespladib. Top traces are the online LC-UV 
chromatograms recorded at 220, 254, and 280 nm for the respective venoms. PBS indicates venom 


















































































Figure S4. (Continued) Duplicate coagulopathic toxicity bioassay chromatograms of nanofractionated 
venom toxins from B. asper, C. rhodostoma, D. acutus, D. russelii, E. carinatus, E. ocellatus and O. 
scutellatus in the presence of various concentrations of varespladib. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. PBS 
indicates venom only samples where PBS was used as a control for varespladib. 
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Figure S4. (Continued) Duplicate coagulopathic toxicity bioassay chromatograms of nanofractionated 
venom toxins from B. asper, C. rhodostoma, D. acutus, D. russelii, E. carinatus, E. ocellatus and O. 
scutellatus in the presence of various concentrations of varespladib. Top traces are the online LC-UV 
chromatograms recorded at 220, 254, and 280 nm for the respective venoms. PBS indicates venom 
only samples where PBS was used as a control for varespladib. 
S5. Inhibitory efficacy of varespladib on venom toxins identified in Table 2. 
The anticoagulant PA2H2_BOTAS was fully neutralized by 0.8 μM varespladib 
and the anticoagulants PA2A_DEIAC and SL_DEIAC were fully neutralized by 4 
μM varespladib. The anticoagulants PA2B8_DABRR, VKT_OXYSC and 
VKT3_OXYSC were fully neutralized by 20 μM varespladib. The pro-coagulants 
VM3A2_DEIAC and VM3AH_DEIAC were neutralized by 20 μM varespladib. In 
contrast, the anticoagulants VM2_BOTAS, PA2AB_CALRH, SLEA_CALRH, 
SLEB_CALRH and VSPF1_CALRH were not inhibited by varespladib. Moreover, 
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the pro-coagulants VSPL_BOTAS, VM1B1_BOTAS, SLA_BOTAS, 
VSPF2_CALRH, SLYA_CALRH, SLYB_CALRH, VSP1_DEIAC, VSPA_DEIAC, 
SLCB_DEIAC, VM1AC_DEIAC, VM11_DEIAC, VM1H5_DEIAC, 
VM3AK_DEIAC, VM3E2_ECHOC, VM3E6_ECHOC, SL1_ECHOC and 
SL124_ECHOC were matched to the time frame of peaks which were moderately 
inhibited by varespladib. Further investigation is needed to decide whether they can 
be neutralized by varespladib. 
Of the identified PLA2 enzymes, no anticoagulant activity was reported in 
UniprotKB for PA2HA_BOTAS, PA2H3_BOTAS, PA2B3_BOTAS, 
PA2A2_BOTAS, PA2BD_CALRH, PA2B3_DABRR, PA2B5_DABRR, 
PA2A1_ECHCA, PA2A5_ECHOC, PA2TA_OXYSC, PA2TB_OXYSC, 
PA21_OXYSC and PA2TC_OXYSC. Of these toxins, PA2A1_ECHCA was fully 
neutralized by 0.8 μM varespladib, PA2A5_ECHOC was fully neutralized by 4 μM 
varespladib, PA2HA_BOTAS, PA2H3_BOTAS, PA2B3_BOTAS, 
PA2A2_BOTAS, PA2B3_DABRR, PA2B5_DABRR, PA2TA_OXYSC, 
PA2TB_OXYSC, PA21_OXYSC and PA2TC_OXYSC were fully inhibited by 20 
μM varespladib. PA2BD_CALRH was not inhibited by varespladib. 
PA2B3_BOTAS was reported to show myotoxic activity [1] and PA2A2_BOTAS 
to catalyze the Ca2+-dependent hydrolysis of 2-acyl groups in 3-sn-
phosphoglycerides [2]. PA2BD_CALRH is known to be enzymatically inactive 
because of the evolutionary loss of its calcium binding site [3]. PA2B5_DABRR 
was reported to catalyze the Ca2+-dependent hydrolysis of the 2-acyl groups in 3-sn-
phosphoglycerides [4,5]. PA2TA_OXYSC was reported as neurotoxic and capable 
of catalyzing the Ca2+-dependent hydrolysis of 2-acyl groups in 3-sn-
phosphoglycerides [6]. PA2TB_OXYSC was also reported to possess neurotoxic 
properties [7]. 
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Animal-derived antivenoms are the only specific therapies currently available for 
the treatment of snake envenoming, but these products have a number of limitations 
associated with their efficacy, safety and affordability for use in tropical snakebite 
victims. Small molecule drugs and drug candidates are regarded as promising 
alternatives for filling the critical therapeutic gap between snake envenoming and 
effective treatment. In this study, by using an advanced analytical technique that 
combines chromatography, mass spectrometry and bioassaying, we investigated the 
effect of several small molecule inhibitors that target phospholipase A2 (varespladib) 
and snake venom metalloproteinase (marimastat, dimercaprol and DMPS) toxin 
families on inhibiting the activities of coagulopathic toxins found in Viperinae 
snake venoms. The venoms of Echis carinatus, Echis ocellatus, Daboia russelii and 
Bitis arietans, which are known for their potent hemotoxicities, were fractionated in 
high resolution onto 384-well plates using liquid chromatography followed by 
coagulopathic bioassaying of the obtained fractions. Bioassay activities were 
correlated to parallel recorded mass spectrometric and proteomics data to assign the 
venom toxins responsible for coagulopathic activity and assess which of these 
toxins could be neutralized by the inhibitors under investigation. Our results showed 
that the phospholipase A2-inhibitor varespladib neutralized the vast majority of 
anticoagulation activities found across all of the tested snake venoms. Of the snake 
venom metalloproteinase inhibitors, marimastat demonstrated impressive 
neutralization of the procoagulation activities detected in all of the tested venoms, 
whereas dimercaprol and DMPS could only partially neutralize these activities at 
the doses tested. Our results provide additional support for the concept that 
combinations of small molecules, particularly the combination of varespladib with 
marimastat, serve as a drug-repurposing opportunity to develop new broad-spectrum 
inhibitor-based therapies for snakebite envenoming. 
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Bites by venomous snakes cause 81,000–138,000 deaths per annum, with the 
majority occurring in the rural resource-poor regions of the tropics and sub-tropics 
[1]. The venomous snakes responsible for the vast majority of severe envenomings 
are members of the Viperidae and Elapidae families [2,3]. Elapid snakes have 
venoms that are highly abundant in neurotoxins that disable muscle contraction and 
cause neuromuscular paralysis [1,4]. Contrastingly, viper venoms typically contain 
numerous proteins that disrupt the functioning of the coagulation cascade, the 
hemostatic system and tissue integrity [4,5]. Envenomings caused by these snakes 
can cause prominent local effects including necrosis, hemorrhage, edema and pain, 
and often result in permanent disabilities in survivors [6,7]. One of the most 
common but serious pathological effects of systemic viper envenoming is 
coagulopathy, which renders snakebite victims vulnerable to suffering lethal 
internal hemorrhages [8]. Venom induced coagulopathy following bites by viperid 
snakes is predominately the result of the synergistic action of venom enzymes, such 
as phospholipases A2 (PLA2s), snake venom serine proteinases (SVSPs) and snake 
venom metalloproteinases (SVMPs) [9-11]. PLA2s can prevent blood clotting via 
anticoagulant effects. Enzymatic PLA2s function by hydrolyzing 
glycerophospholipids at the sn-2 position of the glycerol backbone releasing 
lysophospholipids and fatty acids [12]. SVSPs can proteolytically degrade 
fibrinogen and release bradykinins from plasma kininogens [13,14]. SVMPs act on 
various clotting factors to stimulate consumption coagulopathy and can also degrade 
capillary basement membranes, thereby increasing vascular permeability and 
causing leakage [10,15,16]. 
The only specific therapies currently available for treating snake envenoming are 
animal-derived antivenoms. Consisting of immunoglobulins purified from 
hyperimmunized ovine or equine plasma/serum, these products save thousands of 
lives each year, but are associated with a number of therapeutic challenges, 
including limited cross-snake species efficacies, poor safety profiles and, for many 
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snakebite victims residing in remote rural areas in developing countries, 
unacceptable issues with affordability and accessibility [17]. Small molecule toxin 
inhibitors are regarded as promising candidates for the development of affordable 
broad-spectrum snakebite treatments, as these can block the enzymatic activities of 
venoms [18-20]. Varespladib, an indole-based nonspecific pan-secretory PLA2 
inhibitor has been studied extensively for repurposing for snakebite. Having 
originally been investigated in Phase II and III clinical trials for treating septic 
shock, coronary heart disease and sickle cell disease-induced acute chest syndrome 
[21,22], varespladib has since been shown to be highly potent in suppressing 
venom-induced PLA2 activity, both in vitro and in vivo in murine models [23]. 
Varespladib shows great promise against neurotoxic elapid snake venoms and has 
been shown to prevent lethality in murine in vivo models of envenoming [24], but is 
seemingly also capable of inhibiting certain myotoxic and coagulotoxic symptoms 
induced by snake venoms [25,26]. Moreover, varespladib has been demonstrated to 
inhibit the anticoagulant activity of Pseudechis australis snake venom, which was 
not neutralized by its currently used antivenom [27]. 
A number of other small molecules have shown promise for repurposing to 
inhibit SVMP venom toxins. Marimastat is a broad-spectrum matrix 
metalloprotease inhibitor that functions by binding to the active site of matrix 
metalloproteinases where it coordinates the metal ion in the binding pocket [28,29]. 
As a water-soluble orally bioavailable matrix metalloproteinase inhibitor [30,31], 
marimastat reached phase II and III clinical trials for multiple solid tumor types [32-
34], including pancreatic, lung, breast, colorectal, brain and prostate cancer [35-37]. 
SVMPs are toxins that are structurally and functionally homologous to matrix 
metalloproteinses [38-40]. Like other compounds in this class of drugs (e.g., 
batimastat [41]), marimastat is a promising drug candidate for treating snakebite due 
to its inhibitory capabilities against SVMP toxins [42,43]. Marimastat was found to 
effectively inhibit the hemorrhagic, coagulant and defibrinogenating effects and 
proteinase activities induced by Echis ocellatus venom [42]. Dimercaprol, a 
historical drug approved by the World Health Organization (WHO) for treatment of 
heavy metal poisoning [44], contains two metal-chelating thiol groups and has long 
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been used against arsenic, mercury, gold, lead and antimony intoxication [45-47]. It 
also represents a treatment option for Wilson’s disease in which the body retains 
copper. Moreover, it has been studied as a candidate for acrolein detoxification as it 
can effectively reduce the acrolein concentration in vivo in murine because of its 
ability to bind to both the carbon double bond and aldehyde group of acrolein. The 
water-soluble, tissue-permeable and licensed metal chelator, 2,3-
dimercaptopropane-1-sulfonic acid (DMPS), is also suitable for treating acute and 
chronic heavy metal intoxication including lead, mercury, cadmium and copper 
[48,49]. It was recently shown that both dimercaprol and DMPS displayed potential 
for repurposing as small molecule chelators to treat snake envenoming [20], most 
probably by chelating and removing Zn2+ from the active site of Zn2+-dependent 
SVMPs. Of the two drugs, DMPS showed highly promising preclinical efficacy 
when used as an early oral intervention after envenoming by the SVMP-rich venom 
of the West African saw-scaled viper (Echis ocellatus), prior to later antivenom 
treatment with conventional antivenom [20]. In addition to protecting against 
venom-induced lethality, DMPS was also demonstrated to drastically reduce local 
venom-induced hemorrhage [20]. Thus, marimastat, dimercaprol and DMPS all 
represent promising candidates for drug repurposing as snakebite therapeutics, as 
they either inhibit SVMPs or chelate the Zn2+ ion required for SVMP catalysis. 
Nanofractionation analytics, which is a recently developed high resolution and 
high throughput format of traditional bioassay-guided fractionation, is regarded as 
an effective method for screening complex bioactive mixtures such as venoms to 
rapidly identify and in parallel directly characterize separated venom toxins 
biochemically (i.e., for selected bioactivities), by combing reversed-phase liquid 
chromatography (RPLC) with parallel post-column bioassays, mass spectrometry 
(MS) and proteomics analysis [50-52]. In this paper, the coagulopathic properties of 
various snakes from the medically important viper subfamily Viperinae (Echis 
carinatus, E. ocellatus, Daboia russelii and Bitis arietans) were evaluated using 
nanofractionation analytics in combination with a high-throughput coagulation 
assay, and the inhibitory capabilities of varespladib, marimastat, dimercaprol and 
DMPS against the coagulopathic toxicities of the resulting snake venom fractions 
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were revealed. To this end, bioactivity chromatograms were acquired after 
fractionation, and parallel obtained MS and proteomics data were used to correlate 
the observed bioactivities with the identity of the venom toxins responsible for the 
observed enzymatic effects. Thus, we assessed the ability of varespladib, 
marimastat, dimercaprol and DMPS to neutralize the coagulopathic venom 
components. The results indicated that varespladib in combination with heavy metal 
chelators and/or broad-spectrum protease inhibitors could be viable first line 




Water from a Milli-Q Plus system (Millipore, Amsterdam, The Netherlands) was 
used. Acetronitrile (ACN) and formic acid (FA) were supplied by Biosolve 
(Valkenswaard, The Netherlands). Calcium chloride (CaCl2, dehydrate, ≥ 99%) was 
from Sigma-Aldrich (Zwijndrecht, The Netherlands) and was used to de-citrate 
plasma to initiate coagulation in the coagulation assay. Phosphate buffered saline 
(PBS) was prepared by dissolving PBS tablets (Sigma-Aldrich) in water according 
to the manufacturer’s instructions and was stored at 4 °C for no longer than one 
week prior to use. Sodium citrated bovine plasma was obtained from Biowest 
(Nuaillé, France) as sterile filtered. The plasma (500 mL bottle) was defrosted in a 
warm water bath, and then quickly transferred to 15 mL CentriStarTM tubes 
(Corning Science, Reynosa, Mexico). These 15 mL tubes were then immediately re-
frozen at –80 °C, where they were stored until use. Venoms were sourced from 
either wild-caught specimens maintained in, or historical venom samples stored in, 
the Herpetarium of the Liverpool School of Tropical Medicine (LSTM). This 
facility and its protocols for the expert husbandry of snakes are approved and 
inspected by the UK Home Office and the LSTM and University of Liverpool 
Animal Welfare and Ethical Review Boards. The venom pools were from vipers 
with diverse geographical localities, namely: B. arietans (Nigeria), D. russelii (Sri 
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Lanka), E. carinatus (India) and E. ocellatus (Nigeria). Note that the Indian E. 
carinatus venom was collected from a single specimen that was inadvertently 
imported to the UK via a boat shipment of stone, and then rehoused at LSTM on the 
request of the UK Royal Society for the Prevention of Cruelty to Animals (RSPCA). 
Venom solutions were prepared by dissolving lyophilized venoms into water to a 
concentration of 5.0 ± 0.1 mg/mL and were stored at –80 °C until use. The 
compounds varespladib (A-001), marimastat ((2S,3R)-N4-[(1S)-2,2-Dimethyl-1-
[(methylamino)carbonyl] propyl]-N1,2-dihydroxy-3-(2-methylpropyl) butanedia- 
mide), dimercaprol (2,3-Dimercapto-1-propanol) and DMPS (2,3-dimercapto-1-
propane-sulfonic acid sodium salt monohydrate) were purchased from Sigma-
Aldrich. They were dissolved in DMSO (≥ 99.9%, Sigma-Aldrich) to a 
concentration of 10 mM and stored at –20 °C. Prior to use, these four compounds 
were diluted in PBS buffer to the described concentrations. 
4.2.2. Venom nanofractionation 
All venoms were nanofractionated onto transparent 384-well plates, and the 
plates with fractions were freeze-dried overnight, according to the method described 
in our previous published papers by Slagboom et al. [53] and Xie et al. [52,54]. A 
detailed description can also be found in the Supporting Information (Section S1). 
4.2.3. Plasma coagulation activity assay 
The HTS plasma coagulation assay used in this study was developed by Still et 
al. [55]. Sample preparation, assay performed and data analysis were described in 
our previous published paper by Still et al. [55], Slagboom et al. [53] and Xie et al. 
[52,54]. The final concentrations of the inhibitor solutions used in the coagulation 
bioassay were 20 μM, 4 μM and 0.8 μM, and in some cases 0.16 μM, 0.032 μM and 
0.0064 μM. A detailed description can also be found in the Supporting Information 
(Section S2). 
4.2.4. Correlation of biological data with MS data 
The corresponding accurate mass(es) and proteomics data for each venom 
fraction in this study have already been acquired by Slagboom et al. [53] and as 
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such were correlated with the bioactivity chromatograms obtained in the current 
study. For venoms under study in this project that were not studied by Slagboom et 
al. [53], the same procedure as previously described [53] was followed to acquire 
and process proteomics data on these snake venoms. The UniprotKB database was 
used to determine the toxin class and any known functions for the relevant toxins 
thought to be responsible for the observed coagulopathic toxicities. For LC 
separations performed at different times and in different labs, the retention times of 
eluting snake venom toxins may differ slightly. The LC-UV chromatograms 
(measured at 220 nm, 254 nm and 280 nm), which provided characteristic 
fingerprint profiles for each venom fraction, were used to negotiate these retention 
time shifts. By using the LC-UV data, the chromatographic bioassay data from this 
study was correlated with the MS total-ion currents (TICs), extracted-ion 
chromatograms (XICs), and proteomics data obtained by Slagboom et al. [53]. In 
order to construct useful XICs, MS spectra were extracted from the time frames that 
correlated with regions in the chromatograms for each bioactive peak. Then, for all 
m/z values showing a significant signal observed in the mass spectra, XICs were 
plotted. In turn, these XICs were used for matching with peak retention times of 
bioactive compounds in the chromatograms. The exact masses matching the 
bioactives were tentatively assigned based on matching peak shape and correlation 
with retention times in bioassay traces. More specifically, the m/z-values in the MS 
data were correlated to each bioactive peak using the accurate monoisotopic masses 
determined by applying the deconvolution option in the MS software. For the 
proteomics data, in-well tryptic digestions were previously performed by Slagboom 
et al. [53] on snake venom fractions. These proteomics results were directly 
correlated to the coagulopathic activities that were indicated by the bioassay 
chromatograms. 
4.3. Results 
In this study, a nanofractionation approach was used to evaluate the inhibitory 
effects of varespladib, marimastat, dimercaprol and DMPS on the coagulopathic 
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properties of venom toxins fractionated from a variety of Viperinae snake species. 
A recently developed low-volume HTS coagulation bioassay was used to assess the 
coagulation activities of LC-fractionated venoms in a 384-well plate format. These 
coagulopathic activities were correlated to parallel obtained MS and proteomics 
data to determine which specific venom toxins were neutralized by the potential 
inhibitors. All analyses were performed in at least duplicate to ensure 
reproducibility, and used venom concentrations of 1.0 mg/mL. 
4.3.1. Inhibitory effects of varespladib, marimastat, dimercaprol and DMPS on 
Echis venoms 
Two geographically distinct saw-scaled viper venoms (genus Echis) were 
investigated in this study, specifically from the Indian species E. carinatus and the 
west African species E. ocellatus. The inhibitory effects of varespladib, marimastat, 
dimercaprol and DMPS against the coagulopathic activities observed for LC 
fractions of both venoms were investigated in a concentration-dependent fashion 
(Figures 1 and 2). Duplicate bioassay chromatograms together with a detailed 
description of each coagulopathic peak observed are presented in the Supporting 
Information (Section S3, Figures S1–S8). 
Figure 1 shows the bioassay chromatograms of nanofractionated venom toxins 
from E. carinatus in the presence of different concentrations of varespladib, 
marimastat, dimercaprol and DMPS. Notably, for varespladib, data from Chapter 3 
were used after retention-time alignment taking the difference in gradient dwell 
time (5 min) into account. In the venom-only analysis, potent procoagulation 
activities were observed in the very fast coagulation chromatogram (22.0–22.9 min) 
and the slightly/medium increased coagulation chromatogram (21.2–23.1 min 
and/or 19.9–21.2 min), while anticoagulation activities were observed in the 
anticoagulation chromatogram (19.1–19.9 min). Interestingly, the PLA2-inhibitor 
varespladib inhibited both the anticoagulation and procoagulation activities, with 
the exception of one major peak observed in the slightly/medium increased 
coagulation chromatogram. In contrast, marimastat, dimercaprol and DMPS only 
exerted inhibitory effects on the procoagulation activities of E. carinatus venom.  
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Figure 1. UV absorbance chromatograms and reconstructed coagulopathic toxicity chromatograms of 
nanofractionated toxins from E. carinatus venom in the presence of different concentrations of (a) 
varespladib*, (b) marimastat, (c) dimercaprol and (d) DMPS. The top superimposed chromatograms 
are characteristic profiles of UV traces measured at 220, 254 and 280 nm. PBS indicates venom only 
samples where PBS was used as a control for the inhibitors. *Data taken from Chapter 3 taking 
difference in gradient dwell time into account. 
The anticoagulation activity of E. carinatus venom was fully inhibited by 
varespladib at a 20 μM concentration, while the very fast procoagulation activity 
was fully inhibited by varespladib, dimercaprol and DMPS at a concentration of 4 
μM. Marimastat superseded the other small molecules by fully inhibiting the very 
fast procoagulation activity at a concentration of 0.16 μM. The slightly/medium 
increased coagulation activity was fully inhibited by 0.8 μM marimastat, but a sharp 
positive peak (21.7–22.2 min) was still retained following incubation with 20 μM 
varespladib. Dimercaprol only inhibited the front peak (21.3–22.1 min) present in 
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the slightly/medium increased coagulation activity chromatogram, while DMPS 
inhibited mostly the tailing part (22.2–23.1 min) of this peak at its highest 
concentration tested (20 μM). Overall, DMPS was found to be more effective than 
dimercaprol in abrogating the procoagulation toxicities of E. carinatus venom. 
These findings demonstrate that the tested inhibitors have different specificities, but 
that marimastat most effectively inhibits the procoagulant components, and 
varespladib the anticoagulant components, of E. carinatus venom. 
Figure 2 shows the bioassay chromatograms for nanofractionated toxins from E. 
ocellatus venom in the presence of different concentrations of varespladib, 
marimastat, dimercaprol and DMPS. Notably, for varespladib, data from Chapter 3 
were used after retention-time alignment taking the difference in gradient dwell 
time (5 min) into account. In the venom-only analysis, we observed similar results 
to those obtained for E. carinatus venom; multiple co-eluting sharp peaks were 
present in the very fast coagulation chromatogram (21.1–22.2 min), the 
slightly/medium increased coagulation chromatogram (21.1–23.1 min) and the 
anticoagulation chromatogram (19.4–20.4 min). All peaks decreased in height and 
width with increasing varespladib concentrations. The potent negative peak (19.4–
20.4 min) in the anticoagulation chromatograms was fully inhibited by 4 μM 
varespladib and the later eluting weakly negative peak (21.9 min) by 20 μM 
varespladib. While full inhibition of anticoagulation activities was achieved, the 
procoagulation activities were not fully inactivated at the highest varespladib 
concentration tested (20 μM). However, both the very fast coagulation activity and 
the slightly/medium increased coagulation activity were also somewhat reduced by 
varespladib in a concentration-dependent fashion. Similar findings, whereby both 
very fast and slightly/medium increased coagulation were reduced in a 
concentration dependent manner but not fully abrogated, were also observed for 
dimercaprol, although this inhibitor had no effect on anticoagulant venom activities. 
Marimastat and DMPS also had no effect on anticoagulant venom activity, but 
effectively inhibited the procoagulant actions of E. ocellatus venom. Very fast 
procoagulation activity was fully inhibited at a lower concentration of marimastat 
(0.16 μM) than DMPS (20 μM), while slightly/medium increased coagulation 
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activity was fully inhibited by 4 μM marimastat compared with almost complete 
inhibition observed when using 20 μM DMPS. Thus, similar to findings with E. 
carinatus, marimastat exhibited superior inhibition of procoagulant venom activities, 
while varespladib was the only inhibitor capable of abrogating anticoagulant venom 
effects. 
































































Figure 2. UV absorbance chromatograms and reconstructed coagulopathic toxicity chromatograms of 
nanofractionated toxins from E. ocellatus venom in the presence of different concentrations of (a) 
varespladib*, (b) marimastat, (c) dimercaprol and (d) DMPS. The top superimposed chromatograms 
are characteristic profiles of UV traces measured at 220, 254 and 280 nm. PBS indicates venom only 
samples where PBS was used as a control for the inhibitors. *Data taken from Chapter 3 taking 
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4.3.2. Inhibitory effects of varespladib, marimastat, dimercaprol and DMPS on 
Daboia russelii venom 































































Figure 3. UV absorbance chromatograms and reconstructed coagulopathic toxicity chromatograms of 
nanofractionated toxins from D. russelii venom in the presence of different concentrations of (a) 
varespladib*, (b) marimastat, (c) dimercaprol and (d) DMPS. The top superimposed chromatograms 
are characteristic profiles of UV traces measured at 220, 254 and 280 nm. PBS indicates venom only 
samples where PBS was used as a control for the inhibitors. *Data taken from Chapter 3 taking 
difference in gradient dwell time into account. 
Next, we assessed the inhibitory capability of the same small molecule toxin 
inhibitors on a Viperinae snake from a different genus: the Russell’s viper (Daboia 
russelii), which is a medically-important species found in south Asia [56-58]. The 
inhibitory effects of varespladib, marimastat, dimercaprol and DMPS on the venom 
of D. russelii are shown in Figure 3. Notably, for varespladib, data from Chapter 3 
were used after retention-time alignment taking the difference in gradient dwell 
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time (5 min) into account. Duplicate bioassay chromatograms for D. russelii venom 
analyses can be found in the Supporting Information in Section S4 (Figures S9–
S12). For the venom-only analysis, a strong positive peak was observed for both the 
very fast coagulation activity (21.5–22.4 min) and for the slightly/medium increased 
coagulation activity (21.5–22.8 min). A very broad and strong negative activity 
peak (18.6–21.5 min) was also observed, demonstrating potent anticoagulation 
activity. In terms of procoagulant venom effects, both very fast and slightly/medium 
increased coagulation activities decreased dose-dependently in the presence of 
varespladib, marimastat and dimercaprol, although neither varespladib nor 
dimercaprol could fully neutralize these activities. However, in line with the earlier 
findings for the two Echis spp., full neutralization of both types of procoagulation 
were observed with marimastat, at 0.8 μM for very fast coagulation activity and at 4 
μM for slightly/medium increased coagulation activity. As anticipated, and again in 
line with findings observed with Echis spp., neither of the SVMP-inhibitors 
(marimastat and dimercaprol) abrogated anticoagulant venom activity. In contrast, 
varespladib showed potent inhibition of anticoagulation, as the broad and potent 
negative peak (18.6–21.5 min) decreased to only a very minor negative peak (19.5–
20.2 min; 20 μM varespladib) with increasing varespladib concentrations. DMPS 
showed no inhibition on both the procoagulant and anticoagulant venom activities 
of D. russelii at the tested inhibitor concentrations of 20 μM and 4 μM. 
4.3.3. Inhibitory effects of varespladib and marimastat on Bitis arietans venom 
The inhibitory effects of varespladib and marimastat on the coagulopathic 
properties of venom of the puff adder (B. arietans), which is found widely 
distributed across sub-Saharan Africa and parts of the Middle East, are shown in 
Figure 4. Duplicate bioassay chromatograms for the B. arietans venom analyses are 
shown in the Supporting Information in Section S5 (Figures S13 and S14). In the 
venom-only analyses, anticoagulation activity was observed as two sharp negative 
peaks in the bioactivity chromatograms (16.2–16.7 min and 16.7–17.1 min); 
however, no procoagulation activity was detected, which is consistent with previous 
findings using this venom [59]. Consequently, of the three SVMP-inhibitors used 
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elsewhere in this study, we only selected marimastat for assessment of toxin 
inhibition as a control for the PLA2-inhibitor varespladib. In line with findings from 
the other Viperinae species under study, increasing concentrations of varespladib 
resulted in full inhibition of the two negative anticoagulation peaks, at 
concentrations of 0.16 µΜ and 0.8 µΜ, respectively. Conversely, and also in line 
with our earlier findings, no anticoagulant inhibitory effects were observed with 
marimastat, even at concentrations of 20 µΜ. 































Figure 4. UV absorbance chromatograms and reconstructed coagulopathic toxicity chromatograms of 
nanofractionated toxins from B. arietans venom in the presence of different concentrations of (a) 
varespladib and (b) marimastat. The top superimposed chromatograms are characteristic profiles of 
UV traces measured at 220, 254 and 280 nm. PBS indicates venom only samples where PBS was used 
as a control for the inhibitors. 
4.3.4. Identification of coagulopathic venom toxins neutralized by small molecule 
inhibitors 
The MS and proteomics data previously obtained by Slagboom et al. [53] was 
next used to assign the venom toxins responsible for the observed coagulation 
activities tentative identifications. The resulting identifications are listed in Table 1. 
Large part of these LC-MS and proteomics data was already stated in Table 1 of 
Chapter 2. For clarity and convenience it is provided here again. In addition, all 
tentatively identified anticoagulant PLA2s, including those found in our study not 
previously described as possessing anticoagulant properties in the UniprotKB 
database, are also provided in Table 1. For those toxins for which no exact mass 
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data could be acquired by LC-MS, only the proteomics mass data retrieved from 
Mascot searches are presented in the table. 
Based on the results from Figures 1–4 and Table 1, the inhibitory effects of 
varespladib, marimastat, dimercaprol and DMPS on individual Viperinae venom 
toxins were assessed. PLA2 toxins were identified as toxin components responsible 
for anticoagulation in all species studied, except for B. arietans, for which C-Type 
Lectins (CTLs) were instead identified. All these identified anticoagulant toxins 
were fully abrogated by varespladib at various concentrations, as indicated in Table 
1. Although the CTLs identified from B. arietans venom are highly likely to have 
co-eluted with other venom proteins, no other anticoagulants were identified from 
this venom. The toxins identified from the Mascot results for the procoagulant 
peaks of E. ocellatus venom included both SVMPs and CTLs. All these identified 
toxins were fully abrogated by marimastat at 0.16 μM or by DMPS at 20 μM 
concentrations. No procoagulant toxins could be identified from the Mascot results 
for E. carinatus and D. russelii venoms, but given that these bioactivity peaks were 
fully inhibited by marimastat at low concentrations, it seems reasonable to speculate 
that the procoagulant toxins responsible for these activities are mainly SVMPs. A 
detailed description of the results discussed here is provided in the Supporting 
Information in Section S6. 
There are a number of challenges associated with interpreting the data presented 
here. In cases where multiple toxins elute closely, unambiguously assigning single 
toxins to each detected bioactivity is challenging. For bioactive compounds that 
eluted in activity peaks that were only partly inhibited, it is difficult to critically 
determine which of them was abrogated. This would require further improving LC 
separations under toxin non-denaturating and MS compatible eluent conditions. As 
a critical note, it is important to stress that despite venom toxins generally being 
stable, during chromatography within the nanofractionation analytics pipeline some 




Neutralizing effects of small molecule inhibitors and metal 




























































































































































































































































































































































































































































































































































































































































































































































































There is an urgent need for stable, effective and affordable snakebite treatments 
that can be administered in the field and in rural areas where medical access is 
limited. Small molecule inhibitors that specifically target a number of key classes of 
snake venom toxins have recently gained interest as candidates for therapeutic 
Chapter 4 
132 
alternatives to conventional antivenom. 
This study used a high-throughput screening assay combined with LC 
fractionation and parallel MS and proteomics data to assess the neutralizing 
capabilities of a selected number of small molecule inhibitors and chelators (i.e., 
varespladib, marimastat, dimercaprol and DMPS). The results of this study show 
that these compounds are capable of neutralizing the coagulopathic activities of 
individual toxins present in the venoms of a number of Viperinae species. While 
this is consistent with previous work on small molecule inhibitors and chelators that 
exhibit anti-hemorrhagic and anti-procoagulant activities of snake venoms 
[9,20,23,42,43,60], here we have studied the relative neutralization potencies of 
these small molecules on individual coagulopathic venom toxins. Our findings 
reveal that varespladib is not only effective against the activity of anti-coagulant 
PLA2 toxins, but also shows some inhibitory activity against procoagulant venom 
toxins. Varespladib potently and completely inhibited the anticoagulant activities 
detected in all venoms, except for D. russelii, for which almost complete inhibition 
was observed. Furthermore, varespladib showed some degree of inhibition against 
procoagulant venom activities across the various venoms, despite these activities 
not known to be mediated by PLA2 toxins. Contrastingly, of the SVMP-inhibitors 
tested, we demonstrate that their specificities are restricted to effects on 
procoagulant venom toxins, and that the peptidomimetic hydroxamate inhibitor 
marimastat outperforms the metal chelators DMPS and dimercaprol in terms of 
potency. Marimastat potently inhibited procoagulant activities across the venoms 
tested and was unsurprisingly ineffective against anticoagulant venom activities. 
However, only moderate inhibition was observed for most venoms with the metal 
chelators, and no inhibition was found at all for DMPS on D. russelii venom. 
Neither DMPS nor dimercaprol inhibited the non-SVMP stimulated anticoagulant 
venom activities observed across the venoms. 
The advantages of repurposing licensed medicines (e.g., DMPS and dimercaprol) 
or phase II-approved drug candidates (e.g., marimastat and varespladib) are that 
these molecules have demonstrated safety profiles and thus drug development times 
could be significantly shortened as these agents have extensive pharmacokinetic, 
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bioavailability and tolerance data already associated with them [23,61,62]. The 
small size of these compounds, compared with conventional antibodies, confer 
desirable drug-favorable properties enabling rapid and effective tissue penetration 
and, depending on the pharmacokinetics and physicochemical properties of specific 
inhibitors, often make them amenable for oral delivery [61,63,64]. Indeed, both 
varespladib and DMPS have already been demonstrated to confer preclinical 
efficacy against snakebite via the oral route [20,63,64]. DMPS is readily absorbed 
following oral administration in humans, making it a strong candidate for an oral 
community-based therapy [65]; and there are no major side effects or teratogenic 
effects that have been reported on DMPS in murine models [66,67]. In contrast, 
dimercaprol is challenging for clinical use as it currently requires administration by 
painful intramuscular injection. Dosing regimens of each inhibitor therefore need 
further robust investigation in the context of snakebite in order to help inform lead 
candidate selection. 
Certain small molecule inhibitors have been demonstrated to exhibit broad 
inhibition of specific toxin families across diverse medically-important snake 
species [23,59], as also evidenced here for the various coagulopathic toxins found 
across Viperinae venoms. However, these compounds typically target only a single 
family of enzymatic toxins (although varespladib seems perhaps capable of 
targeting more than one family; see Figures 1a, 2a and 3a), thus presenting a 
challenge for these molecules to become standalone therapeutics, as other non-
inhibited toxins seem likely to still cause pathology in snakebite victims. It is 
therefore more likely that small molecule inhibitors will need to be combined into 
therapeutic mixtures, either with other toxin inhibitors or monoclonal antibodies, to 
generate snakebite therapeutics capable of neutralizing the most important 
pathological snake venom toxin families [26,59,61,62]. Small molecule inhibitors 
could serve as valuable prehospital snakebite treatments to delay the onset of severe 
envenoming before the arrival of victims to secondary or tertiary healthcare 
facilities to receive subsequent therapy (i.e., conventional antivenoms). This is 
important, because treatment delays are known to have major detrimental impacts 
on patient outcomes following snakebite [68,69]. Indeed, compounds such as 
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varespladib and DMPS are already being explored in this regard [20,63,64], as they 
represent promising candidates to be used as bridging therapies for delaying the 
major effects of envenomation, and reducing the long time it typically takes rural, 
isolated, impoverished snakebite victims to receive any form of treatment. 
The many limitations associated with conventional snakebite treatments have 
resulted in their weak demand, low availability and poor affordability, despite huge 
unmet medical need. Small molecule “toxin inhibitors” offer great potential to 
rapidly deliver inexpensive, safe and efficacious interventions in the community 
soon after a snakebite, prior to subsequent admission to a healthcare facility. Many 
small molecule inhibitors also offer superior pharmacokinetics in terms of 
efficiently reaching local tissues, such as bite sites, in contrary to antibodies. The 
findings presented here further support the exploration of such inhibitors as 
potential future snakebite treatments. 
4.5. Conclusions 
In this study, a recently developed HTS coagulation assay was combined with 
LC fractionation and parallel obtained MS and proteomics data to assess the 
neutralizing potency of several small molecule inhibitors and chelators (i.e., 
varespladib, marimastat, dimercaprol and DMPS) against the coagulopathic 
activities of individual toxins found in the venoms of Viperinae snakes. These 
compounds show great promise for the development of affordable, broad-spectrum, 
first-aid and clinical treatment of snakebite. Our data further strengthens recent 
findings suggesting that small molecule inhibitors, such as varespladib and 
marimastat, may have broad, cross-species, neutralizing capabilities that make them 
highly amenable for translation into new "generic” snakebite therapeutics. Given 
our evidence that both inhibitors have different specificities, our findings further 
support the concept that a therapeutic combination consisting of both of these Phase 
II-approved small molecule toxin inhibitors shows potential as a new broad-
spectrum snakebite treatment. 
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S1 Venom nanofractionation 
All venoms were nanofractionated onto transparent 384-well plates (F-bottom, 
rounded square well, polystyrene, without lid, clear, non-sterile; Greiner Bio One, 
Alphen aan den Rijn, The Netherlands) using a Shimadzu UPLC chromatography 
system ('s Hertogenbosch, The Netherlands). The UPLC system was connected 
post-column to a modified Gilson 235P autosampler programmed for 
nanofractionation, which was controlled by the in-house written software Ariadne, 
or was post-column connected to a commercially available FractioMateTM 
nanofractionator (SPARK-Holland & VU, Netherlands, Emmen & Amsterdam) 
controlled by FractioMator software. The UPLC system was equipped with two 
Shimadzu LC-30AD parallel pumps, a Shimadzu SIL-30AC autosampler, a 
Shimadzu CTO-30A column oven, a Shimadzu SPD-M20A Prominence diode array 
detector and a DGU-20A5R Prominence degassing unit. All elements were remote 
controlled by the Shimadzu Lab Solutions software assisted by a Shimadzu CBM-
20A System Controller. Venom solutions (5.0 ± 0.1 mg/mL) diluted in water to a 
concentration of 1.0 mg/mL were injected (50 μl) for nanofractionation after 
gradient liquid chromatography (LC). A Waters XBridge reverse-phase C18 column 
(4.6 × 250 mm with a 3.5 μm particle size and a 300 Å pore size) and a Shimadzu 
CTO-30A column oven maintained at 30 °C were used for LC separations. The total 
eluent flow rate was 0.5 mL/min and was controlled by the two Shimadzu LC-
30AD parallel pumps. The gradient separation was carried out by linearly increasing 
mobile phase B from 0 to 50% during the first 20 min, from 50% to 90% during the 
following 4 min, and was then kept at 90% for 5 min. Subsequently, mobile phase B 
was decreased from 90 to 0% in 1 min and kept at 0% for 10 min. Mobile phases A 
consisted of 98% H2O, 2% ACN and 0.1% FA, while mobile phase B consisted of 
98% ACN, 2% H2O and 0.1% FA. A 9:1 (v/v) split of the column effluent was 
applied, of which the smaller fraction was sent to the UV detector followed by MS, 
and the larger fraction was directed to the nanofraction collector. The 
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nanofractionator was set to continuously collect fractions of 6 s/well. After fraction 
collection, the transparent 384-well plates were freeze-dried overnight using a 
Christ Rotational Vacuum Concentrator (RVC 2−33 CD plus, Zalm en Kipp, 
Breukelen, The Netherlands) equipped with a cooling trap operated at –80 °C. The 
freeze-dried plates were stored at –20 °C until the bioassays were performed. 
S2 Plasma coagulation activity assay 
The HTS plasma coagulation assay used in this study was developed by Still et 
al. [1]. CaCl2 was dissolved in water to a concentration of 20 mM at room 
temperature. A 15 mL CentriStarTM tube with frozen plasma was defrosted to room 
temperature in a warm water bath and then centrifuged at 2000 rpm (805 × g) for 4 
min to remove potential particulate matter. Stock solutions (10 mM) of the 
compounds under investigation (i.e., varespladib, marimastat, dimercaprol and 
DMPS (2,3-dimercapto-1-propane-sulfonic acid sodium salt monohydrate)) were 
diluted in PBS buffer to the required concentrations. Of these diluted solutions, 10 
μl were pipetted into all plate wells containing freeze-dried venom fractions by 
using a VWR Multichannel Electronic Pipet (10 μl of PBS were used for venom-
only analyses as a control). Next, plates were centrifuged for 1 min at 2000 rpm 
(805 × g) in a 5810 R centrifuge (Eppendorf, Germany) and then pre-incubated for 
30 min at room temperature. The final concentrations of the inhibitor solutions used 
in the coagulation bioassay were 20 μM, 4 μM and 0.8 μM, and in some cases 0.16 
μM, 0.032 μM and 0.0064 μM. 
Following incubation, 20 μl of the CaCl2 solution was pipetted into each well of 
a 384-well plate with vacuum-centrifuged (to dryness) venom fractions, followed by 
20 μl of centrifuged plasma using a Multidrop™ 384 Reagent Dispenser (Thermo 
Fisher Scientific, Ermelo, The Netherlands) after in-between rinsing the Multidrop 
with Milli-Q. Immediately after plasma addition, the plate was placed in a 
Varioskan™ Flash Multimode Reader (Thermo Fisher Scientific, Ermelo, The 
Netherlands) and a kinetic absorbance measurement was performed at a wavelength 
of 595 nm at room temperature for 100 min. All analyses were performed at least in 
duplicate for checking the reproducibility. The slope of the signal obtained for each 
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well was normalized by dividing the slope to the median of all the slope signals 
from all wells in that measurement. The coagulation curves were plotted versus the 
chromatographic retention time for each fraction collected in three different ways 
(very fast coagulation activity, slightly/medium increased coagulation activity and 
anticoagulation activity) to fully depict both the procoagulation and anticoagulation 
activities in each well. The slope of the average 0–5 min reading was used to depict 
very fast coagulation activity, the slope of the average 0–20 min reading was used 
for slightly/medium increased coagulation activity, and the single reading at 100 
min was used to assess anticoagulation activity. This way, the procoagulant activity 
is presented in two different distinct bioactivity chromatograms to clearly 
discriminate between very fast coagulation (i.e., maximum absorbance and thus full 
coagulation reached within a few minutes) and slightly/medium increased 
coagulation (i.e., maximum absorbance reached within tens of minutes). 
S3 Inhibitory effects of varespladib, marimastat, dimercaprol and DMPS on 
coagulopathic venom toxins from Echis species 
The Echis species investigated in this study were Echis carinatus (India) and 
Echis ocellatus (Nigeria). Venoms from these snakes were analyzed to assess the 
inhibition of coagulopathic venom toxins by different concentrations of varespladib, 
marimastat, dimercaprol and DMPS. Duplicate reconstructed coagulation bioassay 
chromatograms showing the effectiveness of the tested inhibitors at various 
concentrations against coagulopathic toxins from nanofractionated E. carinatus 
venom are shown in Figures S1–S4. In each Figure, the bioassay chromatograms 
depicted on the right, and which do not have superimposed correlated UV data, 
represent replicates of the chromatograms on the left. 
Varespladib inhibited both anticoagulant and procoagulant venom activities 
(Figure S1). In the venom-only analysis, a weak positive peak (22.1 min) followed 
by an intense sharp positive peak (22.3 min) was observed for the very fast 
coagulation activity. Two sets of intense and broad positive peaks (19.9–21.2 min 
and 21.2–22.8 min), which were the result of several closely co-eluting proteins, 
were observed for the slightly/medium increased coagulation activity. An intense 
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sharp negative peak (19.4–19.9 min) was observed in the anticoagulation 
chromatogram. Upon increasing the varespladib concentration, all bioactivity peaks 
decreased and became narrower. For the very fast coagulation activity, the weak 
positive peak (22.1 min) was readily neutralized by 0.8 μM varespladib. No activity 
was detected at a 4 μM varespladib concentration. For the slightly/medium 
increased coagulation activity, the first cluster of positive peaks (19.9-21.2 min) was 
fully neutralized at a varespladib concentration of 4 μM, while the activity of the 
second positive cluster (21.2–22.8 min) decreased in a concentration-dependent 
manner. Only an intense sharp positive peak (21.9 min) was retained at the highest 
varespladib concentration tested (20 μM). For anticoagulant activity, the activity of 
the negative peak (19.4–19.9 min) decreased in both height and width with 
increasing varespladib concentrations. No activity was detected at 20 μM 
varespladib. 




























Figure S1. Duplicate bioassay chromatograms of nanofractionated E. carinatus venom in the presence 
of different concentrations of varespladib. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
Marimastat strongly inhibited procoagulant activity, while displaying limited 
efficacy against anticoagulant activity, as shown in Figure S2. In the venom-only 
analysis, a positive shoulder peak indicating potent activity was detected for both 
the very fast coagulation activity (22.1–22.9 min) and the slightly/medium increased 
coagulation activity (21.2–23.1 min), and an intense sharp negative peak (19.2–19.9 
min) followed by a weak negative peak (20.3 min) was observed in the 
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anticoagulation chromatogram. By increasing the marimastat concentration, the 
procoagulant activity decreased significantly, while the anticoagulant activity was 
not affected. For the very fast coagulation activity, only a weak positive peak (22.1–
22.9 min) was detected at a marimastat concentration of 0.032 μM, and no activity 
was observed at a 0.16 μM marimastat concentration. For the slightly/medium 
increased coagulation activity, the intense positive shoulder peak (21.2–23.1 min) 
was decreased and became narrower with increasing the marimastat concentrations. 
No activity was observed at 0.8 μM marimastat. Neither the intense sharp negative 
peak (19.2–19.9 min) nor the weak negative peak (20.3 min) in the anticoagulation 
chromatograms were diminished at any marimastat concentration tested. 






























Figure S2. Duplicate bioassay chromatograms of nanofractionated E. carinatus venom in the presence 
of different concentrations of marimastat. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
The inhibitory effects of dimercaprol on E. carinatus venom are shown in Figure 
S3. In the venom-only analysis, an intense positive shoulder peak (22.0–22.4 min) 
was noted in the very fast coagulation chromatogram. A weak positive peak (21.5 
min) followed by an intense positive peak (21.8 min) and another weak positive 
peak (22.3 min) made up a non-baseline separated positive peak (21.3–22.4 min), 
which was followed by a weak peak (22.9 min), was shown in the slightly/medium 
increased coagulation chromatogram. An intense and relatively broad anticoagulant 
negative peak (19.1–19.9 min) was also detected. The anticoagulant activity was not 
influenced by dimercaprol. The activity of the positive shoulder peak (22.0–22.4 
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min) in the very fast pro-coagulation chromatogram was fully inhibited by 4 μM 
dimercaprol. For the slightly/medium increased coagulation activity, the majority of 
non-baseline separated positive peaks (21.3–22.4 min) were neutralized by 0.8 μM 
dimercaprol, and only a sharp and intense positive peak (22.3 min) was retained at 
this concentration. No further neutralization was observed upon increasing the 
concentration of dimercaprol. The latest weak positive peak (22.9 min) which eluted 
after the non-baseline separated positive peak (21.3–22.4 min) was still visible at a 
dimercaprol concentration of 0.8 μM, but was fully inhibited by 4 μM dimercaprol. 




























Figure S3. Duplicate bioassay chromatograms of nanofractionated E. carinatus venom in the presence 
of different concentrations of dimercaprol. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
The inhibitory effect of DMPS on E. carinatus venom is shown in Figure S4. 
Similar to dimercaprol, DMPS showed almost no effect on anticoagulant activity, as 
expected for these metal-chelating drugs targeting SVMPs. For the very fast 
coagulation activity, the intense positive shoulder peak (22.0–22.4 min) was 
reduced to a very weak positive peak (22.1 min) at a concentration of 0.8 μM 
DMPS. No activity was detected at 4 μM DMPS. For the slightly/medium increased 
coagulation activity, the non-baseline separated positive peak (21.3–22.4 min) 
changed into a shoulder peak (21.6–22.7 min) at 0.8 μM DMPS, and was further 
decreased by increasing the DMPS concentration, despite the fact that full 
neutralization was not achieved at the highest DMPS concentration tested. The 
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latest eluting weak positive peak (22.9 min) was reduced, but still visible at 0.8 μM 
DMPS concentration, and was fully inhibited at 4 μM DMPS. 




























Figure S4. Duplicate bioassay chromatograms of nanofractionated E. carinatus venom in the presence 
of different concentrations of DMPS. The top superimposed chromatograms are characteristic profiles 
of UV traces measured at 220, 254 and 280 nm. 
The reconstructed coagulation bioassay chromatograms showing the inhibitory 
effects of different concentrations of varespladib, marimastat, dimercaprol and 
DMPS against nanofractionated venom toxins from E. ocellatus are shown in 
Figures S5–S8. The inhibitory effect of varespladib on E. ocellatus venom is shown 
in Figure S5. For the venom-only analysis, a weak positive peak (20.8 min) 
followed by an intense positive peak (21.1–22.2 min) was observed in the very fast 
coagulation chromatogram, an intense positive shoulder peak (21.1–23.1 min) was 
observed in the slightly/medium increased coagulation chromatogram, and an 
intense negative peak (19.4–20.4 min) followed by a weak negative peak (22.1 min) 
was observed in the anticoagulation chromatogram. In presence of varespladib, the 
weak positive peak (20.8 min) in the very fast coagulation chromatogram was fully 
neutralized at a low varespladib concentration (0.16 μM). The activity of the intense 
positive peak (21.1–22.2 min) in the very fast coagulation chromatogram decreased 
with increasing concentrations of varespladib, but this intense positive peak (21.1–
22.2 min) could not be fully neutralized by the highest varespladib concentration 
tested (20 μM). For the slightly/medium increased coagulation activity, the intense 
positive shoulder peak (21.1–23.1 min) became smaller and narrower upon 
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increasing the varespladib concentration, and became a sharp intense positive peak 
(22.0 min) at a concentration of 0.16 μM varespladib. The activity of this intense 
sharp positive peak (22.0 min) decreased dose-dependently by further increasing the 
varespladib concentration but full neutralization was not achieved. For the 
anticoagulant activity, the intense negative peak (19.4–20.4 min) decreased by 
increasing the varespladib concentration and was fully neutralized by varespladib at 
a concentration of 4 μM. The activity in the latest eluting weak negative peak (22.1 
min) was unaffected by varespladib in the 0.16–4 μM range, but was fully 
neutralized by 20 μM varespladib. 






























Figure S5. Duplicate bioassay chromatograms of nanofractionated E. ocellatus venom in the presence 
of different concentrations of varespladib. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
The inhibitory effect of marimastat on E. ocellatus venom is shown in Figure S6. 
In the venom-only analysis, an intense sharp positive peak (21.4–22.2 min) can be 
seen both in the very fast coagulation activity chromatogram and in the 
slightly/medium increased coagulation activity chromatogram. An intense sharp 
negative peak (19.5–20.1 min) can be seen in the anticoagulation activity 
chromatogram. For the marimastat analyses, the intense sharp negative peak (19.5–
20.1 min) in the anticoagulation chrontogram was not influenced by marimastat, 
while the activity of the intense sharp positive peak (21.4–22.2 min) indicating 
slightly/medium increased coagulation decreased with increasing marimastat 
concentrations. Full inactivation of these procoagulant activities was achieved at a 
Neutralizing effects of small molecule inhibitors and metal 




marimastat concentration of 4 μM. For the very fast coagulation activity, a weak 
positive peak (21.8 min) was still observed at 0.032 μM marimastat, which was 
fully neutralized by 0.16 μM marimastat. 






























Figure S6. Duplicate bioassay chromatograms of nanofractionated E. ocellatus venom in the presence 
of different concentrations of marimastat. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 




























Figure S7. Duplicate bioassay chromatograms of nanofractionated E. ocellatus venom in the presence 
of different concentrations of dimercaprol. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
The inhibitory effects of dimercaprol on E. ocellatus venom is shown in Figure 
S7. Only moderate inhibition was achieved against both the very fast coagulation 
activity (21.2–22.2 min) and the slightly/medium increased coagulation activity 
(21.2–22.2 min). The positive peaks (21.2–22.2 min) decreased with increasing 
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dimercaprol concentrations, but full inhibition was not achieved. Dimercaprol could 
not inhibit the anticoagulant activity (19.5–20.1 min). 
The inhibitory effect of DMPS on E. ocellatus venom is shown in Figure S8. For 
the venom-only analysis, an intense sharp positive peak (21.6–22.3 min) was 
observed both in the very fast coagulation chromatogram and in the 
slightly/medium increased coagulation chromatogram, and a sharp intense negative 
peak (19.4–20.1 min) was noted in the anticoagulation chromatogram. The sharp 
positive peak (21.6–22.3 min) in both the very fast coagulation chromatogram and 
the slightly/medium increased coagulation chromatogram was reduced by 
increasing the DMPS concentration. Full inhibition was achieved for the very fast 
coagulation activity at 20 μM DMPS but was not attained for the slightly/medium 
increased coagulation activity. The anticoagulant activity (19.4–20.1 min) was not 
influenced by DMPS. 




























Figure S8. Duplicate bioassay chromatograms of nanofractionated E. ocellatus venom in the presence 
of different concentrations of DMPS. The top superimposed chromatograms are characteristic profiles 
of UV traces measured at 220, 254 and 280 nm. 
S4 Inhibitory effects of varespladib, marimastat, dimercaprol and DMPS on 
the activities of coagulopathic venom toxins from Daboia russelii 
The reconstructed duplicate chromatograms showing the inhibitory effects of 
varespladib, marimastat, dimercaprol and DMPS on nanofractionated D. russelii 
(Sri Lanka) venom are shown in Figures S9–S12. Varespladib could dose-
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dependently reduce all coagulopathic activities observed, but was not able to fully 
neutralize these activities at the highest concentration tested (20 μM). Marimastat 
and dimercaprol could only reduce the pro-coagulopathic activities in a 
concentration-dependent manner. Marimastat neutralized all pro-coagulant activities 
at a concentration of 4 μM. Dimercaprol could fully neutralize these activities at the 
highest concentration tested (20 μM). DMPS showed no inhibition on these 
activities at tested concentrations of 20 μM and 4 μM. 




























Figure S9. Duplicate bioassay chromatograms of nanofractionated D. russelii venom in the presence 
of different concentrations of varespladib. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
































Figure S10. Duplicate bioassay chromatograms of nanofractionated D. russelii venom in the presence 
of different concentrations of marimastat. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
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Figure S11. Duplicate bioassay chromatograms of nanofractionated D. russelii venom in the presence 
of different concentrations of dimercaprol. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 

























Figure S12. Duplicate bioassay chromatograms of nanofractionated D. russelii venom in the presence 
of different concentrations of DMPS. The top superimposed chromatograms are characteristic profiles 
of UV traces measured at 220, 254 and 280 nm. 
S5 Inhibitory effects of varespladib and marimastat on the activities of 
coagulopathic venom toxins from Bitis arietans 
The reconstructed duplicate chromatograms showing the inhibitory effects of 
varespladib and marimastat on nanofractionated B. arietans (Nigeria) venom are 
shown in Figures S13–S14. At the venom concentration used for the analyses (1.0 
mg/mL), only anticoagulant activity was observed. Varespladib could dose-
dependently reduce all coagulopathic activities, and full neutralization was achieved 
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at a low concentration (0.8 μM). Marimastat did not affect anticoagulant activity, 
even at the highest concentration tested (20 μM). 




























Figure S13. Duplicate bioassay chromatograms of nanofractionated B. arietans venom in the presence 
of different concentrations of varespladib. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 




























Figure S14. Duplicate bioassay chromatograms of nanofractionated B. arietans venom in the presence 
of different concentrations of marimastat. The top superimposed chromatograms are characteristic 
profiles of UV traces measured at 220, 254 and 280 nm. 
S6. Inhibitory efficacy of small molecule inhibitors and metal chelators on 
venom toxins identified and depicted in Table 1. 
PA2A1_ECHCA, which was reported to lack hemorrhagic activity [2], was 
neutralized by 20 μM varespladib, but not affected by marimastat, dimercaprol or 
DMPS. PA2A5_ECHOC, for which no anticoagulant activity has been reported in 
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Uniprot KB, was neutralized by 4 μM varespladib, but not by marimastat, 
dimercaprol or DMPS. The SL1_ECHOC, SL124_ECHOC, VM3E2_ECHOC and 
VM3E6_ECHOC procoagulant candidates were not fully neutralized by varespladib 
and dimercaprol, but were effectively neutralized by 0.16 μM marimastat (i.e., a 
very low concentration) and by 20 μM DMPS. It could unfortunately not be 
determined which exact toxins were inhibited by varespladib and/or by dimercaprol, 
and to what proportion per toxin, as in these cases several venom toxins closely co-
eluted. However, it is highly likely that the SVMPs are the dominant procoagulants 
given that it is known that SVMPs are procoagulant in this species and the SVMP 
inhibitors can block this activity. The PA2B8_DABRR, PA2B5_DABRR and 
PA2B3_DABRR were neutralized by 20 μM varespladib, but not influenced by 
marimastat and dimercaprol. Of these, only PA2B8_DABRR was reported to 
exhibit anticoagulant activity [3]. Only SLA_BITAR and SLB_BITAR were found 
back in the anticoagulation area (negative peak at retention time 16.7–17.1 min), 
which was fully inhibited by a low concentration of varespladib (0.8 μM). This 
anticoagulation area was not influenced by marimastat. 
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Repurposing small molecule drugs and drug candidates is considered as a 
promising approach to revolutionize the treatment of snakebite envenoming. In this 
study, we investigated the inhibiting effects of the small molecules varespladib 
(nonspecific phospholipase A2 inhibitor), marimastat (broad spectrum matrix 
metalloprotease inhibitor) and dimercaprol (metal ion chelator) against 
coagulopathic toxins found in Crotalinae (pit vipers) snake venoms. Venoms from 
Bothrops asper, Bothrops jararaca, Calloselasma rhodostoma and Deinagkistrodon 
acutus were separated by liquid chromatography, followed by nanofractionation and 
mass spectrometry identification undertaken in parallel. Nanofractions of the venom 
toxins were then subjected to a high-throughput coagulation assay in the presence of 
different concentrations of the small molecules under study. Anticoagulant venom 
toxins were mostly identified as phospholipases A2, while procoagulant venom 
activities were mainly associated with snake venom metalloproteinases and snake 
venom serine proteases. Varespladib was found to effectively inhibit most 
anticoagulant venom effects, and also showed some inhibition against procoagulant 
toxins. Contrastingly, marimastat and dimercaprol were both effective inhibitors of 
procoagulant venom activities but showed little inhibitory capability against 
anticoagulant toxins. The information obtained from this study aids our 
understanding of the mechanisms of action of toxin inhibitor drug candidates, and 
highlights their potential as future snakebite treatments. 
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Snake envenoming is a highly relevant public health issue that causes substantial 
morbidity and mortality in tropical regions (more than 138,000 deaths every year) 
[1], but remains largely neglected by funding bodies, public health authorities, the 
pharmaceutical industry and health advocacy groups [2]. The true burden of 
snakebite remains unknown, although it has been estimated to be as high as 
1,841,000 envenomings annually [3]. However, since many tropical snakebite 
victims first seek traditional treatment rather than presenting at a healthcare facility, 
this number may be an underestimate, as it is known that many snakebite victims 
die at home and those deaths remain unrecorded [2,4]. Specific antivenom therapies, 
which consist of immunoglobulins purified from serum or plasma of animals 
following hyperimmunization by selected venom(s), represent life-threatening 
treatments of snake envenoming [5]. They are given intravenously in a clinical 
environment and can neutralize the coagulopathic, hemorrhagic and hypotensive 
actions of snake venoms, among other signs of systemic envenoming [6]. However, 
antivenoms are highly specific in neutralizing only one or several venoms from 
species of a certain geographical location [7,8], due to extensive variation in venom 
composition among different snake species [9]. In addition, antivenom-associated 
adverse reactions are common [10], with both acute reactions (anaphylactic shock 
or immediate hypersensitivity) and delayed reactions (treatment-induced serum 
sickness) reported [11]. Finally, antivenoms are often limited in terms of their 
availability and/or poorly distributed, and are typically unaffordable to those who 
live in impoverished rural regions of the tropics—i.e., those who are at the greatest 
risk of snakebite [12].  
A promising approach for solving the critical therapeutic gap between a 
snakebite occurring and delayed presentation to a hospital setting, is the use of small 
molecule toxin inhibitors that can be administered orally and are able to (at least 
partially) neutralize enzymatic snake venom toxicities [13-17]. The venoms of 
many snakes, particularly those of vipers (Viperinae and Crotalinae; both family 
Viperidae) cause coagulopathic and hemorrhagic toxicities by the combined actions 
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of different toxin isoforms of enzymatic families, such as phospholipases A2 
(PLA2s), snake venom serine proteases (SVSPs), and snake venom 
metalloproteinases (SVMPs) [6,7]. Snake venom hydrolytic enzymes are associated 
with a number of systemic clinical syndromes, of which coagulopathy is one of the 
most important in terms of contribution towards mortality [5,6]. PLA2s can 
hydrolyze glycerophospholipids and hence degrade membranes, or damage 
sarcolemma by hydrophobic interactions [18]. SVSPs can proteolytically degrade 
fibrinogen and regulate factor V and plasminogen to perturb hemostasis [19,20]. 
SVMPs can activate prothrombin and/or factor X, hydrolyze and degrade 
endothelial cell basement membranes, and preclude muscle fiber regeneration, all of 
which may contribute to perturbations of blood coagulation and induce severe 
hemorrhaging [21]. These enzymes can potentially be inhibited by small molecule 
toxin inhibitors, such as the PLA2 inhibitor varespladib [22-24] and the 
metalloproteinase inhibitor marimastat [17,25,26]. Varespladib, which is a 
nonspecific PLA2 inhibitor and was a drug candidate for treating atherosclerotic 
lesions [27], coronary heart disease [28,29], and acute chest syndrome induced by 
sickle cell disease [23], has been the focus of considerable recent research as a 
potential therapeutic candidate for snakebite treatment [13,14,22,24]. Varespladib 
has showed efficient inhibition of venom-induced PLA2 activity [13,22] and has 
been demonstrated to reduce hemorrhage, myotoxicity and neurotoxicity in murine 
models after snake envenomation [13,24], as well as protect against venom-induced 
lethality caused by certain snake species and, thus, is now considered as a potential 
pre-referral drug candidate for treating snakebite [22]. 
Similarly, other small molecule inhibitor-based antidote candidates have been 
studied for their potential to inhibit SVMP and SVSP toxin families, and therefore 
serve as alternative (or adjunct), non-antibody based, future treatments for snakebite 
[7,30]. One such molecule is marimastat, which is a water-soluble broad spectrum 
matrix metalloprotease inhibitor [31,32], and which binds to the active site of matrix 
metalloproteinases to form non-covalent complexes [17,33]. Hence it is considered 
as a potential inhibitor of SVMPs which share regions of structural similarity to 
matrix metalloproteinases [26,34,35]. Marimastat has been evaluated for inhibition 
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of angiogenesis [36] and the spread and growth of cancers [25,32]. Because SVMP 
toxins are major constituents of many snake venoms, marimastat was repurposed as 
a candidate to treat snake envenomation and has since been shown to effectively 
inhibit the metalloprotease activity of snake venoms in vitro and neutralize systemic 
toxicity and lethality in vivo in mice envenomed with viper venoms [17,37]. 
SVMPs are Zn2+-dependent proteinases, which become inactive after Zn2+ 
removal from their active site [38]. Many metal chelator treatments have been 
proven to be safe in humans and are used as marketed drugs for chelating heavy 
metals after heavy metal poisoning [39,40]. A small number of these drugs have 
been shown to be effective in neutralizing the venom-induced proteolytic, myotoxic, 
hemorrhagic and coagulation activities in murine snakebite models [26,41]. 
Dimercaprol, which was developed during World War II by British biochemists [42] 
and is listed by the World Health Organization (WHO) as an essential licensed 
medicine [43], is a widely used antidote in treating heavy metal poisoning [44,45], 
and is recommended for treating Wilson’s disease [46]. A recent study from 
Albulescu et al. [16] showed that dimercaprol could effectively inhibit SVMP 
activity, counteract coagulopathic effects and neutralize lethal effects of 
envenoming caused by certain snake species (Viperinae: Echis) in murine models. 
 In this study we used a combination of nanofractionation analytics and high-
throughput coagulation assaying to investigate the potential of varespladib, 
marimastat and dimercaprol as drug repurposing candidates for new, non-antibody-
based, snakebite treatments against coagulopathic pit viper (Crotalinae) snake 
venoms. The coagulation activities of separated toxins from the venoms of the 
medically important pit vipers Bothrops asper, Bothrops jararaca, Calloselasma 
rhodostoma and Deinagkistrodon acutus were evaluated in the presence of the 
various drug repurposing candidates by using a high-throughput screening (HTS) 
coagulation assay after nanofractionation by liquid chromatography (LC) with 
parallel mass spectrometry (MS). We then identified the coagulopathic toxins, 
including those that were neutralized by the various small molecule toxin inhibitors, 
by correlating the resulting bioactivity chromatograms to the parallel obtained MS 
and proteomics data. Our results show that varespladib, marimastat and dimercaprol 
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exhibit different specificities and potencies against coagulopathic venom toxins, but 
that all show promise as novel therapeutics for treating coagulopathic snakebites. 
5.2. Materials and methods 
5.2.1. Chemical and biological reagents 
Deionized water was purified by a Milli-Q Plus system (Millipore, Amsterdam, 
The Netherlands). Acetonitrile (ACN) and formic acid (FA) (Biosolve, 
Valkenswaard, The Netherlands) were used for the HPLC analyses. Calcium 
chloride (CaCl2 dihydrate; Sigma-Aldrich, Zwijndrecht, The Netherlands) was used 
to de-citrate plasma to initiate coagulation in the coagulation assay. Phosphate 
buffered saline (PBS) buffer was prepared by dissolving PBS tablets (Sigma-
Aldrich) in Milli-Q according to the manufacturer’s instructions, before storage at 
4 °C until use, but for no longer than one week prior to use. Bovine plasma was 
purchased from Biowest (Nuaillé, France; sodium citrated, sterile filtered, 500 mL 
per bottle), and prior to use was defrosted in a warm water bath and then quickly 
transferred to 15 mL CentriStarTM tubes (Corning Science, Reynosa, Mexico) once 
fully defrosted. The 15 mL tubes were then re-frozen immediately and stored at 
80 °C until use. Varespladib, marimastat and dimercaprol (Sigma-Aldrich) were 
dissolved in DMSO (≥ 99.9%, Sigma-Aldrich) to a concentration of 10 mM and 
stored at 20 °C. Prior to use, they were diluted in PBS buffer to the concentrations 
used for testing. Lyophilized venoms from B. asper (Costa Rica “Atlantic”), B. 
jararaca (Brazil), C. rhodostoma (captive bred, Thailand ancestry) and D. acutus 
(captive bred, Chinese ancestry) were provided by the Centre for Snakebite 
Research and Interventions, Liverpool School of Tropical Medicine (UK). This 
facility and its protocols for the expert husbandry of snakes are approved and 
inspected by the UK Home Office and the Liverpool School of Tropical Medicine 
and University of Liverpool Animal Welfare and Ethical Review Boards. The 
lyophilized venoms were dissolved in water at 5.0  0.1 mg/mL concentrations, and 
stored at 80 °C until use. 
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5.2.2. LC-MS with parallel nanofractionation 
A UPLC system ('s Hertogenbosch, The Netherlands), which was controlled by a 
Shimadzu Lab Solutions software by the help of a Shimadzu CBM-20A System 
Controller, was used for venom separation. For each analysis, 50 μL venom solution 
(1.0 mg/mL) was injected by a Shimadzu SIL-30AC autosampler after diluting the 
stock venom solutions (5.0  0.1 mg/mL) in Milli-Q. The gradient separation was 
performed on a Waters XBridge reversed-phase C18 column (4.6 × 250 mm column 
with a 3.5 μm particle size and a 300 Å pore size). The temperature of the column 
was controlled at 30 °C by a Shimadzu CTO-30A column oven. The total solvent 
flow rate was 0.5 mL/min and was controlled by two Shimadzu LC-30AD pumps. 
The mobile phases consisted of eluent A (98% H2O, 2% ACN, and 0.1% FA) and 
eluent B (98% ACN, 2% H2O, and 0.1% FA). The mobile phase gradients were run 
as follows: a linear increase of eluent B from 0 to 50% in 20 min followed by a 
linear increase to 90% B in 4 min, then isocratic elution at 90% for 5 min, 
subsequently the eluent B was decreased from 90% to 0% in 1 min after which an 
equilibration of 10 min occurred. A flow split of 9:1 was applied to the column 
effluent of which the smaller fraction was sent to a Shimadzu SPD-M20A 
prominence diode array detector and then to the mass spectrometer. The larger 
fraction was directed to a FractioMateTM nanofractionator (SPARK-Holland & VU, 
Emmen & Amsterdam, Netherlands) controlled by FractioMator software (Spark-
Holland, Emmen, The Netherlands) or to a modified Gilson 235P robot allowing for 
nanofractionation onto transparent 384-well plates (F-bottom, rounded square well, 
polystyrene, without lid, clear, non-sterile; Greiner Bio One, Alphen aan den Rijn, 
The Netherlands). The nanofractionator was set to collect fractions continuously at a 
resolution of 6 s/well. After fraction collection, the well plates were dried overnight 
in a Christ Rotational Vacuum Concentrator (RVC 2-33 CD plus, Zalm en Kipp, 
Breukelen, The Netherlands), to remove any solvent remaining in the wells. The 
Vacuum Concentrator was equipped with a cooling trap maintained at 80 °C 




5.2.3. Plasma coagulation assay 
The HTS coagulation assay was performed as described by Still et al. [47], 
following assay preparation and inhibitor pre-incubation on the vacuum-centrifuge 
dried nanofractionated well plates. For assay preparation, frozen plasma in 15 mL 
CentriStarTM tubes was defrosted to room temperature in a warm water bath and 
then centrifuged at 2000 rpm (805  g) for 4 min in a 5810 R centrifuge (Eppendorf, 
Germany) to remove possible particulate matter. CaCl2 was dissolved in Milli-Q at 
room temperature to obtain a 20 mM solution. For the pre-incubation step, the 
individual inhibitor stock solutions were first diluted in PBS to the required 
concentrations. Then, from each diluted inhibitor solution prepared, 10 μL was 
pipetted to all wells of plate wells containing freeze-dried nanofractionated venom 
fractions by a VWR Multichannel Electronic Pipet, followed by centrifuging the 
plate for 1 min at 2000 rpm (805  g) in the same 5810 R centrifuge (Eppendorf). 
Next, a pre-incubation step for 30 min at room temperature was performed. Final 
concentrations of inhibitor solutions used for the coagulation bioassay were 20, 4 
and 0.8 μM (with corresponding DMSO final concentrations of 0.02%, 0.004% and 
0.0008%, respectively). Venom-only analyses were performed as control 
experiments, for which 10 µL PBS instead of inhibitor solution was added to all 
wells of the vacuum-centrifuge-dried nanofractionated well plates. For initiating the 
coagulation assay, 20 μL of CaCl2 solution, followed by 20 μL plasma, was pipetted 
onto all wells of the 384-well plates by a Multidrop™ 384 Reagent Dispenser 
(Thermo Fisher Scientific, Ermelo, The Netherlands) with rinsing of the Multidrop 
with deionized water in between dispensing. Immediately after robotically pipetting 
the CaCl2 and plasma solutions to a plate, a Varioskan™ Flash Multimode Reader 
(Thermo Fisher Scientific) was used to measure the absorbance of each well 
kinetically for 100 min at 595 nm at 25 °C. Each nanofractionation analysis was 
performed in at least duplicate. The slope value of each well was normalized by 
dividing these slope values with the median value from all wells in that single 
measurement, as described by Slagboom et al. [48] and Xie et al. [49]. The 
coagulation chromatograms were then plotted by using the normalized slope values 
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(y-axis) against the time of nanofraction collection (x-axis). For visualizing 
coagulation activity, the average rate of the kinetic coagulation curve from 0 to 5 
min was plotted for very fast coagulation activity, from 0 to 20 min was plotted for 
slightly/medium increased coagulation activity, and the single reading of the 
coagulation curve at 100 min was plotted for anticoagulation activity. 
Procoagulation was plotted in two different ways since all significantly increased 
procoagulation curves reached their maximum absorbance before 20 min and thus 
plotting the short 5 min kinetic time window allows discrimination of the most 
potent acting procoagulation activities. 
5.2.4. Correlation of biological data with MS and proteomics data 
To identify the venom toxins that exhibited activity in the plasma coagulation 
assay, we used the proteomics data and corresponding accurate mass(es) described 
by Slagboom et al. [48]. For venoms under study in this project that were not 
studied by Slagboom et al. [48], the same procedure as previously described [48] 
was followed to acquire and process proteomics data on these snake venoms. The 
UniprotKB database was used to search for information on class and possible 
known functions for the relevant toxins. To import the proteomics data for the 
venoms included in this study that were also included in the study of Slagboom et al. 
[48], the fingerprint profile LC-UV traces (measured at 220, 254 and 280 nm) for 
the same venom analyses acquired in both studies were used to align 
chromatograms with each other to accommodate for potential slight differences in 
chromatographic retention times. Consequently, the coagulopathic bioactivity peaks 
together with UV data acquired for each nanofractionated venom fraction obtained 
in this study could be linked to the MS-total ion current (TIC) data, to the extracted 
ion current (XIC) data, and to the protein IDs from the proteomics data acquired by 
Slagboom et al. [48]. In order to construct XICs, an MS spectrum corresponding to 
each bioactive peak found in the bioassay chromatogram was first extracted from 
the MS data by averaging the spectra acquired from the 50% and higher peak height 
range of each bioactive peak. Then, XICs were plotted of the clearly observed m/z-
values and were then used to match these peak retention times with the bioactivity 
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peaks in the bioactivity chromatograms. The matched exact masses were assigned to 
each corresponding bioactive peak observed in the bioassay chromatogram by 
matching peak shape and retention time. This way, the m/z-values found from the 
MS data were correlated to each bioactive peak, and the accurate monoisotopic 
masses were determined by applying the deconvolution option in the MS software. 
5.3. Results 
In this study, venoms from a variety of Crotalinae snake species were 
nanofractionated by LC followed by low volume HTS coagulation assaying to 
evaluate the inhibiting effects of varespladib, marimastat and dimercaprol on 
separated venom toxins that induce coagulopathic activities. For veraspladib, the 
data obtained with the coagulation assay as reported in Chapter 3 were used. To 
allow proper comparison, the chromatographic data on varespladib were aligned 
taking the difference in gradient dwell time (5 min) into account. The bioactive 
venom toxins identified were assigned by correlating bioactivity chromatograms to 
parallel obtained MS data and by using proteomics data obtained for proteins 
present in wells showing coagulopathic activities. Using this approach, the 
neutralizing specificities of these molecules on a variety of venom toxins were 
revealed. All analyses were performed at least in duplicate using venom 
concentrations of 1.0 mg/mL. Note that despite venom toxins being, in general, 
rather stable during RPLC within the nanofractionation analytics pipeline, some 
venom toxins might have (partly) denatured and thereby lost their enzymatic 
activity; consequently, the coagulation traces of venom-only analyses in control 
experiments may vary slightly from each other.  
5.3.1. Inhibitory effects of varespladib, marimastat and dimercaprol on 
coagulopathic venom toxins from snake species of the genus Bothrops 
Two venoms from the most medically important genus of snakes in Latin 
America were investigated in this study (B. asper, Costa Rica and B. jararaca, 
Brazil). Envenomings by Bothrops spp. can result in severe local tissue damage, 
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pain and inflammation, as well as systemic hemotoxicity characterized by 
hemorrhage and coagulopathy [50-52]. The coagulopathic activity of the obtained 
venom fractions from both species was assayed in the presence of different 
concentrations of varespladib, marimastat and dimercaprol (Figures 1 and 2). 
Notably, for varespladib in Figure 1, data from Chapter 3 were used after retention-
time alignment taking the difference in gradient dwell time (5 min) into account. 
Duplicate bioassay chromatograms were measured to assess repeatability and 
detailed descriptions of each signal peak observed in the chromatograms are given 
in the Supporting Information Section S1. 
For B. asper venom, in the venom-only analysis (indicated as “PBS” in the 
figures) revealed a sharp intense positive peak (20.9 min) followed by a broad 
intense positive peak (21.2‒22.4 min) in both the very fast coagulation activity 
chromatograms and the slightly/medium increased coagulation activity 
chromatograms. A broad negative peak (18.9‒21.5 min) was also observed in the 
anticoagulation activity chromatograms, demonstrating that this venom exhibits 
both pro- and anticoagulant activities. The broad peaks observed are likely the result 
of co-eluting bioactive venom toxins. When testing the venom fractions in the 
presence of small molecule toxin inhibitors, we found that varespladib inhibited 
some of the observed anticoagulation activities and reduced the potency of a 
number of the procoagulant venom toxins. Contrastingly, marimastat and 
dimercaprol inhibited procoagulant venom effects to varying extents, but had little 
inhibitory impact on anticoagulant toxins. For the very fast coagulation activity, the 
first eluting sharp positive peak (20.9 min) decreased in size with increasing 
concentrations of both varespladib and marimastat. The intensity of the broad 
intense positive peak (21.2‒22.4 min) was also reduced substantially by varespladib 
and marimastat, and the tailing part was fully neutralized by 20 μM of both 
varespladib and marimastat. In contrast, both peaks (20.9 and 21.2‒22.4 min) 
showed limited change in the presence of dimercaprol. However, the 
slightly/medium increased coagulation activity was almost fully neutralized by 20 
μM dimercaprol. The front sharp positive peak (20.9 min) was inhibited by all the 
three inhibitors in a concentration-response manner, while the majority of the broad 
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Figure 1. UV absorbance chromatograms and reconstructed bioassay chromatograms of coagulopathic 
venom fractions of B. asper in the presence of different concentrations of (a) varespladib*, (b) 
marimastat and (c) dimercaprol. The top superimposed chromatograms are characteristic profiles of the 
UV trace detected at 220, 254 and 280 nm. PBS indicates venom only samples where PBS was used as 
a control for the inhibitors. *Data taken from Chapter 3 taking difference in gradient dwell time into 
account. 
intense positive peak (21.2‒22.4 min) was inhibited by 20 μM varespladib, but only 
the tailing part of this peak was inhibited by 20 μM marimastat. For anticoagulant 
venom activity, the front part of the broad negative peak (21.2‒22.4 min) was fully 
neutralized by a concentration as low as 0.8 μM varespladib, while the remaining 
part was not inhibited at all by this molecule. Surprisingly, the broad negative peak 
was split into two individual peaks (18.9‒20.0 and 20.1‒21.0 min) by 0.8 μM 
marimastat, but both peaks remained unchanged in the presence of increasing 
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concentrations of marimastat. No inhibition of anticoagulation activity was 
observed for dimercaprol. 















































Figure 2. UV absorbance chromatograms and reconstructed bioassay chromatograms of coagulopathic 
venom fractions of B. jararaca in the presence of different concentrations of (a) varespladib, (b) 
marimastat and (c) dimercaprol. The top superimposed chromatograms are characteristic profiles of the 
UV trace detected at 220, 254 and 280 nm. PBS indicates venom only samples where PBS was used as 
a control for the inhibitors. 
Next, B. jararaca venom was fractionated and the fractions assessed in the 
presence of varespladib, marimastat and dimercaprol, as outlined above for B. asper. 
The resulting bioassay chromatograms of B. jararaca analyses are shown in Figure 
2. A positive peak with a co-eluting shoulder peak (20.2‒21.7 min) was observed in 
both the very fast coagulation chromatogram and the slightly/medium increased 
coagulation chromatogram in the venom-only analysis. This peak decreased in a 
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relatively comparable manner with increasing concentrations of varespladib, 
marimastat and dimercaprol, although full inhibition was not achieved at the highest 
concentration of any of the inhibitors tested (20 μM). Contrasting strongly with its 
congener B. asper, only a very weak negative peak (20.5‒21.1 min) was detected, 
demonstrating limited anticoagulant venom activity; this peak was not inhibited by 
varespladib, marimastat or dimercaprol at any of the concentrations tested. 
5.3.2. Inhibitory effects of varespladib, marimastat and dimercaprol on 
coagulopathic venom toxins from C. rhodostoma and D. acutus 
Next, we assessed the inhibitory capability of the same small molecule toxin 
inhibitors on two monotypic medically important Crotalinae snake species, namely 
C. rhodostoma from Southeast Asia [53], and D. acutus from southern China and 
northern Vietnam [54]. Venoms from both species are abundant in hemotoxic 
compounds that can deregulate blood coagulation and cause severe coagulopathy in 
snakebite victims [55,56]. In this study, their venoms were fractionated and the 
coagulopathic activity of the obtained fractions was assessed in the presence of 
varespladib, marimastat and dimercaprol. The resulting bioassay chromatograms are 
shown in Figures 3 and 4. Notably, for varespladib, data from Chapter 3 were used 
after retention-time alignment taking the difference in gradient dwell time (5 min) 
into account. The duplicate bioassay chromatograms of the C. rhodostoma and D. 
acutus venom analyses, including detailed descriptions of each bioactivity peak, are 
provided in the Supporting Information Section S2. The bioactivity chromatogram 
of C. rhodostoma venom (Figure 3) showed two sharp positive peaks (19.7 and 20.4 
min) for the very fast coagulation activity as well as for the slightly/medium 
increased coagulation activity, while a moderate negative peak (19.9 min) was 
observed for the anticoagulation activity. Both procoagulation activities were 
gradually reduced by increasing concentrations of varespladib and marimastat. 
These procoagulation activities, however, were not fully neutralized by the highest 
varespladib or marimastat concentrations tested (20 μM), suggesting perhaps a non-
specific inhibitory effect. In contrast to these findings, we observed very limited 
inhibition of both procoagulant peaks with dimercaprol. The negative 
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anticoagulation peak (19.9 min) observed was not inhibited by any of the inhibitory 
molecules tested. 
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Figure 3. UV absorbance chromatograms and reconstructed bioassay chromatograms of coagulopathic 
venom fractions of C. rhodostoma in the presence of different concentrations of (a) varespladib*, (b) 
marimastat and (c) dimercaprol. The top superimposed chromatograms are characteristic profiles of the 
UV trace detected at 220, 254 and 280 nm. PBS indicates venom only samples where PBS was used as 
a control for the inhibitors. *Data taken from Chapter 3 taking difference in gradient dwell time into 
account. 
The bioassay chromatograms constructed from the measurement of LC 
nanofractions of D. acutus venom in the presence of the different concentrations of 
varespladib, marimastat and dimercaprol are shown in Figure 4. In the venom-only 
analysis, a co-eluting intense positive peak (21.0‒22.2 min) was followed by a very 
weak positive peak (22.7‒23.2 min) in the very fast coagulation activity 
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Figure 4. UV absorbance chromatograms and reconstructed bioassay chromatograms of coagulopathic 
venom fractions of D. acutus venom in the presence of different concentrations of (a) varespladib*, (b) 
marimastat and (c) dimercaprol. The top superimposed chromatograms are characteristic profiles of the 
UV trace detected at 220, 254 and 280 nm. PBS indicates venom only samples where PBS was used as 
a control for the inhibitors. *Data taken from Chapter 3 taking difference in gradient dwell time into 
account. 
chromatogram. The later eluting weak positive peak (22.7‒23.2 min) was fully 
neutralized by both varespladib and marimastat at a 4 μM concentration. The broad 
intense positive peak (21.0‒22.2 min) was substantially reduced by varespladib in a 
concentration-dependent fashion, but was only slightly inhibited by the highest 
marimastat concentration tested (20 μM). In the slightly/medium increased 
coagulation activity chromatogram, several positive peaks eluted close together 
(21.2‒23.4 min) and were observed as non-baseline separated peaks in the venom-
only analysis. They were all reduced by increasing varespladib concentrations and 
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the tailing part of the broad peak was fully neutralized at 20 μM varespladib. 
Marimastat had a limited effect on these peaks, with only the tailing part of the 
peaks partly neutralized at the highest concentration tested (20 μM). For both the 
very fast coagulation activity and the slightly/medium increased coagulation activity, 
dimercaprol showed no inhibitory effect at 0.8 μM, though showed moderate 
inhibition at 4 and 20 μM. For anticoagulant venom activity, a sharp intense 
negative peak (20.7 min), followed by a very weak negative peak (21.5 min), was 
observed in the venom-only analysis. The intense negative peak (20.7 min) was 
reduced in a dose dependent manner by varespladib, with complete inhibition 
achieved at the 4 μM concentration, whereas the weak negative peak (21.5 min) was 
not affected by varespladib. Neither of these anticoagulation activity peaks was 
affected by marimastat and dimercaprol. 
5.3.3. Identification of coagulopathic venom toxins neutralized by the small 
molecule inhibitors varespladib, marimastat and dimercaprol 
The venom toxins responsible for the coagulation activities observed for each of 
the four snake venoms were tentatively identified by correlating the acquired data 
with MS and proteomics data previously obtained by Slagboom et al. [48] (Table 1). 
Large part of these LC-MS and proteomics data was already stated in Table 1 of 
Chapter 2. For clarity and convenience it is provided here again. Bioactivities were 
linked to accurate molecular masses and tentative protein identities by aligning the 
characteristic LC-UV chromatograms obtained for each venom. For those toxins 
where no exact mass data was acquired by LC-MS, only the proteomics data 
obtained from the Mascot searches is provided. 
By comparing Table 1 with Figures 1‒4, the inhibiting effects of varespladib, 
marimastat and dimercaprol on individual Crotalinae venom toxins were assessed. 
Most anticoagulant toxins identified were PLA2s. The PLA2s in B. asper venom 
were partly neutralized by 20 μM varespladib, and in D. acutus venom were fully 
neutralized at a concentration of 4 μM varespladib. However, no anticoagulant toxin 
was identified from the Mascot results for B. jararaca venom, and no inhibition was 
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marimastat and dimercaprol. The tentatively identified procoagulant toxins were 
mainly SVMPs, SVSPs and C-type lectins (CTLs). Only two SVMPs in D. acutus 
venom identified as procoagulant toxins were fully inhibited by 4 μM marimastat, 
and by 20 μM varespladib. The potential inhibition of SVMPs by varespladib can 
indicate that varespladib may not exert its effect solely by inhibition of the 
phospholipid hydrolyzing activity of PLA2s, though further research is required to 
robustly test this hypothesis. Critically, as several venom toxins were found to co-
elute in regions where bioactives were observed, the unambiguous identification of 
the individual contribution of each toxin to each coagulation bioactivity peak, and 
their relative contributions to coagulotoxicity, are difficult to interpret. Additionally, 
some non-polar (late eluting) venom toxins might (partially) denature during LC 
separation and become biologically inactive and as such may not be detected by the 
coagulopathic bioassay. A detailed description of the results discussed here is 
provided in the Supporting Information Section S3. 
5.4. Discussion 
Snake envenoming by pit vipers is usually characterized by coagulopathy, 
hemorrhage and local effects, such as swelling and tissue damage around the site of 
the bite [1]. Our study investigated the neutralizing capabilities of promising small 
molecule-based drug candidates on the coagulopathic activities of pit viper venoms 
by using nanofractionation analytics. All venoms showed both procoagulation 
activities and anticoagulation activities, albeit only trace anticoagulant activity was 
observed with B. jararaca venom. Our findings reveal that the PLA2 inhibitor 
varespladib inhibited many of the observed anticoagulation activities, and 
surprisingly also exhibited varying inhibitory effects on several of the observed 
procoagulation activities. However, future work is required to unravel the 
mechanisms of this inhibition of procoagulant activity, given that such toxins are 
unlikely to be PLA2s. We cannot rule out that non-specific effects at high inhibitor 
concentrations are responsible for these observations. Snake venom PLA2s 
hydrolyze phospholipids to release fatty acids and lysophospholipids, resulting in 
Neutralizing effects of small molecule toxin inhibitors on  




damage to cell membranes, or prolong/delay prothrombin time to prevent blood 
clotting. These toxins, often acting synergistic with other venom toxin families such 
as SVMPs and SVSPs [57,58], contribute to various toxicities observed following 
snake envenoming, including hemotoxic, myotoxic and neurotoxic effects, and thus 
are one of the main players in resulting morbidity and mortality [48,59,60]. By 
using varespladib, the enzymatic toxicities mediated by PLA2s can be alleviated, 
delayed and/or abrogated [14,22,24,61]. However, additional work is required to 
fully understand the inhibitory potential of varespladib for snakebite. For example, 
Wang et al. [13] previously demonstrated that varespladib was capable of fully 
inhibiting the hemorrhagic toxicity induced by D. acutus venom when it was 
administered subcutaneously or intramuscularly to mice, whilst also having some 
inhibitory effect of the myotoxic activities caused by this venom. Despite these 
findings, our results show that not all coagulopathic toxins found in D. acutus 
venom were inhibited by varespladib, and indeed similar observations were 
observed with the other venoms under study. Thus, while varespladib undoubtedly 
remains a highly promising snakebite therapeutic, more work is required to fully 
understand its toxin-neutralizing specificity. 
The SVMP inhibitors marimastat and dimercaprol only partly inhibited the 
procoagulation activities revealed in this study, and showed little inhibitory activity 
against anticoagulant toxins (mostly identified as PLA2s). These findings are in line 
with the anticipated specificity of their mechanism of action, which interact via 
different mechanisms on the active sites of SVMPs [16,17,37]. Despite previous 
studies showing that marimastat and dimercaprol inhibited SVMP activity from the 
venoms of Crotalus atrox and Echis spp. [16,17,37], here we found that marimastat 
and dimercaprol showed only a degree of inhibition against certain procoagulant 
toxins present in the venoms of the pit vipers under study. However, these findings 
can be rationalized, given that many of the procoagulant toxins tentatively identified 
here were not SVMPs (Table 1). Interestingly, neither marimastat nor dimercaprol 
had a noticeable inhibitory effect on the coagulotoxicity of C. rhodostoma venom, 
and indeed no SVMP toxins were identified among the bioactives detected in this 
study. Thus, specific inhibitors against C-type lectins and/or SVSP toxins may be 
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required to prevent procoagulant venom effects caused by this species. It is worth 
noting that Albulescu et al. [37] recently demonstrated that the serine protease 
inhibitor nafamostat was capable of broadly neutralized the SVSP activity of a 
variety of viper venoms (including B. asper) in a dose-dependent manner, and thus 
use of this molecules seems likely to be a logical starting point for future inhibition 
studies using C. rhodostoma venom. 
It is worth highlighting that these inhibitor-based therapeutic candidates have 
different specificities and act on different toxin classes found in snake venoms. 
Therefore, in the long term, utilizing combinations of such molecules (e.g., the 
PLA2 inhibitor varespladib, SVMP inhibitor marimastat and/or chelator dimercaprol, 
together with serine protease inhibitors and other venom toxin inhibitors) seems 
likely to be a potentially viable strategy for the development of adjunct and/or 
stand-alone treatments of snakebite, that may be of great value for use as early 
interventions in remote rural areas where treatment delays contribute to poor patient 
outcomes. In the recent study of Albulescu et al. [37], we demonstrated that a 
therapeutic combination of varespladib and marimastat protected experimental 
animals from the lethal effects of a variety of viper venoms, including that of B. 
asper studied here. A combination of various different inhibitors (or indeed 
modalities, e.g., small molecules and monoclonal antibodies or nanobodies) may 
prove to be the only viable approach to obtain affordable broad-spectrum 
therapeutics for treating snakebite globally [9,22,26]. However, considerable further 
work is required to robustly explore this view, ideally via the application of both in 
vitro and in vivo studies, using both a diversity of chemical entities as potential 
inhibitory agents and a variety of snake venoms that represent full (global) toxin 
diversity. In the longer term, such in vivo studies should also explore appropriate 
dosing schedules and administration routes of identified lead candidates to robustly 
predict their translational potential for use in human clinical trials. Our findings here 
reinforce the notion that small molecule based toxin inhibitors are viable entities as 
next-generation snakebite therapeutics, and though hurdles associated with 
overcoming variable venom compositions and distinct toxin inhibiting specificities 
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remain, there is a strong rationale for future research programmes to continue to 
evaluate these molecules as valuable repurposing candidates for snakebite. 
5.5. Conclusions 
The coagulation activities of toxins isolated from the venoms of the Crotalinae 
snakes B. asper, B. jararaca, C. rhodostoma and D. acutus were investigated by the 
application of a recently developed HTS coagulation assay after venom 
nanofractionation by LC. The inhibitory potential of the small molecule toxin 
inhibitors varespladib, marimastat and dimercaprol against the bioactivities of 
nanofractionated pit viper venom toxins was then evaluated. All inhibitors under 
study are either registered drugs or at least phase II approved candidates known to 
inhibit PLA2 or protease activity. This implies that these compounds are clinically 
safe and as such will this significantly increase the chances of these compounds to 
be developed into eventual snakebite treatments as compared to studying non-
clinically tested compounds. Coagulopathic venom toxins were tentatively 
identified by correlating bioassay activity chromatograms to MS and proteomics 
data obtained in parallel. Our results showed that the three repurposed drug 
candidates exhibited varying inhibitory effects against distinct pro- and 
anticoagulant venom toxins identified in each venom. We conclude that 
combinations of small molecule drugs capable of inhibiting distinct toxin families 
may be required to ensure broad neutralization of a diversity of snake venoms. 
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S1. Inhibiting effects of varespladib, marimastat and dimercaprol on venoms 
from Bothrops species 
The inhibiting effects of varespladib, marimastat and dimercaprol were 
investigated on both nanofractionated B. asper and B. jararaca venom toxins for 
coagulation activity. The reconstructed bioassay chromatograms for B. asper venom 
are shown in Figures S1‒S3. In this study, each coagulation bioassay was performed 
at least in duplicate on nanofractionated venom toxins for reproducibility 
assessment. In each Figure, the right-side bioassay chromatograms which do not 
have superimposed correlated UV data depict the duplicate results of the left side 
chromatograms. For each venom, the concentration of 1.0 mg/mL was used for 
nanofractionation. The bioassay chromatograms consist of three parts to fully depict 
all coagulation activities; the very fast coagulation activity (lower series of 
superimposed bioassay chromatograms), the slightly/medium increased coagulation 
activity (middle set of bioassay chromatograms), and the anticoagulation activity 
(upper series of superimposed bioassay chromatograms). 
The effect of varespladib on B. asper venom after nanofractionation is shown in 
Figure S1. For the very fast coagulation activity, a sharp positive peak (20.9 min) 
followed by a broad positive peak (21.2‒22.4 min) was observed in the venom-only 
analysis (10 µL PBS solution was added before pre-incubation and is shown as 
“PBS” in the graphs). The sharp positive peak (20.9 min) was decreased in a 
concentration-dependent manner by increasing the varespladib concentration. The 
broad positive peak (21.2‒22.4 min) changed into several sharp positive peaks after 
varespladib addition, and the activity of these peaks decreased further with 
increasing varespladib concentrations. Neither the sharp positive peak (20.9 min) 
nor the broad positive peak (21.2‒22.4 min) could be fully neutralized by 
varespladib at the highest concentration of 20 μM tested. For the slightly/medium 
increased coagulation activity, a sharp positive peak (20.9 min) followed by a broad 
positive peak (21.2‒22.4 min), as was also observed in the very fast coagulation 
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chromatograms, was observed in the venom-only analysis. Varespladib also showed 
a concentration-dependent effect on the sharp positive peak (20.9 min). Full 
inhibition of both peaks however was not achieved at a 20 μM varespladib 
concentration. For the anticoagulation activity, a sharp negative peak (19.4 min) 
followed by a broad negative peak (19.9‒20.9 min) and a tailing sharp negative 
peak (21.1 min) were observed in the chromatogram of the venom-only analysis. 
The first sharp negative peak (19.4 min) was already fully neutralized at a 0.8 μM 
varespladib concentration, while the broad negative peak (19.9‒20.9 min) and the 
tailing sharp negative peak (21.1 min) were not inhibited at all by varespladib. 




























Figure S1. Reconstructed coagulation chromatograms in duplicate of nanofractionated B. asper venom 
toxins in presence of different concentrations of varespladib. The top superimposed chromatograms are 
characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
The effect of marimastat on B. asper venom after nanofractionation is shown in 
Figure S2. In the venom-only analysis, a sharp positive peak (21.0 min) and a 
positive shoulder peak (21.3‒22.1 min) were detected for the very fast coagulation 
activity; the sharp positive peak (21.0 min) decreased with increasing marimastat 
concentrations. The tailing part of the positive shoulder peak (21.3‒22.1 min) was 
already neutralized by 0.8 μM marimastat while the front part was shown to have 
less effect on the 0.8 μM and also the 4 μM marimastat concentrations. Only a very 
weak positive peak (21.0 min) was left at the marimastat concentration of 20 μM 
tested. For the slightly/medium increased coagulation activity, three sharp positive 
peaks (21.0, 21.5, and 21.9 min) were observed in the venom-only chromatogram. 
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The front two peaks (21.0 and 21.5 min) decreased with no inactivation achieved 
for the 20 μM marimastat analysis, while the third positive peak (21.9 min) was 
split into two smaller peaks which were eventually neutralized at the 20 μM 
marimastat concentration. For the anticoagulation activity, a large broad negative 
peak (18.9‒21.0 min) followed by a small sharp negative peak (21.1 min) was 
observed in the venom-only analysis. The broad negative peak (18.9‒21.0 min) was 
split into two negative peaks (18.9‒20.0 and 20.1‒21.0 min) but the activity of these 
two peaks (18.9‒20.0 and 20.1‒21.0 min) together with the later eluting weak 
negative peak (21.1 min) were not found to be inhibited at all by marimastat. To 
summarize, no full neutralization was achieved by marimastat for the pro-
coagulation activity as well as the anticoagulation activity. 




























Figure S2. Reconstructed coagulation chromatograms in duplicate of nanofractionated B. asper venom 
toxins in presence of different concentrations of marimastat. The top superimposed chromatograms are 
characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
The effect of dimercaprol on inhibiting nanofractionated B. asper venom 
coagulation toxins is shown in Figure S3. Two sharp positive peaks (21.1 and 21.5 
min) were detected for the very fast coagulation activity in the venom-only analysis 
and both showed a limited response to dimercaprol. A sharp positive peak (20.9 min) 
followed by a broad positive peak (21.2‒22.8 min) was observed for the 
slightly/medium increased coagulation activity in the venom-only analysis. The 
sharp positive peak (20.9 min) decreased by increasing dimercaprol concentrations. 
The broad positive peak (21.2‒22.8 min) showed a limited response to 0.8 μM 
Chapter 5 
186 
dimercaprol, but was reduced significantly at the 4 μM dimercaprol analysis. Only 
weak activities were left for both these two peaks at the 20 μM dimercaprol analysis. 
A weak negative (19.4 min) and a broad negative peak (19.9‒20.9 min) followed by 
one additional weak negative peak (21.2 min) for the anticoagulation activity in the 
venom-only analysis. No inhibition was observed at all by dimercaprol for the 
anticoagulation activity. 




























Figure S3. Reconstructed coagulation chromatograms in duplicate of nanofractionated B. asper venom 
toxins in presence of different concentrations of dimercaprol. The top superimposed chromatograms 
are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
The reconstructed duplicate chromatograms showing inhibiting effects of 
varespladib, marimastat and dimercaprol on B. jararaca venom after 
nanofractionation are depicted in Figures S4‒S6. 



























Figure S4. Reconstructed coagulation chromatograms in duplicate of nanofractionated B. jararaca 
venom toxins in presence of different concentrations of varespladib. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
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Figure S5. Reconstructed coagulation chromatograms in duplicate of nanofractionated B. jararaca 
venom toxins in presence of different concentrations of marimastat. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 




























Figure S6. Reconstructed coagulation chromatograms in duplicate of nanofractionated B. jararaca 
venom toxins in presence of different concentrations of dimercaprol. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
S2. Inhibiting effects of varespladib, marimastat and dimercaprol on venoms 
from Calloselasma and Deinagkistrodon species 
The duplicate plasma coagulation bioassay results for C. rhodostoma and D. 
acutus venoms inhibited by varespladib, marimastat and dimercaprol are shown in 
Figures S7‒S12. Figure S7 shows the bioassay chromatograms for nanofractionated 
C. rhodostoma venom toxins in presence of varespladib. In the venom-only analysis, 
two sharp positive peaks (19.7 and 20.5 min) are shown in the very fast coagulation 
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chromatogram; a sharp positive peak (19.7 min) together with a broad positive peak 
(20.3‒21.6 min) which consisted of three closely eluting peaks is shown for the 
slightly/medium increased coagulation activity. The activity of these positive peaks 
was reduced by increasing varespladib concentrations, but none of them were fully 
neutralized with the highest varespladib concentration tested (20 μM). Two negative 
peaks (19.8 and 20.1 min) were observed for the anticoagulation activity in the 
venom-only analysis. The first negative peak (19.8 min) was fully neutralized by 
varespladib at the concentration of 4 μM, while the activity of the second negative 
peak (20.1 min) was not significantly affected by varespladib.  




























Figure S7. Reconstructed coagulation chromatograms in duplicate of nanofractionated C. rhodostoma 
venom toxins in presence of different concentrations of varespladib. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
The inhibiting effect of marimastat on C. rhodostoma venom is shown in Figure 
S8. In the venom-only analysis, two sharp positive peaks (19.7 and 20.3 min) are 
shown for both the very fast coagulation activity and the slightly/medium increased 
coagulation activity, and a moderate negative peak (19.9 min) was observed for the 
anticoagulation activity. Both the anticoagulation activity and the later eluting 
positive peak (20.3 min) in the very fast coagulation activity chromatograph were 
not affected significantly by marimastat. The first sharp positive peak (19.7 min) in 
both the very fast coagulation activity and the slightly/medium increased 
coagulation activity chromatogram reduced by increasing marimastat concentrations, 
but full inactivation was not achieved at even the highest marimastat concentration 
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tested (20 μM). The second intense positive peak (20.3 min) for the slightly/medium 
increased coagulation activity was not inhibited by 0.8 μM marimastat. The 
intensity of this peak (20.3 min) decreased significantly at the 4 μM marimastat 
analysis, although the peak (20.3 min) showed about the same intensity for the test 
with a marimastat concentration of 20 μM. A possible explanation for this 
observation is that this peak (20.3 min) consisted of at least two co-eluting pro-
coagulant toxins of which one could be neutralized by 4 μM marimastat, while the 
other one was not inhibited at all. 




























Figure S8. Reconstructed coagulation chromatograms in duplicate of nanofractionated C. rhodostoma 
venom toxins in presence of different concentrations of marimastat. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 


























Figure S9. Reconstructed coagulation chromatograms in duplicate of nanofractionated C. rhodostoma 
venom toxins in presence of different concentrations of dimercaprol. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
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The inhibiting effect of dimercaprol on C. rhodostoma venom is shown in Figure 
S9. In the venom-only analysis, a sharp positive peak (19.7 min) followed a relative 
broad positive peak (20.3‒23.0 min) was observed for both the very fast coagulation 
activity and the slightly/medium increased coagulation activity, and a moderate 
negative peak (19.9 min) was observed for the anticoagulation activity. Both 
procoagulation activities were inhibited by dimercaprol in a very limited extent at 4 
μM, but no further inhibition was observed by further increasing the dimercaprol 
concentration to 20 μM. The anticoagulation activity was not influenced by 
dimercaprol at any tested concentration. 




























Figure S10. Reconstructed coagulation chromatograms in duplicate of nanofractionated D. acutus 
venom toxins in presence of different concentrations of varespladib. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
Figures S10‒S12 show the bioassay chromatograms for nanofractionated D. 
acutus venom toxins in presence of different concentrations of varespladib, 
marimastat and dimercaprol. The effect of varespladib on D. acutus venom is shown 
in Figure S10. Two intense positive peaks (21.2 and 21.7 min) together with a weak 
positive peak (22.3 min) are shown for the very fast coagulation activity in the 
venom-only analysis. The intensity of these peaks was decreased with increasing 
varespladib concentrations of which the weak peak (22.3 min) was fully inhibited at 
4 μM varespladib. After increasing the varespladib concentration to 20 μM, only a 
weak positive shoulder peak (21.0‒21.9 min) was left. In the slightly/medium 
increased coagulation activity chromatogram, a sharp positive peak (21.2 min) 
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followed by a co-eluting broad positive peak (21.3‒23.4 min, probably consisting of 
several closely co-eluting venom toxins) was observed. Both were reduced by 
increasing the varespladib concentration, the majority of the signal of the broad 
positive peak (21.3‒23.4 min) was neutralized by 20 μM varespladib. Only a small 
positive peak (21.0‒22.0 min) was left in the 20 μM varespladib analysis. A sharp 
intensive negative peak (20.7 min) followed by a sharp weak negative peak (21.5 
min) was found for the anticoagulation activity in the venom-only analysis. The 
intensive negative peak (20.7 min) was reduced by increasing the varespladib 
concentration and was fully neutralized at 4 μM varespladib. In contrast, the weak 
negative peak (21.5 min) could not be neutralized at all by varespladib. 




























Figure S11. Reconstructed coagulation chromatograms in duplicate of nanofractionated D. acutus 
venom toxins in presence of different concentrations of marimastat. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
The effect of marimastat on D. acutus venom is shown in Figure S11. An intense 
positive peak (21.1‒22.1 min) followed by a very weak positive peak (22.9 min) is 
shown in the very fast coagulation activity chromatogram of the venom-only 
analysis. The intensity of both positive peaks did not change with 0.8 μM 
marimastat, while increasing the marimastat concentration to 4 μM resulted in a 
slightly sharper for the intense positive peak (21.1‒22.1 min) and inactivation of the 
weak positive peak (22.9 min). By further increasing the marimastat concentration 
to 20 μM, no significant difference was observed compared to the chromatogram 
from the 4 μM marimastat analysis. Probably in this case, several toxins co-eluted 
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of which some could be neutralized while others could not. For the slightly/medium 
increased coagulation activity, several moderately positive peaks (20.9‒240.3 min) 
eluting close together and were observed as non-baseline separated peaks in the 
venom-only analysis. These peaks had a limited influence of marimastat and only 
the marimastat concentration of 20 μM partly neutralized the later eluting peaks. For 
the anticoagulation activity, there was a sharp and intense negative peak (20.5 min) 
in the chromatogram which was not inhibited at all by marimastat. 
The effect of dimercaprol on D. acutus venom is shown in Figure S12. A 
positive peak (21.6‒23.3 min) was observed in both the very fast coagulation 
chromatogram and the slightly/medium increased coagulation chromatogram. They 
were concentration-dependently inhibited by dimercaprol, however, no full 
inactivation was achieved at the highest concentration tested (20 μM). A potent 
sharp negative peak (20.7 min) was shown in the anticoagulation activity, which 
was not influenced at all by dimercaprol. 




























Figure S12. Reconstructed coagulation chromatograms in duplicate of nanofractionated D. acutus 
venom toxins in presence of different concentrations of dimercaprol. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
S3. Inhibitory efficacy of small molecule inhibitors and metal chelators on 
venom toxins that identified and given in Table 1. 
In B. asper venom, proteomics results indicated the toxins PA2H2_BOTAS, 
PA2HA_BOTAS, PA2H3_BOTAS, PA2B3_BOTAS, PA2A2_BOTAS and 
VM2_BOTAS as tentative anticoagulant toxins, while VSPL_BOTAS, 
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VM1B1_BOTAS and SLA_BOTAS were identified as procoagulant toxins. Of 
these toxins, PA2H2_BOTAS was neutralized by 0.8 μM varespladib, while 
VM2_BOTAS, a SVMP co-eluting with PLA2s, was not neutralized by the 
inhibitors tested. The toxins PA2HA_BOTAS, PA2H3_BOTAS, PA2B3_BOTAS 
and PA2A2_BOTAS were assigned to anticoagulation activities that were partly 
inhibited by 20 μM varespladib. Most procoagulant toxins partly co-eluted in the 
activity peaks and could only partly be inhibited by varespladib, marimastat and 
dimercaprol. As such, it could not be determined which ones were the active ones 
and from these which ones were (partly) inhibited. The LC-MS data this way 
provided clear additional confirmation, next to the proteomics data, of the bioactive 
PLA2s involved in the anticoagulation toxicities measured. 
In B. jararaca venom, the procoagulation activity was inhibited in a dose-
response manner by varespladib, marimastat and dimercaprol, but full neutralization 
was not achieved by any of the tested inhibitors. The toxins VSPA_BOTJA, 
VSP1_BOTJA, VSP2_BOTJA, VSP12_BOTJA, VSP14_BOTJA and 
VSP20_BOTJA were identified as procoagulants. These procoagulant toxins partly 
co-eluted in the activity peaks and could only partly be inhibited by varespladib, 
marimastat and dimercaprol. As such, it could not be determined which ones were 
the active ones and from these which ones were (partly) inhibited. No toxins were 
identified from Mascot searches for the weak anticoagulation activity observed. 
In C. rhodostoma venom, the toxins PA2BD_CALRH, PA2AB_CALRH, 
VSPF1_CALRH, SLEA_CALRH and SLEB_CALRH were assigned as candidates 
responsible for the observed anticoagulation activity. The toxins VSPF2_CALRH, 
SLYA_CALRH and SLYB_CALRH were tentatively assigned to cause the 
procoagulation activity. The toxin PA2BD_CALRH has been reported to display 
calcium independent myotoxicity by Tsai et al. [1] in the UniprotKB. The 
anticoagulation activities observed were neither inhibited by varespladib nor by 
marimastat. The procoagulation activities were partly inhibited both by varespladib 
and by marimastat, however no full inhibition was observed. 
In D. acutus venom, the toxins PA2A_DEIAC and SL_DEIAC were tentatively 
identified as being responsible for the anticoagulation activity observed, which 
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could be neutralized by 4 μM varespladib but could not be neutralized by 
marimastat. The toxins VSP1_DEIAC, VSPA_DEIAC, SLCB_DEIAC, 
VM1AC_DEIAC, VM11_DEIAC, VM1H5_DEIAC and VM3AK_DEIAC were 
tentatively assigned to the procoagulation activity observed, which was only partly 
inhibited by varespladib, marimastat or dimercaprol. The procoagulant toxins 
VM3A2_DEIAC and VM3AH_DEIAC were both fully inhibited by 4 μM 
marimastat and by 20 μM varespladib. 
Reference 
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from Callosellasma rhodostoma venom gland: Cloning and sequencing of 10 of the 
cDNAs, three‐dimensional modelling and chemical modification of the major isozyme. 
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Snakebite is classified as a priority Neglected Tropical Disease by the World 
Health Organization. Understanding the pathology of individual snake venom toxins 
is of great importance when developing more effective snakebite therapies. Snake 
venoms may induce a range of pathologies, including hemolytic activity. Although 
snake venom-induced erythrocyte lysis is not the primary cause of mortality, 
hemolytic activity can greatly debilitate victims and contributes to systemic 
hemotoxicity. Current assays designed for studying hemolytic activity are not 
suitable for rapid screening of large numbers of toxic compounds. Consequently, in 
this study, a high-throughput hemolytic assay was developed that allows profiling of 
erythrocyte lysis, and was validated using venom from a number of medically 
important snake species (Calloselasma rhodostoma, Daboia russelii, Naja 
mossambica, Naja nigricollis and Naja pallida). The assay was developed in a 
format enabling direct integration into nanofractionation analytics, which involves 
liquid chromatographic separation of venom followed by high-resolution 
fractionation and subsequent bioassaying (and optional proteomics analysis), and 
parallel mass spectrometric detection. Analysis of the five snake venoms via this 
nanofractionation approach involving hemolytic assaying provided venom-
cytotoxicity profiles and enabled identification of the toxins responsible for 
hemolytic activity. Our results show that the elapid snake venoms (Naja spp.) 
contained both direct and indirect lytic toxins, while the viperid venoms (C. 
rhodostoma and D. russelii) only showed indirect lytic activities, which required the 
addition of phospholipids to exert cytotoxicity on erythrocytes. The hemolytic 
venom toxins identified were mainly phospholipases A2 and cytotoxic three finger 
toxins. Finally, the applicability of this new analytical method was demonstrated 
using a conventional snakebite antivenom treatment and a small-molecule drug 
candidate to assess neutralization of venom cytotoxins. 
 
  





Snakebite is defined as a Neglected Tropical Disease (NTD) by the World 
Health Organization (WHO), with annual mortality ranging from 81,000 to 138,000 
and morbidity rates surpassing 400,000 [1-3]. The regions in the world that are most 
heavily affected are the rural impoverished areas of the tropics and sub-tropics [3]. 
Despite its medical importance, snakebite remains systemically neglected by 
governments and public health communities [3]. Snake venoms consist of complex 
mixtures of proteins and peptides that vary between snake species and that are 
capable of causing various pathologies following envenoming, including 
neurotoxicity, hemotoxicity and cytotoxicity [3,4]. Some of the most relevant toxin 
families found in snake venoms include phospholipases A2 (PLA2s), snake venom 
metalloproteinases (SVMPs), snake venom serine proteases (SVSPs) and three-
finger toxins (3FTxs) [4-6]. Some of these toxins directly affect the hemostatic 
system and are capable of causing local and/or systemic hemorrhage. Hemostatic 
activities caused by such toxins include disruption of the vascular cell lining, 
inhibition or activation of clotting factors, vasodilation, inhibition of platelet 
aggregation and erythrocyte lysis [4,5,7,8]. The latter comprises destruction of the 
erythrocyte membrane.  
Erythrocyte lysis can result either from direct lysis or from indirect hemolysis. 
Indirect lysis requires the presence of phospholipids and is probably caused by 
disruption of the cell membrane by hydrolysis products of the phospholipids [9,10]. 
Although snake venom-induced erythrocyte lysis seldom causes life-threatening 
pathology by itself, it may have a debilitating effect on snakebite victims and can be 
seen as one of the major contributing pathologies associated with hemotoxic activity 
[11-13]. Venom components that cause lysis by degradation of the erythrocyte 
membrane are considered direct lytic toxins and are only found in the venoms of 
elapid snakes, as opposed to the indirect lytic activities of viperid (vipers) snake 
venoms [14-16]. Previous studies have shown the requirement of exogenous 
phospholipids for hemolytic activity of PLA2s found in viper venoms [14,16,17].  
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Standard hemolytic activity assays used for testing patient blood samples are not 
designed to enable rapid screening of a large number of cytotoxic compounds. 
Previous studies on hemolytic activity of snake venoms are mostly inefficient in 
terms of their limited throughput and resolution (i.e. time-consuming and laborious). 
In a recent study, however, Ramírez-Carreto et al. performed a higher throughput 
hemolytic activity assay in 96-well plate format to study the venom of a sea 
anemone for identification of pore-forming toxins [18]. In the study of Ramírez-
Carreto et al., the toxin identification process involved elaborate purification steps 
prior to toxin identification. The development of a straightforward and miniaturized 
high-throughput screening (HTS) method based on high-density well plates that is 
combined with direct parallel toxin identification would be highly valuable for the 
study of hemolytic activity caused by snake venoms. 
In this study, a HTS erythrocyte lysis assay was developed in 384-well plate 
format. As part of the assay development, various conditions, including the NaCl 
concentration of the assay medium, erythrocyte count and incubation time were 
optimized. In addition, the effects of surfactants on promoting erythrocyte lysis, and 
the potential cytotoxicity enhancing effects of phospholipids (egg yolk emulsions 
were used in this study) via facilitation of indirect lysis were assessed. The 
developed assay was then used for profiling hemolytic venom toxins using venom 
from five medically important snakes using nanofractionation analytics. This 
encompasses an integrated analytical approach in which venom toxins are separated 
by liquid chromatography (LC) and then fractionated in high resolution onto high 
density well plates (384-well plates were used in this study) for subsequent 
bioassaying. In parallel via a flow split, mass spectrometry (MS) data were 
measured from the LC effluent for toxin assignment purposes [19]. The content of 
wells containing venom toxins were also subjected to proteomics analysis to enable 
identification of the toxins responsible for the observed hemolytic activities. We 
demonstrate that the developed assay can be used for profiling venom-induced 
hemolysis and for providing characteristic erythrocyte cytotoxicity profiles of 
individual toxins found in crude snake venoms. 






Water was purified with a Milli-Q Plus system (Millipore, Amsterdam, The 
Netherlands). The HPLC grade acetonitrile (ACN) and formic acid (FA) were 
purchased from Biosolve (Valkenswaard, The Netherlands). NaCl, Trisodium 
citrate dihydrate, Tween-20, Triton X-100, egg yolk, Ficoll, Trypan blue and 
Dulbecco’s phosphate buffered saline (PBS) were purchased from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Varespladib (A-001) and marimastat (also 
purchased from Sigma-Aldrich) were dissolved in DMSO (≥ 99.9%, Sigma-Aldrich) 
to a concentration of 10 mM prior to storage at –20 °C. For assaying, these stocks 
were diluted in 0.5% NaCl in water to the desired concentrations. Snake venom 
sourced from Calloselasma rhodostoma (captive bred, Thailand ancestry), Daboia 
russelii (Sri Lanka), Naja mossambica (Tanzania), Naja nigricollis (Nigeria) and 
Naja pallida (Tanzania) were lyophilized and provided by the Centre for Snakebite 
Research and Interventions, Liverpool School of Tropical Medicine (UK). The 
lyophilized venoms were dissolved into water to a concentration of 5.0  0.1 
mg/mL and stored at 80 °C. Prior to use, each venom solution was diluted in water 
to the defined concentrations in this study. Monospecific equine F(ab')2-based 
Malayan pit viper antivenom used in this study for cytotoxicity neutralization tests 
of Calloselasma rhodostoma venom, was from the Queen Saovabha Memorial 
Institute, The Thai Red Cross Society (Bangkok, Thailand). 
6.2.2 High-resolution nanofractionation of snake venoms 
Venoms were separated by LC followed by parallel MS detection and 
nanofractionation using a post-column split. A Waters XBridge reversed-phase C18 
column (4.6 × 250 mm, packed with a 3.5 μm particle size and a 300 Å pore size) 
was used and maintained at 30 °C using a Shimadzu CTO-30A column oven. The 
total solvent flow rate was 0.5 mL/min, controlled by two Shimadzu LC-30AD 
parallel pumps. Mobile phase A was composed of 98% H2O, 2% ACN and 0.1% FA, 
while mobile phase B was 98% ACN, 2% H2O and 0.1% FA. Gradient elution was 
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performed as follows: a linear increase of mobile phase B from 0% to 50% in the 
first 20 min, followed by another 4 min from 50% to 90%, then kept at 90% for 5 
min, subsequently mobile phase B was decreased from 90% to 0% in 1 min and 
kept at 0% for 10 min for re-equilibration. For each analysis, 50 μL venom solution 
was injected by a Shimadzu SIL-30AC autosampler. The column effluent was split 
into a 1:9 ratio. The 10% fraction was sent to a Shimadzu SPD-M20A Prominence 
diode array detector (UV detector) and then optionally to MS detection (maXis 
QTOF, Bruker Daltonics, Germany). The 90% fraction was sent to a fraction 
collector. This was either a commercially available FractioMateTM nanofractionator 
(Spark-Holland & VU, Netherlands, Emmen & Amsterdam) controlled by 
FractioMator software (Spark-Holland, The Netherlands, Emmen) or a modified 
Gilson 235P autosampler controlled by in-house developed Ariadne software. The 
fractions were collected at a resolution of 6 s/well onto transparent 384-well plates 
(F-bottom, rounded square well, polystyrene, without lid, clear, non-sterile; Greiner 
Bio One, Alphen aan den Rijn, The Netherlands). The well plates with collected 
fractions were subsequently dried overnight using a Christ Rotational Vacuum 
Concentrator (RVC 2−33 CD plus, Zalm en Kipp, Breukelen, The Netherlands) 
operated at −80 °C with help of a cooling trap. The dried plates were stored at 
−20 °C until bioassaying. 
6.2.3 Isolation of red blood cells from whole blood 
Red blood cells were isolated from multiple healthy donor-derived buffy coats 
(Sanquin, Amsterdam). Erythrocyte isolation was performed at room temperature. 
The 50 mL collected blood was citrated and diluted in 130 mL PBS-1% citrate 
solution and mixed gently (without shaking). The PBS-1% citrate solution was 
prepared by dissolving trisodium citrate dihydrate in PBS solution. After diluting, 
30 mL of the citrated blood was pipetted into a 50 mL tube containing 15 mL Ficoll 
solution. This tube was subsequently centrifuged for 30 min at 700×g (no brakes, 
acc=4, dec=1) using an AllegraTM X-12 Centrifuge (Beckman Coulter). After 
centrifuging, the blood was separated as three layers; the top layer consisting of 
plasma, the middle layer containing mono nuclear cells and the bottom layer 




consisting of erythrocytes. The bottom layer was pipetted into a new 50 mL tube for 
further washing. The erythrocytes were washed three times with 50 ml 0.9% NaCl 
solution (with in-between centrifuging for 10 min at 700×g (no brakes, acc=4, 
dec=1)) and then re-suspended in 0.9% NaCl solution (1:10, v/v). Cell counts were 
determined by cellular staining with trypan blue followed by cell counting in 
duplicate using a Bürker counting chamber. By using the determined cell counts, the 
erythrocytes could be diluted to desired cell counts during assay optimization. 
6.2.4 Erythrocyte lysis assay 
The erythrocyte lysis assay was based on measuring the absorbance of 
erythrocyte suspensions at 540 nm by a platereader in 384-well plate format. 
Erythrocyte lysis was detected as an increase in absorbance of the erythrocyte 
suspensions, after allowing non-lysed erythrocytes to settle (cell lysis results in red 
coloration of the upper clear solution). During the first stage of assay development, 
the effects of the erythrocyte count, the NaCl solution concentration and the 
incubation time were investigated on assay performance in Eppendorf tube format. 
The stock erythrocyte suspension was diluted in NaCl solutions of different 
concentrations (0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 0.9%) to total volumes of 
1 mL (in 1.5 ml Eppendorf tubes) to generate suspensions with different erythrocyte 
counts, varying between 0.6, 1.5, 3.0 and 6.0 (×107)/mL. During the incubations 
conducted in Eppendorf tubes, 50 μL aliquots were taken from the upper layers of 
the settling cellular suspensions at different time points (0, 10, 20, 30, 45 or 60 min) 
and were transferred to the wells of a 384-well plate for final platereader 
measurement. After 60 min, the suspensions were centrifuged (30 s at 805×g; 2000 
rpm) to allow full sedimentation of all erythrocytes before transferring the last 
supernatants to the 384-well plate. The optimal NaCl concentration is the lowest 
NaCl concentration that produces an osmotic pressure in the cells under which they 
stay intact during the course of the experiment. This concentration of NaCl results 
in the erythrocytes having the least stability and hence largest vulnerability to lysis 
when in presence of hemolytic venom toxins. The optimal incubation time is the 
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shortest time needed for all non-lysed erythrocytes to fully settle (and thus not 
interfere with the eventual platereader measurement). 
Next, the optimal erythrocyte count, NaCl concentration and incubation time 
were used for subsequent assay development fully conducted in 384-well plates 
containing nanofractionated cytotoxic venom toxins. For this, 50 μL of diluted 
erythrocyte suspension was pipetted at room temperature using a Multidrop™ 384 
Reagent Dispenser (Thermo Fisher Scientific, Ermelo, The Netherlands) onto 384-
well plates containing vacuum centrifuged venom fractions (see Section 6.2.2: 
High-resolution nanofractionation of snake venoms). The erythrocyte suspensions 
in these plates were then incubated at room temperature under a 75° angle that 
allows settling of erythrocytes on one side of each well in the plates in order to 
prevent interference with the subsequent platereader absorbance measurements. 
This way an increase in absorbance can be associated with erythrocyte lysis 
resulting in an increase in red coloration (and not with settled intact erythrocytes at 
the bottom of each well). After the incubation step, the absorbance of each well was 
measured on a Varioskan™ Flash Multimode Reader (Thermo Fisher Scientific, 
Ermelo, The Netherlands) at a wavelength of 540 nm at 25 °C. Hemolytic activity 
was then depicted as bioactivity chromatograms by plotting the absorbance of each 
well versus the chromatographic retention time for each fraction collected. The last 
parameters to be investigated for assay development included testing the effects of 
the surfactants Triton X-100 and Tween-20 on facilitating erythrocyte lysis, and the 
effect of egg yolk for studying indirect lysis by cytotoxins that require the presence 
of phospholipids to exert their cytotoxicity. 
6.2.5 Inhibiting effects of varespladib, marimastat and antivenom on venom-induced 
lytic activity 
Following assay development and integration into nanofractionation analytics, 
the inhibitory effects of the PLA2 inhibitor varespladib, the SVMP inhibitor 
marimastat and species-specific antivenom on lytic activity were investigated for 
several of the venoms under study, for proof-of-concept demonstration of the utility 
of the assay. For this, 5 µL volumes of various concentrations of varespladib 




solutions (resulting in final assay concentrations of 20, 4 and 0.8 μΜ), 5 µL 
volumes of a marimastat solution (resulting in a final assay concentration of 20 μΜ) 
or 5 µL volumes of an antivenom solution (directly taken from Malayan pit viper 
antivenom vial) were added to all wells of freeze-dried 384-well plates (5 µL 
volumes of a 0.5% NaCl solution were added to venom-only control plates). For 
each solution, one well plate with nanofractionated venom toxins was used. For 
these bioassay pipetting steps, a VWR Multichannel Electronic Pipette was used. 
Directly after pipetting the solutions, plates were centrifuged for 1 min at 805 × g 
(2000 rpm) using a 5810 R centrifuge (Eppendorf, Germany) followed by pre-
incubation for 30 min at room temperature. Meanwhile, the erythrocyte lysis assay 
solutions were prepared as described above (Section 6.2.4) of which 45 µL volumes 
were added to the plates after the pre-incubation step. This was then followed by 
assay incubation and platereader measurement as described above (Section 6.2.4). 
All analyses were performed in at least duplicate. 
6.2.6 Correlation of biological data to MS and proteomics data 
In one of our previous studies [19], venoms of the snake species C. rhodostoma 
and D. russelii, which were included in this study, were analyzed using the 
nanofractionation approach with parallel MS detection, which yielded accurate 
molecular masses of eluting venom toxins and their coagulopathic activities. In 
addition, proteomics data was acquired after in-well tryptic digestion followed by 
nanoLC-MS/MS analysis of the contents of the wells. Using the data acquired, the 
UniprotKB database was searched with Mascot for information on the toxin class 
and possible known functions of the toxins under study. Correlation of the LC-UV 
data for the venoms acquired in the present study with the LC-UV data obtained in 
the previous study, allowed for the bioassay data from the present study to be 
correlated with the MS and proteomics data obtained from the previous study [19]. 
For the venoms of the snake species N. mossambica, N. nigricollis and N. pallida, 
of which no MS and proteomics data was available from the nanofractionation 
analytics approach, the same procedure as described by Slagboom et al. [19] was 
used to acquire similar datasets. 
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6.3. Results and discussion 
Hemolysis caused by snake envenoming may result in secondary kidney damage 
or renal failure [20-22]. Erythrocyte lysis can be the result of the action of various 
cytotoxins and hemotoxins [7,11,14,16]. Important classes of hemolytic snake 
venom toxins include cytotoxic PLA2s, cytotoxic 3FTxs, SVMPs, L-amino acid 
oxidases, C-type lectins and hyaluronidases [23,24]. Cytotoxins have also 
previously been sub-classified based on their specific cellular activity, such as 
myotoxins, cardiotoxins and generic cytotoxins, though few studies have assessed 
the generality of their mechanisms of action [3,23,25]. This study describes the 
development and application of a low-volume 384-well plate format assay for 
assessing hemolytic activity that was integrated into a high-throughput screening 
and nanofractionation analytics pipeline. First, the hemolysis assay was optimized 
by varying the NaCl concentration, erythrocyte count and incubation time, followed 
by assessment of the effects of surfactants and the assay’s capability of measuring 
indirect lytic activity by incorporating phospholipids (i.e. egg yolk). Following 
optimization, the assay was combined with nanofractionation analytics to profile 
venoms from five hemolytic snakes, specifically: C. rhodostoma, D. russelii, N. 
mossambica, N. nigricollis and N. pallida. Snake venoms were separated by LC 
followed by nanofractionation analytics with post-column hemolytic activity 
assessment next to parallel LC-MS and proteomics-based venom toxin 
identification. The resulting data were used to identify hemolytic toxin components 
from the venoms of the five medically important snake species.  
6.3.1 Development of the erythrocyte lysis assay 
The erythrocyte lysis assay performance was first investigated by diluting 
washed and re-suspended erythrocytes into NaCl solutions of different 
concentration. Incubation of this first set of experiments was performed in 
Eppendorf tubes, permitting straightforward sampling from the upper layers of the 
tubes containing settling erythrocytes for subsequent transfer to well plates for 
eventual platereader measurement. The goal here was to evaluate the stability of 




erythrocytes in the different NaCl concentrations tested, and to evaluate the effect of 
various incubation times. The optimal NaCl concentration was determined as the 
lowest concentration of NaCl that did not result in cell lysis by osmosis. This 
concentration is expected to have the erythrocytes in a surrounding where they are 
least stable and hence most prone to venom-induced lysis. All incubations were 
conducted in Eppendorf tubes from which at different time points, aliquots were 
taken from the upper layers of the settling cellular suspensions and were transferred 
to wells in a well plate for final platereader measurement. Lysed cells result in red 
coloration of the solution, which is measured by the platereader. To simultaneously 
assess the effect of cell sedimentation, aliquots were taken at different time points. 
The results obtained are shown in Figure 1a. During incubation, the erythrocytes 
slowly settled and depending on the NaCl concentration, erythrocyte lysis was 
observed as the result of osmotic pressure, indicated by a change in supernatant 
color. The resulting absorbance of the supernatants (i.e. around 1.0 at 540 nm) did 
not change significantly at NaCl concentrations ranging from 0.0% to 0.4%, while a 
clear concentration-response was observed from 0.5% to 0.9% NaCl. These results 
indicate that erythrocytes lysed quickly (directly at the begining of the incubation 
period) at NaCl concentrations ranging from 0.0% to 0.4%, as evidenced by a 
plateau of absorbance over time. Additionally, no sedimented erythrocytes were 
observed at the end of the experiment for these NaCl concentrations, indicating 
complete cellular lysis. At NaCl concentrations ranging from 0.5% to 0.9%, the 
erythrocytes did not lyse but slowly sedimented resulting in a decrease in 
absorbance (i.e. yielding clear top layers in each Eppendorf tube) over time and 
sedimented erythrocytes were observed clearly at the end of the experiment. 
Photographic images of the erythrocytes at the end of the experiment revealed a 
correlation between NaCl concentration and erythrocytes morphology (or lysis for 
the lower NaCl concentrations) (see Supporting Information, Section S1). At NaCl 
concentrations ranging from 0.5% to 0.9%, a high average absorbance (over 2.0) 
was observed at the beginning of the experiment, due to erythrocytes observed in 
suspension in the top layer of the Eppendorf tubes. During the time frame of the 
experiment, erythrocytes slowly settled, resulting in a time-dependent decrease in 
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supernatant absorbance. The optimal incubation time is the time required for all 
non-lysed erythrocytes to fully settle (and thus not interfere with the eventual 
platereader measurement). After 60 min incubation, all Eppendorf tubes were 
centrifuged (ensuring full settlement of all erythrocytes) followed by acquiring the 
last aliquot for measurement (i.e. the “after centrifugation” readings displayed in 
Figure 1a) from each tube. As mentioned above, optimal conditions were met at a 
NaCl concentration of 0.5% and an incubation time of (at least) 60 min, in which 
the average absorbance measured was close to the average absorbance of the 
aliquots measured after the final centrifugation step. This indicated that an 
incubation time of 60 min was appropriate as no significant increase in erythrocyte 
sedimentation occurred thereafter, and was confirmed visually with similar red 
erythrocyte sediment at the 60 min incubation time point and after centrifugation. 























































Figure 1. Absorbance of top layers of erythrocyte suspensions measured at different NaCl 
concentrations, erythrocyte counts and incubation times. a) Absorbance measured at different 
incubation times using a NaCl concentration between 0 and 0.9%; b) Absorbance measured after a 60 
min incubation time for different erythrocyte counts using a NaCl concentration between 0 and 0.9%. 
Next, measurements were performed with different erythrocyte counts using the 
defined 60 min incubation time. As observed in Figure 1b, full erythrocyte lysis was 
observed at NaCl concentrations ranging from 0.0% to 0.4% for all erythrocyte 
counts tested at these NaCl concentrations. As a result, the supernatant absorbances 
were found to increase linearly with erythrocyte count. For the higher NaCl 
concentrations tested, absorbances decreased drastically at concentrations of NaCl 




of 0.5% and higher (similar to the previous experiment described, see Figure 1a). 
For all subsequent assays described in this study, an erythrocyte count of 
3.0×107/mL was used as it gave a good assay window at an acceptable erythrocyte 
count. The results of all measurements performed during this assay optimization 
step (i.e. the effect of all tested concentrations of NaCl in combination with all 
erythrocyte counts tested, at all tested incubation times) are provided in the 
Supporting Information (Section S2). 
The optimization experiments yielded erythrocyte assay conditions with an 
erythrocyte count of 3.0×107/mL, a NaCl concentration of 0.5% and an incubation 
time of 60 min. These conditions were next transferred to full 384-well plate format 
(i.e. both the incubation and the readout performed in 384-well plate format). For 
this, onto vacuum-centrifuged to dryness 384-well plates containing fractionated 
venom samples, 50 μL of a suspension of erythrocytes with a count of 3.0×107/mL 
in 0.5% NaCl was pipetted by robotic pipetting. Then, the plates were incubated for 
60 min under an angle of 75° at 25 °C, which was followed by final readout at 540 
nm in a platereader. 








Figure 2. Erythrocytes lysis bioactivity chromatograms resulting from nanofractionated venoms of C. 
rhodostoma, D. russelii, N. mossambica, N. nigricollis and N. pallida (venom concentration of 5.0 
mg/mL). Positive peaks in the chromatograms indicate erythrocyte lysis activity. 
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Figure 3. Superimposed erythrocyte lysis bioactivity chromatograms resulting from assaying 
nanofractionated venoms of N. mossambica, N. nigricollis and N. pallida analyzed at venom 
concentrations of 1.0, 2.0, 3.0, 4.0 and 5.0 mg/mL. The top superimposed chromatograms are 
characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
This assay format was integrated into nanofractionation analytics and used for 
cytotoxic venom profiling. Each of the five medically-important snake venoms 
(concentration of 5.0 mg/mL) was analyzed by LC and nanofractionated on 384-
well plates, followed by application of the erythrocyte lysis assay to the fractions. 
The venoms of the spitting cobras N. mossambica, N. nigricollis and N. pallida 
showed clear erythrocyte lysis activity, visualized as positive peaks in the 
bioactivity chromatograms, while the venoms of C. rhodostoma and D. russelii did 
not show any notable cytotoxic activity (Figure 2). After measurement, erythrocytes 
lysis was also clearly visible (by visible inspection) in bioactive wells containing 




cytotoxins from N. mossambica, N. nigricollis and N. pallida venoms. A typical 
photographic image of one of these 384-well plates, and photographs with 
discussion on the visual inspection of the cellular morphology of the erythrocytes by 
microscopy, together with duplicate bioactivity chromatogram results, are shown in 
the Supporting Information (Section S3). 
Next, the venoms of N. mossambica, N. nigricollis and N. pallida were tested 
over a concentration range (1.0, 2.0, 3.0, 4.0 and 5.0 mg/mL) using the 
nanofractionation approach, to investigate dose-response effects (Figure 3). As 
anticipated, lower venom concentrations resulted in decreased areas of the lysis 
peaks of the bioactivity chromatogram, indicating reduced erythrocyte lysis. At the 
highest venom concentrations tested, however, similar cytotoxicity peaks were 
observed due to full lytic activity of all erythrocytes was attained at these 
concentrations tested. As erythrocyte lysis measured for these three venoms was 
still clearly visible at a venom concentration of 1.0 mg/mL, this concentration was 
used for further experiments. All described nanofractionation experiments were 
conducted at least in duplicate, and duplicate bioactivity chromatograms are shown 
in the Supporting Information (Section S4). 
6.3.2 Secondary optimization of the erythrocyte lysis assay  
Subsequent optimization of the erythrocyte lysis bioactivity assay following 
integration with nanofractionation analytics was performed by studying the effect of 
subtle differences in NaCl concentration (i.e. 0.45%, 0.50%, 0.55%, 0.60% and 
0.65%) using an erythrocyte count of 3.0×107/mL in combination with N. pallida 
venom at a concentration of 1.0 mg/mL. The results obtained from these analyses 
are shown in Figure 4 and the duplicate bioactivity chromatograms of these 
experiments are displayed in the Supporting Information (Section S5). At 0.45% 
NaCl, a large portion of the erythrocytes lysed in all wells due to osmotic pressure 
and resulted in high background absorbance (see insert panel, top left of Figure 4). 
This resulted in a reduction in erythrocyte numbers available for lysis in wells with 
nanofractionated lytic venom toxins and, in turn, resulted in a lower lytic activity 
peak and high levels of background noise in the bioactivity chromatograms. At 
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NaCl concentrations between 0.50% and 0.60%, the majority of erythrocytes in 
wells not containing cytotoxic venom toxins remained viable during the 
measurement period, and post-measurement microscopy analysis revealed that 
increasing NaCl concentrations resulted in enhanced shrinking of the erythrocytes. 
In other words, the higher NaCl concentration resulted in a decrease of the 
susceptibility of the erythrocytes for lysis by cytotoxic venom toxins. In Figure 4, 
this is observed by the single cytotoxic peak (retention time of 16.5 min) that 
decreased in intensity upon increasing NaCl concentrations. At the highest 
concentration tested (i.e. 0.65% NaCl), no lytic activity was observed. From these 
results, we concluded the optimal NaCl concentration was 0.50%, and this was used 
thereafter as the final assay concentration.  
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Figure 4. Bioactivity chromatograms of nanofractionated venom from N. pallida (venom 
concentration of 1.0 mg/mL) resulting from optimization experiments with different NaCl assay 
concentrations. The inserted bar graph shows the absorbance in wells not containing cytotoxic venom 
components, tested under these different NaCl concentrations. The top superimposed chromatograms 
are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
Next, the effect of the surfactants Triton X-100 and Tween-20 on facilitating 
erythrocyte lysis was studied with N. pallida venom. Detergents or surfactants are 
known to interfere with cell membranes, disrupting the lipid bilayer [26,27] by 
solubilizing membrane proteins and thereby increasing membrane permeability [27]. 
The non-ionic detergent Triton X-100 is an alkylphenoxy-polyethoxy surfactant  
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Figure 5. Effect of various concentrations of surfactants on venom-induced erythrocyte lysis: (a) 
Triton X-100, and (b) Tween-20. Surfactants were tested on nanofractionated toxins from N. pallida 
venom (1.0 mg/mL). The insert bar graph shows absorbance in wells not containing cytotoxic venom 
components, tested under different concentrations of the surfactants. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
which is able to disrupt biological membranes by inducing a phase transition from 
membrane lamellae to mixed protein-lipid-detergent micelles [28,29]. Tween-20 is 
a non-ionic surfactant which is reported to contribute to cell wall collapse [30], to 
remove proteins from the membrane surface [31], and to influence the membrane 
lipid composition and the membrane fluidity [32]. The surfactants may destabilize 
erythrocytes, hence making them more susceptible for lytic activity, thereby 
increasing assay sensitivity. Both Triton X-100 and Tween-20 are also potential 
agents that can render an increase in phospholipid solubility (such as the egg yolk 
used in this assay as emulsion).  Upon increasing the concentration of Triton X-100 
or Tween-20, erythrocyte stability against lytic venom activity indeed was found to 
decrease for both surfactants tested, as observed by a concentration-dependent 
increase in the positive lytic activity (as indicated by the peak at 16.5 min in Figure 
5). However, at the highest concentration tested (i.e. 0.1 mg/mL for Triton X-100 
and 1.0 mg/mL for Tween-20), most erythrocytes were found to have lysed directly 
(see the high background signals in the insert panels, top left of Figures 5a and 5b). 
This evidently prevents lysis from being measured in wells containing cytotoxic 
venom toxins. Our results confirmed that both Triton X-100 and Tween-20 could 
potentially be used as agents that increase assay sensitivity. The duplicate 
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bioactivity chromatograms of these experiments are provided in the Supporting 
Information (Section S6). 
Next, the effect of egg yolk on facilitating indirect lysis of erythrocytes was 
investigated on both viper (C. rhodostoma and D. russelii) and elapid (Naja spp.) 
venoms. Without the addition of egg yolk (as described earlier in Figure 2), no lytic 
activity was observed for the two viper venoms, whereas a sharp lysis peak was 
observed for each of three elapid venoms. By adding egg yolk, the lytic activity 
profile (observed as positive peaks) for all venoms under study increased in a 
concentration-dependent manner (Figure 6). Egg yolk concentration-dependent 
increases in lytic activity were observed at retention times of ~20 min for C. 
rhodostoma venom and ~18 min for D. russelii venom. A similar concentration-
dependent pattern was observed when the egg yolk concentration was increased for 
the elapid venoms. Moreover, upon increasing the egg yolk concentration for all 
three elapid venoms tested, a second bioactivity peak (at ~20 min) appeared 
adjacent to the one already visible without the addition of egg yolk (at ~16.5 min) 
(Figure 6). At the highest concentrations of egg yolk tested, baseline fluctuations 
were found to increase, while the total observed lytic activity in the bioactivity 
chromatograms slightly decreased. Taking these observations into consideration, an 
optimal egg yolk emulsion concentration of 1.75 mg/mL was selected. The 
duplicate bioactivity chromatograms of these experiments are provided in the 
Supporting Information (Section S7). 
Although the hemolytic activity observed in the snake venoms under study is not 
thought to play a major role in overall venom lethality, it can be considered as a 
manifestation of pathophysiological relevance [11,13]. A previous study by 
Condrea et al. [14,16] showed that PLA2s isolated from elapid venom were capable 
of hydrolyzing phospholipids, whereas those isolated from viper venoms could not, 
unless exogenous phospholipids were added. Indirect hemolysis can be activated by 
adding exogenous phospholipids to venom phospholipases [16,33]. Egg yolk 
consists of lipids and proteins, of which ~50% are phospholipids, which thus could 
be used to induce indirect lytic activity [34-36]. Indeed, egg yolk has been used 
previously to study the indirect hemolytic activity of snake venoms and was  














































































Figure 6. The effect of egg yolk on erythrocyte lysis activity caused by nanofractionated C. 
rhodostoma, D. russelii, N. mossambica, N. nigricollis and N. pallida venoms (1.0 mg/ml). Egg yolk 
concentrations ranged from 0 to 10 mg/mL. The top superimposed chromatograms are characteristic 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































reported to enable lysis by hydrolytic activity of PLA2s in viper venoms [16,17,37]. 
Our results here show clear increases in total venom-induced lytic activity for both 
viper and elapid venoms following the addition of egg yolk in a concentration-
dependent manner.  
6.3.3 Identification of hemolytic venom toxins 
Hemolytic toxins were identified by correlating the positive cytotoxic 
erythrocytes lysis peaks with acquired MS and proteomics data which were (i) 
previously measured by Slagboom et al. [19] for C. rhodostoma and D. russelii 
venoms and (ii) measured in this study under the same experimental conditions as 
Slagboom et al. for the venoms of N. mossambica, N. nigricollis and N. pallida. The 
obtained results are displayed in Table 1. For the toxins of which no exact mass data 
could be acquired by LC-MS (e.g. for toxins in the higher mass range such as 
SVSPs), only proteomics data obtained from the Mascot searches is provided. The 
masses retrieved from the Mascot data (Uniprot) are also presented in the Table. 
These masses represent the toxin masses in their linear shape (i.e. without cysteine 
bridges and/or other Post Translational Modifications (PTMs)). Many venom toxins 
have several (known) cysteine bridges and possible other PTMs, including possible 
(de)amidations causing mass differences of 1 Da per (de)amidation in a venom 
toxin. To compare the deconvoluted monoisotopic masses from the LC-MS data 
with masses found in Uniprot, the number of cysteine bridges (and potential other 
known PTMs and presence or absence of pro- and signal peptides) was looked at 
and retrieved. By using this retrieved information, toxins were drawn in Chemdraw 
including known cysteine bridges, from which masses were calculated by 
Chemdraw. Besides cysteine bridges, for the toxins in the table no other known 
PTMs (such as pro- or signal peptides) were reported in Uniprot. The number of 
cysteine bridges retrieved from Uniprot as well as the recalculated toxin masses 
taking the cysteine bridges into account are also presented in the Table. For the two 
viper venoms under study, PLA2s were the main cytotoxic toxins identified, 
whereas for the three elapid venoms studied, 3FTxs were the major cytotoxic toxin 
type in addition to PLA2s. It has to be noted that unambiguously assigning single 




toxins to each detected bioactivity peak, especially when the peak is broad, is quite 
challenging, due to multiple toxins closely co-eluting. An additional caveat is that 
despite venom toxins generally being stable, some venom toxins might have (partly) 
denatured upon exposure to the LC eluent and thereby lost their activity. 
6.3.4 Inhibitory effects of antivenom and the small molecule snakebite treatment 
candidates varespladib and marimastat on venom-induced erythrocyte lysis. 
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Figure 7. The inhibiting effects of (a) Malayan pit viper antivenom on C. rhodostoma venom-induced 
erythrocyte lysis activity, (b) varespladib on venom-induced erythrocyte lysis activity caused by N. 
mossambica, N. nigricollis and N. pallida venoms. All venoms were nanofractionated at a 1.0 mg/mL 
concentration, and inhibitor concentrations are displayed in the figures. The top superimposed 
chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
As final proof-of-concept of the capability of the developed erythrocyte lysis 
assay, we investigated the inhibitory effects of conventional treatment (antivenom) 
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and the new small molecule-based treatment candidates varespladib and marimastat 
on nanofractionated cytotoxins. First, we explored neutralization of C. rhodostoma 
venom toxins using a species-specific antivenom. As anticipated, the observed lytic 
activity in the bioactivity chromatogram (sharp peak at 20.0 min in Figure 7a) of 
nanofractionated C. rhodostoma venom was fully inhibited by this antivenom at the 
tested concentration. Next, the inhibitory capability of varespladib on venom-
induced erythrocyte lysis caused by the venoms of N. mossambica, N. nigricollis 
and N. pallida was explored (Figure 7b). Varespladib is a broad-range PLA2 
inhibitor known for its capability of neutralizing pathological snake venom PLA2s 
[38-40], and African spitting cobra venoms (i.e. the Naja species under study) are 
known to contain considerable abundances of PLA2s, which seemingly contribute to 
venom cytotoxicity [41,42] (Table 1). Broad peaks showing hemolytic activities 
were observed in the bioactivity chromatograms of each of the three investigated 
venoms in the venom-only control experiments. The addition of varespladib 
resulted in only a subtle, though visible, reduction in venom activity (Figure 7b). 
The intensity of the positive lytic activity peaks for N. mossambica and N. 
nigricollis venoms were dose-dependently reduced, though only limited lytic 
inhibition was achieved at the highest concentration tested (i.e. 20 μM). For N. 
pallida venom, the tailing part of the single bioactivity peak observed was very 
slightly reduced, at a varespladib concentration of 0.8 μM varespladib, but the 
addition of increasing concentrations of varespladib failed to confer additional 
inhibition. From Table 1 it can be seen that for the Naja venoms both cytotoxic 
3FTxs and PLA2s were found as bioactives. As varespladib is not capable of 
neutralising the 3FTxs, these findings are consistent with other studies that suggest 
that cytotoxic 3FTxs are the primary cytotoxins responsible for the majority of cell 
lysis caused by the venoms of spitting cobras (and their near relatives) [42-44]. As a 
control experiment, we also used marimastat (which is a broad range SVMP 
inhibitor) at a concentration of 20 μM, to assess its inhibitory capability against N. 
pallida venom (results of this experiment can be found in the Supporting 
Information Figure S12). As anticipated, no inhibition was observed as marimastat 
is a metalloprotease inhibitor and no SVMPs are involved in cytotoxicity of N. 




pallida venom. All duplicate bioactivity chromatograms of the experiments shown 
in this section are provided in the Supporting Information (Section S8). 
6.4. Conclusions 
This study describes the development and application of a high-throughput 
erythrocyte lysis assay in 384-well plate format. The assay protocol developed relies 
on absorbance measurement of the red coloration of the medium after lysis of 
erythrocytes. In order to prevent measurement interferences from settling 
erythrocytes, plate incubation was conducted under an angle of 75° outside the 
platereader. This way, non-lysed erythrocytes settled to the sides of the wells 
thereby not forming a red precipitation layer over the complete bottom of each well, 
through which the absorbance measurements were finally performed in platereader 
format. This way, cellular lysis resulting in change in coloration could be measured 
as positive signal. For the optimized assay, a total volume of 50 μl assay medium, 
containing 0.5% NaCl and 1.75 mg/mL egg yolk emulsion in water, was added to 
each well by robotic pipetting. To this medium, erythrocytes were suspended to a 
count of 3.0×107/mL, and after an incubation time of 60 min at 75° angle at 25 °C, 
the final readout in platereader format at 540 nm was performed. The developed 
assay was then integrated into nanofractionation analytics and the platform was 
used for further fine-tuning of the assay using venoms of the medically important 
snakes C. rhodostoma, D. russelii, N. mossambica, N. nigricollis and N. pallida. 
The elapid snake venoms (Naja spp.) showed both direct and indirect lytic activities, 
while the viperid venoms (C. rhodostoma and D. russelii) only showed indirect lytic 
activities which required the addition of phospholipids (i.e. egg yolk) to exert 
cytotoxicity on erythrocytes. The venoms under study were profiled and the 
resulting cytotoxic peaks observed were correlated with parallel acquired MS and 
proteomics data in order to identify the cytotoxic venom components in these 
venoms. The results showed PLA2s and 3FTxs were the major toxins contributing to 
the hemolytic activity observed. In a final proof-of-concept experiment, we 
demonstrated the value and future applicability of the described methodology for 
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investigating the efficacy of current and new snakebite therapies at neutralizing 
snake venom cytotoxins. 
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S1. Photographic images of the erythrocytes following the first tests performed 
in Eppendorf tubes 
 
Figure S1. Photographic images of the erythrocytes following initial testing in Eppendorf tubes (after 
centrifugation). 
At the end of each experiment, after a brief centrifugation step, the effect of the 
different NaCl concentrations tested on the extent of erythrocytes shrinking, or 
osmotic cellular rupture, was visually inspected and typical results are shown in 
Figure S1. For each experiment shown in the figure (with different cell counts), the 
NaCl concentrations in the Eppendorf tubes from the left to the right are increased 
from 0.0% to 0.9% (with incremental steps of 0.1% NaCl concentration). At low 




NaCl concentrations, the cells were lysed by high osmotic pressure, which was 
observed as a transparent bright red color resulting from ruptured cells. In contrast, 
for the higher NaCl concentrations, sedimented red blood cells were observed and 
the supernatants were clear.  
S2. Effect of the NaCl concentration, cell count and incubation time on 
erythrocyte lysis 
























































NaCl (%)  



























































Figure S2. Absorbances of top layers of erythrocyte suspensions measured at different NaCl 
concentrations, erythrocyte counts and incubation times. 
The effect of the NaCl concentration, cell count and incubation time on 
erythrocyte lysis was tested for different NaCl concentrations, erythrocyte counts 
and incubation times. The results are shown in Figure S2. Note that the Y-axis scale 
is not the same for each of the sub-figures. At NaCl concentrations between 0.0% to 
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0.4%, all cells lysed almost immediately (visual observations) due to osmotic 
pressure, resulting in similar absorbances measured in the top layers taken at 
different time points for platereader absorbance measurements during the 
incubations (an additional centrifugation step was included only for the last time 
point). At NaCl concentrations ranging from 0.5% to 0.9%, the erythrocytes were 
homogeneous in suspension at the beginning of the tests, and they did not lyse but 
slowly sedimented, resulting in a decrease in absorbance (i.e. yielding clear top 
layers in each Eppendorf tube) and clearly observable sedimented erythrocytes at 
the end of the experiments (as also shown in Figure S1). Moreover, by increasing 
the erythrocytes count, the absorbance differences changed erythrocytes count 
dependently in a linear manner. 
S3. Results of the hemolytic assay integrated into nanofractionation analytics 
for cytotoxic venom profiling 
















Figure S3. Erythrocytes lysis bioactivity chromatograms in duplicate resulting from nanofractionated 
venoms of C. rhodostoma, D. russelii, N. mossambica, N. nigricollis and N. pallida analyzed at a 
venom concentration of 5.0 mg/mL. Positive peaks in the chromatograms indicate erythrocyte lysis 
activity. 
The hemolytic assay with optimized assay conditions of a 3.0×107/mL 
erythrocytes count in 0.5% NaCl and an incubation time of 60 min was 
subsequently integrated into the nanofractionation analytics for cytotoxic venom 
profiling of both viperid and elapid snake venoms. The results of duplicate  






Figure S4. Photographic image, after performing the hemolytic assay, of a 384 well plate with 
nanofractionated N. pallida toxins. All wells show a transparent solution with erythrocytes settled on 
the bottom side of each well (this is because the incubation is performed with the well plates 
positioned at a 75° angle outside of the platereader before actual platereader measurement) except for 
the wells indicated in the figure that show a bright transparent red color indicating cellular lysis. 
(Upper photo shows a visualization of a nanofractionated well plate observed from the top side of the 
plate after incubation; Lower photo shows a visualization of another nanofractionated well plate from 
the bottom side of the plate). 
bioactivity chromatograms of the first set of nanofractionation analytics 
experiments for hemolytic venom profiling are shown in Figure S3. The elapid 
snakes showed potent lytic activity while no activity was observed for viperid snake 
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venoms. A photo of a typical 384-well plate after platereader analysis is shown in 
Figure S4, with clear lysis observed in the indicated wells, while in all other wells, 
sedimented intact erythrocytes can be seen in the bottom corner of each of these 
wells (N. pallida venom at a concentration of 5.0 mg/ml was analyzed). The cellular 
morphologies before and after lysis in this plate were also inspected under a 
microscope (Zeiss Axiophot, Germany) by using a 40 × objective lens. These 
observations are shown in Figure S5. Almost full cellular lysis at the end of the 
experiment, with only few intact erythrocytes detected, with morphological swelling, 
was observed. This further confirmed that almost complete erythrocytes lysis 
occurred in these wells. 
 
Figure S5. Visual inspection by microscope of a well with non-lysed erythrocytes (a) and one well 
with lysed erythrocytes (b). The left picture shows a microscope photo of a well not containing any 
nanofractionated cytotoxin(s) and the right picture shows a microscope photo of a well containing a 
nanofractionated cytotoxin(s) (this right picture photo was taken through the microscope of one of the 
indicated wells highlighted in Figure S4). Cellular morphology changes are clearly observed for the 
few remaining non-lysed cells in this well with mostly lysed erythrocytes. 
S4. Duplicate bioactivity chromatograms for depicting venom concentration-
response effects in the erythrocyte lytic activity assay 
The concentration-response effects were investigated for venoms from N. 
mossambica, N. nigricollis and N. pallida snakes, nanofractionated at 
concentrations of 1.0, 2.0, 3.0, 4.0 and 5.0 mg/mL, respectively. The duplicate 
bioactivity chromatograms are shown in Figure S6. In the sub-figures, the bioassay 
chromatograms depicted on the right side, which do not have superimposed 
correlated UV data, represent replicates of the chromatograms on the left side. 


































































Figure S6. Superimposed duplicate erythrocyte lysis bioactivity chromatograms resulting from 
nanofractionated venoms of N. mossambica, N. nigricollis and N. pallida, analyzed at venom 
concentrations of 1.0, 2.0, 3.0, 4.0 and 5.0 mg/mL. The top superimposed chromatograms are 
characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
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S5. Duplicate bioactivity chromatograms of nanofractionated venom of N. 
pallida for final fine-tuning of the NaCl assay concentration 
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Figure S7. Duplicate bioactivity chromatograms of nanofractionated venom from N. pallida (venom 
concentration 1.0 mg/mL was injected) resulting from tests with different NaCl assay concentrations, 
for further optimization/fine-tuning of the NaCl assay concentration. The inserted bar graphs show the 
absorbance in wells not containing cytotoxic venom components, tested under different NaCl 
concentrations. The top superimposed chromatograms are characteristic profiles of UV traces 
measured at 220, 254 and 280 nm. 
S6. Effect of the surfactants Triton X-100 and Tween-20 on facilitating 
erythrocyte lysis 
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Figure S8. Effect of various concentrations of Triton X-100 on venom-induced erythrocyte lysis 
(duplicate results are shown in the sub-figures on the left and right). The inserted bar graph shows 
absorbance in wells not containing cytotoxic venom components, tested under different concentrations 
of the surfactants. The top superimposed chromatograms are characteristic profiles of UV traces 
measured at 220, 254 and 280 nm. 
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Figure S9. Effect of various concentrations of Tween-20 on venom-induced erythrocyte lysis 
(duplicate results are shown in the sub-figures on the left and right). The inserted bar graph shows 
absorbance in wells not containing cytotoxic venom components, tested under different concentrations 
of the surfactants. The top superimposed chromatograms are characteristic profiles of UV traces 
measured at 220, 254 and 280 nm. 
Duplicate bioactivity chromatograms showing effects of the surfactants Triton 
X-100 and Tween-20, tested at different concentrations, on facilitating erythrocyte 
lysis are shown in Figures S8 and S9, respectively. For this experiment, well plates 
with nanofractionated toxins from N. pallida venom, injected at a concentration of 
1.0 mg/mL for analysis, were used. In each figure, a bar graph is inserted to indicate 
relative absorbance in wells not containing cytotoxic venom components tested 
under different concentrations of the surfactants. 
S7. Effect of egg yolk on facilitating indirect lysis of erythrocytes by cytotoxic 
venom toxins 
The effect of egg yolk on facilitating indirect lysis of erythrocytes was 
investigated on both viperid venoms and on elapid venoms. Each venom was 
nanofractionation at a 1.0 mg/ml concentration. By adding egg yolk, the lytic 
activity profile (observed as positive peaks) for all venoms under study was 
increased in a concentration-response manner. Duplicate bioactivity chromatograms 
of typical results obtained are as shown in Figure S10. 
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Figure S10. Effect of egg yolk on facilitating venom induced erythrocyte lysis activity of 
nanofractionated cytotoxic venom toxins present in venoms of C. rhodostoma, D. russelii, N. 
mossambica, N. nigricollis and N. pallida species (venoms nanofraction at a 1.0 mg/mL 
concentration). The top superimposed chromatograms are characteristic profiles of UV traces 
measured at 220, 254 and 280 nm. 
























































Figure S10. (Continued) Effect of egg yolk on facilitating venom induced erythrocyte lysis activity of 
nanofractionated cytotoxic venom toxins present in venoms of C. rhodostoma, D. russelii, N. 
mossambica, N. nigricollis and N. pallida species (venoms nanofraction at a 1.0 mg/mL 
concentration). The top superimposed chromatograms are characteristic profiles of UV traces 





S8. Inhibitory effect of antivenom, varespladib and marimastat on venom-
induced erythrocyte lysis activity 
The inhibiting effect of antivenom, varespladib and marimastat on venom-
induced lytic activity was investigated following nanofractionation for the selected 
venoms (1.0 mg/ml). The duplicate results are shown in Figures S11-S13. 
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Figure S11. The neutralizing effect of Malayan pit viper antivenom on C. rhodostoma venom-induced 
erythrocyte lysis activity (venom nanofractionation at a 1.0 mg/mL concentration). The top 
superimposed chromatograms are characteristic profiles of UV traces measured at 220, 254 and 280 
nm. 
 
















Figure S12. The inhibiting effect of marimastat on N. pallida venom-induced erythrocyte lysis activity 
(venom nanofractionation at a 1.0 mg/mL concentration). The top superimposed chromatograms are 
characteristic profiles of UV traces measured at 220, 254 and 280 nm. 
 
































































Figure S13. The inhibiting effect of varespladib on venom-induced erythrocyte lysis activity caused 
by N. mossambica, N. nigricollis and N. pallida venoms (venom nanofractionation at a 1.0 mg/mL 
concentration). The top superimposed chromatograms are characteristic profiles of UV traces 


















This thesis describes recent research achievements in the field of snake venom 
bioactivity profiling and toxin identification, incorporating efficacy assessment of 
snakebite treatments in their capacity of neutralizing venom toxins. For this 
accomplishment, so-called nanofractionation analytics played a central role. 
Nanofractionation analytics embody a recently developed high-resolution and high-
throughput format of bioassay-guided fractionation and represents a comprehensive 
analytical approach for the screening of bioactives in complex mixtures, such as in 
crude venoms. The approach encompasses both toxin identification and biochemical 
characterization in relatively rapid fashion. Nanofractionation analytics comprise 
modern liquid chromatography (LC), such as reversed-phase liquid chromatography 
(RPLC), with on-line UV absorbance (providing relative quantification of venom 
components) and high-resolution mass spectrometry (MS) detection (providing 
accurate molecular masses of individual toxins). In addition, a post-column split 
allows for high-resolution fractionation in parallel followed by bioassaying and 
optional proteomics analysis of collected fractions. For bioassaying, the low-volume 
fractions of the column effluent, collected in a high-density well plate (e.g. 384 well 
plates) at a typical frequency of 2 to 10 s per well, are vacuum-centrifuged to 
dryness. Subsequently, the content in the dried wells are submitted to a high-
throughput screening (HTS) bioassay, or to a sample preparation fit for proteomics 
analysis. The nanofractionation platform thus makes it possible to hyphenate 
bioassays to LC separations in an at-line format. From the data obtained, bioactivity 
chromatograms can be constructed and correlated with the parallel obtained UV, 
MS, and proteomics data. Eventually, the approach allows toxin activities to be 
correlated to individual toxin identities. 
This thesis in particular focuses on investigating and understanding the 
neutralizing effects of antivenoms and small molecule inhibitors on individual snake 
venom toxins. To achieve this goal, analytical advances in the nanofractionation 
format had to be made and new bioassays had to be developed. The overarching 




objective was to gain new insights aiding the development and testing of (candidate) 
snakebite treatments. 
Snakebite results in over a hundred thousand deaths globally each year, and three 
to four times more cases of permanent morbidities. Snakebite has therefore been 
placed on the top list of Neglected Tropical Diseases (NTD) in 2017 by the World 
Health Organization (WHO). Venomous snakes exert their pathologies by their 
secreted venoms after envenoming of victims by defensive bites. Resulting major 
pathologies include neurotoxicity, hemotoxicity and cytotoxicity/mytotoxicity. 
Snake venoms are complex, largely protein-based secretions composed of numerous 
toxic enzymes and peptides, but also containing small organic molecules and 
inorganic components. Venom composition varies hugely between venomous snake 
species. Venom variation evolutionary and biologically can be related to natural 
selection pressure, to family, genus, species and individual characteristics, to 
geographical location, living habitat and available pray, to sex and age, and to 
venom gland morphology of species. Standard snakebite treatment currently is 
predominantly antivenom-based, next to adjunct treatment by ventilator-based life-
support systems for counteracting paralysis of lung function by certain neurotoxic 
elapid snakebites. Snakebite treatment with antibodies is far away from providing 
adequate solution due to their limited availability, varying quality and specificity, 
and restricted utility to specific venoms. New generations of antivenoms or other 
therapeutic approaches are highly needed to increase the efficacy and affordability 
of snakebite treatment. For this, it is critical to understand which toxins from snake 
venoms can be neutralized or inhibited by therapeutic (candidates). The here 
presented thesis touches upon new analytics to address this issue.  
7.2. Outline 
Chapter 1 gives a generic introduction to snakebite, snakebite treatment and 
candidates for snakebite treatment. Attention is paid to existing analytics for 
studying snake venoms and antivenoms. The chapter ends with discussing the need 
for new analytical approaches that allow the efficient study of individual snake 
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venom toxins and how their activity is affected by antivenom and potentially 
neutralizing compounds.  
In Chapter 2, a recently developed HTS coagulation assay was integrated with 
nanofractionation analytics to assess the coagulopathic properties of venom toxins 
in fractions obtained following LC separation of venoms. Bioactivity profiles of 
fractionated venoms from the medically important snake species of Bothrops asper 
(Terciopelo viper), Calloselasma rhodostoma (Malayan pit viper), Deinagkistrodon 
acutus (Sharp-nosed viper), Daboia russelii (Russell's viper), Echis carinatus (Saw-
scaled viper), Echis ocellatus (Ocellated saw-scaled viper) and Oxyuranus 
scutellatus (Coastal taipan) were obtained. These venoms are known to be capable 
of causing coagulopathic effects. Both the procoagulant and anticoagulant activities 
of venom fractions were assessed in 384-well plate format, and the coagulopathic 
venom toxins found were identified by MS and proteomics analysis. After that, the 
neutralizing potency of various antivenoms against the procoagulant and 
anticoagulant activities of the individual toxins was assessed. In addition, the cross-
reactivity of antivenoms against venoms of closely related snake species was 
evaluated to assess their efficacy, or lack thereof, in the neutralization of venom 
components. Coagulopathic activity was correlated with MS and proteomics data to 
determine which types of venom components were neutralized and, if so, to what 
extent. In this and following chapters, MS and proteomics data acquired in previous 
studies for the same venoms were used, avoiding elaborate re-measurements. For 
newly studied venoms, the appropriate MS data were measured by using the same 
procedure during this research. The efficacy of antivenoms appeared to vary among 
different venoms, and also significant cross-reactivity was observed for many 
closely related snake species. The results also clearly indicated that study of 
neutralization efficacies by antivenom for individual venom toxins is possible, 
offering more detailed insights than when looking solely at crude venoms. The 
cross-reactivity analysis results also can add great value to knowledge on antivenom 
neutralization capabilities for different snake venoms, although careful 
interpretation is warranted as the measured neutralization profiles relate specifically 
to the bioassay used. In this regard, careful consideration of the multifunctionality 




of snake venoms has to be adhered to. The data obtained on antivenom 
neutralization can guide future research on the development of next generation 
antivenoms for treating snakebite. The cross-reactivity results are valuable for 
evaluating the potential use of antivenoms on distinct (but related) snake species 
and/or the same snake species from different geographic locations. 
In Chapter 3, a coagulation assay and a phospholipase A2 (PLA2) assay were 
incorporated in the nanofractionation analytics approach to assess the ability of 
varespladib (nonspecific PLA2 inhibitor) to inhibit the activity of enzymatic PLA2s 
and to neutralize coagulopathic toxicities induced by individual venom toxins 
present in the venoms of the same 7 snake species studied in Chapter 2. Where the 
focus of Chapter 2 was on investigating antivenoms for their ability to neutralize 
venom toxins from several medically important snakes, this chapter investigates the 
small molecule varespladib for the same purpose. All venoms analyzed in this study 
showed constituents with clear coagulopathic toxicities, while only the venoms of 
Bothrops asper (Terciopelo viper), Daboia russelii (Russell's viper), Echis 
carinatus (Saw-scaled viper) and Oxyuranus scutellatus (Coastal taipan) displayed 
components with clear enzymatic PLA2 activity. Varespladib was not only capable 
of inhibiting the PLA2 activities of hemotoxic snake venoms, but was also 
demonstrated to effectively neutralize the coagulopathic toxicities (most profoundly 
anticoagulation) induced by venom toxins. This suggests that enzymatic PLA2 
activities are associated to anticoagulation events. The study also revealed that 
several of the procoagulant venom toxins were neutralized to some degree by 
varespladib. This suggests that the mechanism underlying venom inhibition may not 
be solely based on inhibition of the active site of venom PLA2s, as venom toxins 
responsible for procoagulant activities are typically others than PLA2s. These 
findings further emphasize the potential clinical utility of varespladib in mitigating 
the toxic effects of certain snakebites. 
In Chapters 4 and 5, the nanofractionation approach was used to evaluate the 
effects of several small molecule compounds on inhibiting the activity of 
coagulopathic toxins. Small molecule drugs and drug candidates are regarded as 
promising, easily accessible, alternatives for the snake envenoming treatment. 
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Chapters 4 and 5 describe studies on the potential of several small molecule 
inhibitors for being used as snakebite treatment drugs counteracting pathological 
enzymatic toxicities induced by snake venom toxins. The two chapters investigated 
the effect of these inhibitors on venoms from Viperinae and Crotalinae snakes, 
respectively. Small molecule inhibitors may target PLA2s (e.g. varespladib) or snake 
venom metalloproteinases (SVMPs) by active site inhibition (e.g. marimastat) or by 
Zn2+ removal (e.g. dimercaprol and DMPS). The potency of these small molecule 
candidates in inhibiting individual toxins from snake venoms was investigated. The 
venoms of the following snakes were studied: Viperinae snakes (Echis carinatus 
(Saw-scaled viper), Echis ocellatus (Ocellated saw-scaled viper), Daboia russelii 
(Russell's viper) and Bitis arietans (African puff-adder)), and Crotalinae snakes 
(Bothrops asper (Terciopelo viper), Bothrops jararaca (Brazilian pit viper), 
Calloselasma rhodostoma (Malayan pit viper) and Deinagkistrodon acutus (Sharp-
nosed viper)). Bioassay activities obtained after fractionation were correlated to 
parallel recorded MS and proteomics data to assign the venom toxins responsible 
for coagulopathic activity and to assess which of these toxins were neutralized by 
the inhibitors under investigation (i.e. varespladib, marimastat, dimercaprol and/or 
DMPS). The results showed that both procoagulation activities and anticoagulation 
activities were found for all venoms at the venom concentrations tested except for 
Bitis arietans (African puff-adder) venom for which only clear anticoagulation 
activity was detected. For Bothrops jararaca (Brazilian pit viper) venom, only trace 
anticoagulant activity was observed. Anticoagulant venom toxins were mostly 
identified as PLA2s, while procoagulant venom activities were mainly associated 
with SVMPs and snake venom serine proteases (SVSPs). Varespladib was found to 
effectively inhibit most anticoagulant venom toxins, and also showed some 
inhibition against a few procoagulant toxin effects. Of the SVMPs inhibitors, 
marimastat demonstrated impressive neutralization of the procoagulation activities 
detected for all tested Viperinae snake venoms, whereas dimercaprol and DMPS 
could only partially neutralize these activities at the doses tested in the Viperinae 
snake venoms. In contrast, these small molecules were less efficient in inhibiting 
procoagulant activities of Crotalinae (pit viper) snake venoms. Despite exhibiting 




different specificities and potencies against their coagulopathic venom toxins, the 
small molecule inhibitors under study all show promise as novel therapeutics for 
treating coagulopathic snakebites. Varespladib in combination with broad-spectrum 
(metallo)protease inhibitors and/or Zn2+ removing (heavy metal) chelators could be 
a viable first line therapeutic candidate cocktail and/or adjunct treatment of 
coagulopathic snakebite envenoming. This information obtained aids our 
understanding of the mechanisms of action of toxin inhibitor drug candidates, and 
highlights their potential as future snakebite treatments. Although hurdles associated 
with overcoming variable venom compositions and distinct toxin inhibiting 
specificities remain, there is a strong rationale for future research programs to 
continue to evaluate these molecules as valuable repurposing candidates for 
snakebite. All inhibitors under study are either registered drugs or at least phase II 
approved candidates known to inhibit PLA2 or protease activity. This implies that 
these compounds are clinically safe and as such will this significantly increase the 
chance of these compounds to be developed into eventual snakebite treatments as 
compared to studying non-clinically tested compounds. 
In Chapter 6, a high-throughput hemolytic assay was developed that allows 
profiling of erythrocyte lysis of venoms of medically important snake species. The 
assay protocol developed and described in this thesis relies on absorbance 
measurement of the red coloration of the medium after lysis of erythrocytes. The 
optimized assay medium contained 0.5% NaCl and 1.75 mg/mL egg yolk emulsion 
in water. To this medium, erythrocytes were suspended to a cell count of 
3.0×107/mL. After robotic pipetting of this erythrocytes suspension to all wells of a 
384-well plate containing nanofractionated venom toxins, an incubation time of 60 
min under an angle of 75° at room temperature was followed by final readout in 
platereader format at 540 nm. The applicability of the developed assay in 
combination with nanofractionation analytics was successfully demonstrated by 
profiling cytotoxic venoms of Calloselasma rhodostoma (Malayan pit viper), 
Daboia russelii (Russell's viper), Naja mossambica (Mozambique spitting cobra), 
Naja nigricollis (Black-necked spitting cobra) and Naja pallida (Red spitting cobra). 
Such hyphenated analytical pipelines allowed visualization of venom-induced 
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cytotoxicity profiles in combination with identification of the cytotoxic venom 
toxins responsible. The results showed that the tested elapid snakes contained both 
direct and indirect lytic toxins, while the tested viperid snakes only showed indirect 
lytic activities which needed phospholipid addition (in the form of egg yolk) in 
order to exert cytotoxicity on the erythrocytes. The cytotoxic PLA2s and three-
finger toxins (3FTxs) were the major toxins contributing to the hemolytic 
cytotoxicity activities observed. Finally, the usefulness of this new analytical 
method was demonstrated by testing conventional snakebite antivenom treatment 
and small-molecule drug candidates for treating snakebite to assess their 
neutralization capability of venom cytotoxins. 
7.3. Perspectives 
The results obtained in this thesis underline the potential of nanofractionation 
analytics for straightforward, rapid and sensitive venom profiling, including the 
investigation of the efficacy of snakebite treatment (candidates) on neutralizing 
individual venom toxins. The approach allowed studying of presently used 
antivenoms at the molecular level, and highlighted the potential clinical utility of 
small molecule inhibitors as candidates for snakebite treatment. These outcomes 
may help guiding future research on the development of novel options for treating 
snakebite. Still, several limitations came forward from the research presented in this 
thesis, and efforts are required to overcome these issues. 
Although RPLC is a common choice for the analysis of peptides and proteins, it 
was observed in this study that the obtained separation efficiency generally was not 
sufficient for achieving baseline separation of the venom toxins. Overlap of toxins 
hinders assigning individual toxins to certain observed bioactivity peaks. Therefore, 
in cases where multiple toxins eluted closely, unambiguously pinpointing individual 
toxins to particular bioactivities appeared challenging. In addition, for bioactivity 
peaks composed of multiple components that were only partly diminished due to an 
inhibitor, it was difficult to accurately determine which of the bioactive components 
was inhibited. Clearly, improvement of the LC resolution is indicated in order to 




circumvent these issues. For the RPLC separations in this study, we used FA as 
acidic eluent additive. FA renders many venom toxin enzymes intact during 
separation, but it does not provide efficient protein separation and high peak 
capacity. A widely known remedy for enhancing the separation efficiency of 
peptide and protein in RPLC is the addition of trifluoroacetic acid (TFA) to the 
gradient eluent, as e.g. applied in venomics studies. However, when assessment of 
the bioactivity of venom toxins is the goal (as is in our nanofractionation approach 
towards venom profiling), evidently non-denaturing eluent conditions need to be 
used in order to allow post-column bioassays to provide useful results for the 
separated protein toxins. Moreover, the LC eluent has to be properly compatible 
with electrospray ionization (ESI)-MS detection. Unfortunately, TFA is a strong 
acid causing the eluent to have a very low pH, which may result in partial or full 
denaturation of certain toxins. This is true in particular for larger enzyme toxins, 
including many pro-coagulopathic enzymes. Another drawback of using TFA in LC 
eluents is that it is notoriously known to cause ionization suppression and proteins 
adduct formation in ESI, seriously reducing the obtainable LC-MS sensitivity. 
These considerations largely disqualify TFA as a viable option for improving toxin 
LC resolution in a nanofractionation setting. Hence, for now, one of the remaining 
challenges for achieving high performance venom profiling by our 
nanofractionation approach is to achieve adequate protein separations in 
combination with sensitive, interference-free MS detection while in parallel 
maintain biological activity of the toxins in the fractionated venoms. Future work 
should therefore focus on developing LC separation conditions suitable for these 
efforts. 
Another point of concern is the use of acetonitrile (ACN)-containing eluents 
during RPLC of venom samples. Since we apply bioassays to the fractionated 
venoms, the separated toxins need to elute in their intact native state in order to 
retain their activity. Although many venom toxins show relative stability under the 
applied RPLC conditions, some toxin complexes and especially large toxins still 
may (partly) denature under high ACN concentrations and potentially lose their 
pathological activity. This in turn would not allow accurate assessment of potential 
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neutralization capabilities of antivenom or small molecule inhibitors for these less 
stable venom toxins. For now, when applying RPLC, we need to accept a small 
percentage loss of activity. Fortunately, as follows from comparison to the activity 
of crude venom, the large part of the total coagulation activity remains detectable 
after RPLC in our ACN-H2O-FA eluents gradient, allowing for assessment of the 
efficacy of inhibitors for reducing the coagulation pathologies induced by PLA2s, 
SVMPs and SVSPs.  
Current general-purpose high-resolution mass spectrometers are not well suited 
for the efficient detection of proteins with molecular masses exceeding 20-30 kDa. 
This is one of the reasons why the LC-MS analyses presented in this thesis do not 
reveal many venom toxins with masses larger than PLA2s, such as SVSPs and 
SVMPs. This drawback could be circumvented by employing mass spectrometers of 
which the settings are better optimized for detecting macromolecules in the high 
mass range. Another limitation of the analytics as applied so far lies in the 
proteomics measurements, which largely were performed using manual protocols, 
thereby rendering it tedious and very time consuming. The venom fractions were 
pretreated and digested one by one, followed by manual transfer of the digest 
mixtures to sample vials in the nanoLC-MS instrument and long runs per sample. 
Subsequent assignment of the unknown proteins required an extensive data 
processing and interpretation procedure. Advances in this regard would constitute 
an automated pipeline comprising high-throughput tryptic digestion of 
nanofractionated venom toxins in 384-well plate format followed by direct transfer 
of these well plates to nanoLC-MS analyses using very fast nanoLC gradients. This 
ideally would then be followed by automated data processing together with 
automatically compressing and sorting all data into easy data formats (e.g. Excel). 
Future work should focus on establishment of such integrated proteomics 
workflows. 
Next to advancing analytics, follow-up biochemical and biological research 
should focus on unraveling the inhibition mechanisms of varespladib and the other 
small molecules investigated for anticoagulant and procoagulation toxins, and for 
cytotoxins. Typically, small molecule drug candidates for combatting snakebites 




target a single family of enzymatic toxins and exhibit different specificities for the 
various toxins within one family. Only in some cases, the same inhibitor can act on 
different toxin classes. Therefore, when using only one inhibitor as drug candidate, 
it is expected that non-inhibited enzymatic toxin families will still cause their 
pathologies in snakebite victims. Hence, there is a serious challenge to overcome 
before these small molecule candidates can be regarded standalone therapeutics for 
snakebite treatment. A combination of several toxin-enzyme-class inhibitors may be 
a viable approach for obtaining an affordable broad-spectrum treatment able to 
efficiently and affordably treat snakebite non-specifically and globally. Moreover, 
combinations of small molecule inhibitors together with venom-specific antivenoms 
may eventually be a successful option to efficiently neutralize the most relevant 
pathological toxins after envenoming of snakebite victims. Therefore, future 
research could focus on finding appropriate combination strategies, and on 
investigating other potential small molecule snakebite therapy candidates. 
Nanofractionation analytics could also be used in a valuable manner to study the 
significance and potential impact of snake venom variations (i.e. studying venoms 
extracted from different individuals of the same snake species). A better 
understanding of venom variation will allow developing more generally applicable 
snakebite treatments. 
Overall, the results obtained in this thesis underline the value of 
nanofractionation analytics as a tool complementary to antivenomics in snakebite 
treatment research. Nanofractionation analytics in snakebite research highlighted 
the potential of small molecule inhibitors as therapy candidates for treating 
snakebite and will help guiding future research on the development of next 
generation antivenoms for treating snakebite. We anticipate that with funding for 
venom research increasing, knowledge of venom composition will increase and 
further improvements in analytical, biochemical and biological technology will be 
achieved. The advent of new techniques in these fields will open up new ways of 
exploring venom composition, functioning, and ways to neutralize the devastating 































































（Calloselasma rhodostoma）、尖吻蝮（Deinagkistrodon acutus）、山蝰（Daboia 
russelii）、锯鳞蝰（Echis carinatus）、非洲锯鳞蝰（Echis ocellatus）和海岸太攀蛇












术有机地结合，系统考察了 7 种蛇毒（同第二章）中毒素的凝血毒性和 PLA2 活性，
并评估了 varespladib（非特异性广谱 PLA2 抑制剂）对这些活性的抑制作用。研究结
果表明，所有蛇毒都表现出明显的凝血毒性，然而只有粗鳞矛头蝮（B. asper）、山
蝰（D.russelii）、锯鳞蝰（E. carinatus）和海岸太攀蛇（O. scutellatus）的毒液表现












制 PLA2 活性部位（例如 varespladib），或抑制蛇毒金属蛋白酶（SVMP）活性部位
（例如 marimastat），甚至还可以把 Zn2+从 SVMPs 活性位移除而使得 SVMPs 无法发
挥毒性（例如 dimercaprol 和 DMPS）。研究中所用到的蛇毒主要来源于蝰蛇科（锯
鳞蝰（E. carinatus）、非洲锯鳞蝰（E. ocellatus）、山蝰（D. russelii）和非洲鼓腹咝







要是 SVMP 和蛇毒丝氨酸蛋白酶（SVSP）。Varespladib 能有效地抑制大多数的抗凝
血毒素，对少数促凝血毒素也具有一定的抑制作用。在 SVMP 抑制剂中，marimastat









于蛇毒的红细胞溶解毒性分析。通过方法学优化，最佳的反应液为含有 0.5% NaCl 和
1.75 mg/mL 蛋黄卵磷脂的水乳剂，其中悬浮的红细胞数为 3.0×107/mL。用移液器将该
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反应液加入到含有毒液馏分的 384 孔板中后，将孔板竖立（75 度）在室温中培养 60 
min，最后在 540 nm波长下测量吸光度。本章从马来亚红口蝮（C. rhodostoma）、山






































PLA2s、SVMPs 和 SVSPs 诱导的凝血病理学的治疗效果。 
目前通用的高分辨质谱仪无法灵敏地检测分子量高于 20-30kDa 的蛋白质，这也
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